Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 1of 170Clinical Study Protocol
Study Intervention DNA -damage response agents
Study Code D5339C00001
Version Amendment 4
Date 04November 2022
A Modular Phase 2a Multicentre Open -Label Study to Investigate 
DNA -dam age Response Agents (or Combinations) in Patients 
With Advanced Cancer Whose T umours Contain Molecular 
Alterations (PLANETTE)
Sponsor Name: [CONTACT_245011]: 151 85 Södertälje, Sweden
Regulatory Agency Identifier Number(s)
EudraCT number: 2020 -002529 -27
IND number : [ADDRESS_781770] procedures. The Clinical Study  Protocol  ispublicly  registered and the results are 
disclosed and/or published according to the [COMPANY_008] Global Policy  on Bi oethics and in 
compliance wi th prevailing laws and regulat ions.
Protocol Number: D5339C00001
Amendment Number: 4
Study  Intervent ion:DNA -damage response agents
Study  Phase: 2a
Short Title: A Study  Invest igatingDNA -damage Response Agents in Molecularly Alt ered 
Advanced Cancer
Acronym :PLANETTE study
Medical Monitor Name [CONTACT_9352] [CONTACT_592720] -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 2of 170International c o-ordinating investigator s
 New 
York , NY, [ZIP_CODE] -5606 , [LOCATION_003].
 San Francisco, CA , [ZIP_CODE] , [LOCATION_003].
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Clinical Study Proto col-Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 3of 170PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE
DOCUMENT HISTORY
Document Date
Amendment 4 04-Nov-2022
Amendment 3 04-Apr-2022
Amendment 2 27-May-2021
Amendment 1 12-Aug-2020
Original Protocol 17-Jun-2020
The summary of changes for Amendment 4is provided below. Refer to Appendix Mfor a
summar yof the previous amendment.
Amendment 4 (04-Nov-2022)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of th e European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment
To cl arify access to IMP and management of patients ongoing on treatment at final Data Cut 
off (DCO )
Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
CORE
6.1Intervention 
after Final DCOAddition of text to core protocol to 
clarify  options for continuation of 
treatment for patients receiving 
benefit at time of final DCO.Please see overall rationale Substantial
MODULE 1(Section 11):
Ceralasertib Monotherapy in ATM Altered Advanced Solid Tumours (aST) and Prostate Cancer
11.1.[ADDRESS_781771] ivities................................ ................................ ....................... 11
2 INTRODUCTION -CORE ................................ ................................ ............... 12
2.1 Study  Rati onale ................................ ................................ ................................ 12
2.2 Back ground ................................ ................................ ................................ ......12
2.3 Benefit/Risk Assessment ................................ ................................ ................... [ADDRESS_781772] yle Considerat ions................................ ................................ ................... 19
5.3.1 Contraception ................................ ................................ ................................ ...20
5.4 Screen Failures ................................ ................................ ................................ .20
6 STUDY INTERVENTION -CORE ................................ ................................ ..20
6.1 Intervention after the Final DCO ................................ ................................ ....... 21
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL -CORE ................................ ............ [ADDRESS_781773] to Follow -up................................ ................................ ............................. 23
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 5of 1708 STUDY ASSESSMENTS AN D PROCEDURES -CORE ................................ 24
8.1 Efficacy Assessments ................................ ................................ ........................ 24
8.2 Safety Assessments ................................ ................................ ........................... 24
8.2.1 Physical Examinat ions................................ ................................ ...................... 24
8.2.2 Vital Signs................................ ................................ ................................ ........ 24
[IP_ADDRESS] Seated bl ood pressure and pulse rate ................................ ................................ .24
[IP_ADDRESS] Body  temperature ................................ ................................ ............................. [ADDRESS_781774] ing AE and SAE Informat ion................ 26
8.3.2 Follow-up of  AEs and SAEs ................................ ................................ ............. 27
8.3.3 Causalit y Collection................................ ................................ .......................... 28
8.3.4 Adverse Events Based on Signs and Symptoms ................................ ................ 28
8.3.5 Adverse Events Based on Examinat ions and Tests ................................ ............ 28
8.3.6 Hy’s Law ................................ ................................ ................................ .......... 29
8.3.7 Disease Progressi on................................ ................................ .......................... 29
[IP_ADDRESS] New cancers ................................ ................................ ................................ .....29
[IP_ADDRESS] Handling of deaths ................................ ................................ ............................ 29
8.3.8 Reporting of Serious Adverse Events ................................ ................................ 30
8.3.9 Pregnancy ................................ ................................ ................................ ......... 30
[IP_ADDRESS] Maternal Exposure ................................ ................................ ............................ 30
[IP_ADDRESS] Paternal  Exposure ................................ ................................ ............................. 31
8.3.10 Medicat ion Error ................................ ................................ ............................... 31
8.4 Overdose ................................ ................................ ................................ .......... 32
8.5 Hum an Bi ological  Samples ................................ ................................ ............... 32
8.5.1 Pharmacokinet ics................................ ................................ .............................. 32
8.5.2 Pharmacodynamics ................................ ................................ ........................... 32
8.6 Human Bio logical  Sample Bi omarkers ................................ ............................. 33
8.7 Optional Genomics Ini tiative Sample ................................ ................................ 33
8.8 Health Economics or Medi cal Resource Utilisation and Health Economics ....... 33
9 STATISTICAL CONSIDER ATIONS -CORE ................................ ................. 33
10 REFERENCES -CORE ................................ ................................ .................... 34
11 MODULE 1: CERALASERTIB MONO THERAPY IN ATM ALTER ED 
ADVANCED SOLID TUMOU RS (AST) AND PROSTAT E CANCER ........... [ADDRESS_781775] ivities (SoA) ................................ ................................ ............. 39
11.2 INTRODUCTION -MODULE 1................................ ................................ ......44
11.2.1 Module Rationale ................................ ................................ ............................. 44
[IP_ADDRESS] Advanced Solid Tumours ................................ ................................ .................. 45
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage respon se agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 6of [ZIP_CODE].2.1.2 Prostate Cancer ................................ ................................ ................................ .46
11.2.2 Background ................................ ................................ ................................ ......47
[IP_ADDRESS] Role of ATR ................................ ................................ ................................ .....47
[IP_ADDRESS] Disease Linkage ................................ ................................ ................................ 47
11.2.3 Benefit/Risk Assessment ................................ ................................ ................... 48
[IP_ADDRESS] Risk Assessment ................................ ................................ ............................... 48
[IP_ADDRESS] Benefit Assessment ................................ ................................ ........................... 48
[IP_ADDRESS] Overall Benefit: Risk Conclusio n................................ ................................ ......49
11.3 OBJECTIVES AND ENDPOINTS -MODULE 1................................ ............ 49
11.3.1 Cohort A: aST ................................ ................................ ................................ ...49
11.3.2 Cohort B: mCRPC ................................ ................................ ............................ 50
11.4 MODULE DESIGN -MODULE 1................................ ................................ ...51
11.4.1 Overall Design ................................ ................................ ................................ ..51
11.4.1 .1 Cohort A................................ ................................ ................................ ........... 51
[IP_ADDRESS] Cohort B................................ ................................ ................................ ........... 52
[IP_ADDRESS] Confirmation o f ATM Protein Expressio n and ATM Mutation Status ............... 53
11.4.2 Scientific Ra tionale f or Study  Design ................................ ............................... 54
11.4.3 Justification for Dose ................................ ................................ ........................ 54
11.4.4 End of Study  Definit ion................................ ................................ .................... 55
11.5 MODULE POPULATION -MODULE 1................................ ......................... 55
11.5.1 Inclusio n Cri teria (Cohort A [aST] and Cohort B [mCRPC]) ............................ 56
[IP_ADDRESS] Screening Part 1 (Molecular eligibilit y)................................ ............................ 56
[IP_ADDRESS] Screening Part 2 (Study  eligibilit y)................................ ................................ ..57
[IP_ADDRESS] Cohort A –aST................................ ................................ ................................ .57
[IP_ADDRESS] Cohort B –mCRPC ................................ ................................ .......................... 58
11.5.2 Exclusio n Cri teria (Cohort A [aST] and Cohort B [mCRPC]) ........................... [ADDRESS_781776] yle Considerat ions................................ ................................ ................... 61
[IP_ADDRESS] Meals and Dietary  Restri ctions................................ ................................ ......... 61
[IP_ADDRESS] Skin ................................ ................................ ................................ .................. 61
[IP_ADDRESS] Contr aception ................................ ................................ ................................ ...61
11.5.4 Screen Failures ................................ ................................ ................................ .61
11.6 STUDY INTERVENTION -MODULE 1................................ ........................ 62
11.6.1 Study  Intervent ion Administered ................................ ................................ ....... 62
11.6.2 Preparati on/Handling/Storage/Accountabilit y of Intervent ions.......................... 62
11.6.3 Measures to Minimise Bias: Rando misat ion and Blinding ................................ .63
11.6.4 Study  Intervent ion Compliance ................................ ................................ ......... 63
11.6.5 Concomitant Therapy ................................ ................................ ........................ 63
[IP_ADDRESS] Therapy  that may  NOT be administered ................................ ............................ 65
[IP_ADDRESS] Drug -Drug Interaction Between Ceralasert ib and Other Drugs .......................... 65
11.6.6 Dose Modificat ion................................ ................................ ............................ 67
[IP_ADDRESS] General Guidance ................................ ................................ ............................. 67
[IP_ADDRESS] Guidance for Dose Modificat ion and Interruption ................................ ............. 68
[IP_ADDRESS] Individual Stoppi[INVESTIGATOR_2121] ................................ ................................ .............. [ADDRESS_781777] ives and Endpo ints –Cohort A ...................................................... [ADDRESS_781778] ives and Endpo ints –Cohort B ....................................................... [ADDRESS_781779] igational Products ........................................................................... 62
Table 8 Guidance for Dose Modificat ions, Interrupti ons and Discont inuat ions for 
Ceral asertib ............................................................................................. 68
Table 9 Dose Reduction Levels for Ceralasertib ................................................... 70
Table 10 Requi rements for Docum entati on of  Progressi on..................................... 75
Table 11 L aboratory  safet y variables ...................................................................... 77
Table 12 Popul ations for Analysis .......................................................................... 81
Table 13 Summary  of Analyses and Data Cut -off Tri ggers ..................................... 82
Table 14 Drugs Known to be Inhibitors of CYP3A4 ............................................. 103
Table 15 Drugs Known to be Inhibitors and Inducers of CYP2C8 ........................ 104
Table 16 Drugs Known to be Inhibitors or Ind ucers of P -gp................................. 104
Table 17 Drugs Known to be Inhibitors or Inducers of BCRP ............................... 106
Table 18 Drugs Known to be Metabolised by [CONTACT_097]3A4 and/or CYP2B6 and Have 
a Narrow Therapeutic Index ................................................................... [ADDRESS_781780] OF APPENDICES
Appendix A Changes Related to Mitigation of Study  Disrupti ons Due to Cases of 
Civil Crisis, Natural Disaster, or Public Healt h Crisis .............................. 94
Appendix B Regulatory , Ethical , and Study  Oversight Consi derati ons......................... 96
Appendix C [LOCATION_001] Heart Associat ion................................ ................................ .101
Appendix D Guidelines Regarding Potential Interactions of Ceralasertib wit h 
Concomitant Medications ................................ ................................ ......102
Appendix E Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ................................ ................................ ......... [ADDRESS_781781] 1.1 (Response Evaluat ion Cri teria in Solid Tum ours) ............... [ADDRESS_781782] ive Tumour Response Using 
PCWG3 (Prostate Cancer Working Group Criteria 3) in Bone Lesio ns..127
Appendix H Adverse Eve nts: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ................................ ................................ ......131
Appendix I Handling of Human Bio logical  Samples ................................ ................ 136
Appendix J Optional Genomics Ini tiative Sample ................................ ..................... 138
Appendix K ATM Alterations Classificat ion Guidance ................................ .............. 141
Appendix L Abbreviat ions................................ ................................ ........................ 144
Appendix M Protocol  Amendment Hi story ................................ ................................ .150
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 11of 170Overall Design
This is a modular, phase 2a, open -label, mult icentre study  of DNA -damage response agents 
(or combinat ions) administered to participants with advanced/metastatic so lid tumours and/or 
haematological malignancies with molecular al terati ons.
This study  is modular in design and t he core module provides the overall framework for the 
study  and specific details of the participant populatio n and m olecular al terati ons will  be 
described in each module. A substant ial protocol  amendment wi th relevant supportive 
rationale will be approved before starting a new module.
Number of Participants:
Please refe r to individual modules for details.
Intervention Groups and Duration :
This protocol has a modular design, with the potential for future treatment arms to be added 
via protocol amendment. 
This protocol refers to the fo llowing m odules and study  drugs. For specific informat ion on 
each of the study  drugs, pl ease refer to the relevant module.
Module 1 (Section 11): Ceral asertib monotherapy  in ATM altered tum ours
Data Monitoring Committee: No
Statistical methods
Please refer to individual modules for details.
1.[ADDRESS_781783] agents (or combinat ions), 
administered to parti cipants wi th advanced/metastatic so lid and/or haem atological 
malignancies with molecular al terati ons. This protocol provides the overall framework for the 
study  (core m odule) and specific details of the participant population and mo lecular 
alterati ons will be described in each module. A substan tial protocol  amendment wi th relevant 
supportive rationale will beapproved before starting a new module.
The term  “study  intervent ion” throughout the protocol, refers to study  treatm ent/drug.
2.[ADDRESS_781784] ion of specific tumour ty pes, or disease agnostic. The participant 
popul ations considered are those with advanced/metastatic so lid and/or haematological 
malignanc ies wi th molecular al terati ons.
2.[ADDRESS_781785] ionable mutations 
with targeted therapy  (Coyne et al , 2017 ).
During the l ast [ADDRESS_781786] ice by [CONTACT_592721].
Many  potenti al targets on genet ic level, which are essent ial for proliferation, survival and 
metastati c spread of cancer cells, were i dentified. Some of those -so-called driver -mutations –
have been elucidated as highly  efficient therapeutic targets and nowadays there is a rapid 
progress in the development of new and more potent mo lecular targeted therapi[INVESTIGATOR_592682] ( Tan et al , 2016 ).
Clinical Study Protocol -Amend ment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 13of 170With this gaining knowledge in cancer geno mics, mo lecular bio logy and the development of 
targeted therapi[INVESTIGATOR_014], the classic concept of phase I -III tri als has been extended by  [CONTACT_592722]. Basket and umbrella trials entered the field of clinical research ( Zimmer et al, 
2019 ). One of the biggest mo lecular profiling trials, the NCI -MATCH (Molecular Analysis 
for Therapy  Choi ce) Tri al is a landmark preci sion medicine which is aiming to evaluate > 100 
mutati ons in a basket study  design.
Current ly, the leading example is the use of BRCA1/[ADDRESS_781787] patients whose 
tumours m ay be hypersensit ive to poly(ADP -ribose) polymerase (PARP) inhibitor treatment 
(Bryant et al , 2005 and Farmer et al , 2005 ), which has brought impressive survival rates in 
ovari an (Moore et al, 2018. ), breast ( Robson et al, 2017 ) and pancreat ic cancer (Golan et al , 
2019 ).
Furtherm ore, effect ive drugs have been approved for tumo ur agnosti c cancers based on studi es 
where pat ients have been selected acc ording to m olecular profiling. For instance, larotrectinib 
(Vitravki ) as m onotherapy  is indicated for the treatment of adult and paediatric patients with 
solid tumours that display a Neurotrophic Ty rosine Receptor Kinase (NTRK) gene fusion, 
who have a dise ase that is locally advanced, metastatic or where surgical resect ion is likely  to 
resul t in severe m orbidi ty, and who have no satisfactory  treatm ent opti ons ( Vitravki SMPC). 
Pembrozilumab was approved for the treatment of adult and paediatri cpatients with 
unresectable or metastatic, microsatellite instabilit y-high (MSI -H) or mismatch repair 
deficient: solid tumo urs that have progressed fo llowing pri or treatm ent and who have no 
satisfactory  alternative treatm ent opti ons, or col orectal  cancer t hat has progressed fo llowing 
treatm ent wi th a fluoropy rimidine, oxaliplat in, and irinotecan. This indicat ion is approved 
under accelerated approval based on tumo ur response rate and durabilit y of response 
(Key truda SMPC).
2.3 Benefit/Risk Assessment
The benefi t/risk assessments of the specific DDR agents (or combinat ions) are outlined in the 
respective modules. More detailed informat ion about the known and expected benefit s and 
risks and reasonably expected AEs are provided in the respect ive IBs.
[ADDRESS_781788] Mitigation During Study Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis
The gui dance given below supersedes instructions provi ded elsewhere in this CSP and should 
be implemented only during cases of civil crisis, natural disaster, or public healt h crisis (eg, 
during quarant ines and result ing site closures, regional travel restrict ions, and considerat ions if 
site personnel or stud y partici pants becom e infected with SARS -CoV -[ADDRESS_781789] ion) which would prevent the conduct of study -related activit ies at study  sites, thereby 
[CONTACT_592723]’s abilit y to conduct the study . The 
inves tigator or desi gnee shoul d contact [CONTACT_592724] d be implemented.
To ensure continuit y of the clinical study  during a civil crisis, natural disaster, or public healt h 
crisis, changes m ay be implemente d to ensure the safet y of study  parti cipants, maintain 
compliance wi th GCP , and minimize risks to study integrit y. 
Where allowable by  [CONTACT_122593], ethi cs commi ttees, heal thcare provi der gui delines 
(eg, hospi[INVESTIGATOR_96626]) or local government, these changes may include the fo llowing opti ons:
Obtaining consent/reconsent for the mit igation procedures (note, in the case of verbal 
consent/reconsent, the ICF should be signed at the participant’s next contact [CONTACT_476688]).
Rescreening: Addit ional rescreening for screen failure and to confirm eligibilit y to 
participate in the clinical study  can be performed in previously  screened parti cipants. The 
investigator should confirm this wit h the designated [COMPANY_008] study  physician. 
Hom e or Rem ote v isit: Perf ormed by  a site qualified health care professio nal or health 
care professio nalprovi ded by  a thi rd-party vendor.
Telemedicine visit: Remote contact [CONTACT_271077], virtual or video visits, and m obile heal th devices. 
At-home study  intervent ion adm inistrati on: Performed by  a site qualified healt h care 
professio nal, health care professio nalprovi ded by  a third-party  vendor or by  [CONTACT_427648]’s caregiver, if possi ble. Addit ional information related to 
the visit can be obtained via telemedicine. 
Clinical Study Protocol -Amendment [ADDRESS_781790] of variation between 
individuals and how this informat ion can be ut ilised to bring better drugs to clinic.
Assignment of pa rticipants to treatment arms will be made based upon the status of the 
relevant m olecular aberrati on in a parti cipant's tumour. The strength of clinical hypothesis as 
well as the prevalence of each aberration will be considered when overlappi[INVESTIGATOR_592683] -occur ring 
qualifying mo lecular criteria are encountered. Guidelines to inform cohort allocation for 
participants wi th overl appi[INVESTIGATOR_592684] m ore than a single qualifying aberration will be 
detailed separately where applicable .
4.[ADDRESS_781791] co mpleted the study  if he/she has co mpleted all phases of 
the study  including the last visit or the last scheduled procedure shown for the individual 
module that they  are included in.
The end o f the study  is defined as the date of the last visit of the last participant in the study  or 
last scheduled procedure for the last participant in the study .
5 STUDY POPULATION -CORE
The core study  populati on requi remen ts are described below, please refer to individual 
modules for further specific details.
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 18of 170Prospective approval o f protocol  deviati ons to recrui tment and enrolment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
The inclusio n criteria that are applicable to all modules in the study are described in this 
section. Please also refer to the relevant module for specific criteria applicable to each cohort. 
Where criteria are more stringent in the module rather than the c ore, the investigator should 
adhere to the module criteria.
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Informed Consent
1Capable of giving signed informed consent as described in Appendix Bwhich includes 
compliance wi th the requi rements and restri ctions listed in the ICF and in this protocol .
2Provisio n of written Optional Genet ic Research Information informed consent prior to 
collect ion of samples for optional genet ic research that supports Geno mic Init iative.
Age
3Parti cipant m ust be at least 18 years of age inclusive, at the time of signing the informed 
consent.
Sex
4 Contr aceptive use by [CONTACT_134092] (see 
Secti on5.3.1 ).
Other
5Parti cipant i s willing and able to comply  with the study  protocol  for the durati on of  the 
study  including undergo ing treatment and scheduled visits and examinat ions. 
5.2 Exclusion Criteria
The exclusio n criteria that are app licable to all modules in the study are described in this 
section. Please also refer to the relevant module for specific criteria applicable to each cohort. 
Where criteria are more stringent in the module rather than the core, the investigator should 
adher e to the m odule cri teria.
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1Persi stent toxi cities (> CTCAE Grade 2) caused by  [CONTACT_499474] , excluding 
alopecia and CTCAE Grade 2 peri pheral  neuropa thy.
2History  of another primary  malignancy  except for: 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 19of 170Malignancy  treated wi th curative intent and with no known active disease ≥[ADDRESS_781792] dose of study  drug and of l ow potent ial risk for recurrence 
Adequately treated non -melanoma skin ca ncer or lent igo maligna wit hout evidence 
of disease 
Adequately treated carcinoma in situ without evidence o f disease 
Localised non -invasive primary under surveillance
3Concurrent severe and/or uncontrolled medical condit ion (e.g., severe COPD, severe 
Parkinson’s disease, active inflammatory bowel disease) or psychiatric condit ion 
(screening for chronic disease is not required).
Prior/Concurrent Clinical Study Experience
4Parti cipants wi th a known hypersensit ivity to study  intervent ions or any  of the excipi[INVESTIGATOR_592685].
Other Exclusions
5Major surgery  within 2 weeks of starting study  intervent ion: parti cipants m ust have 
recovered fro m any effects of any  major surgery .
6Involvement in the planning and/or conduct of the study (applies to both [COMPANY_008] 
staff and/or staff at the study  site).
7Judg ement by  [CONTACT_592725] h study  procedures, restrict ions and requirements.
8Previous enrolment in t he present study . 
9Parti cipants wi th gastrointestinal disorders likely to interfere with absorption of the study  
intervent ion.
10Pregnant (confirmed wit h posit ive pregnancy test) or breast feeding women.
In addition, the following are considered criteria for exclusion from the optional 
exploratory host genetic research:
11Previous allogenic bone marrow transplant.
12Non-leukocyte depleted whole blood transfusio n wit hin [ADDRESS_781793] igator should adhere to the individual module 
criteria.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 20of 1705.3.1 Contraception
Male participants: Must use a condom (with spermicide) during the study , and for [ADDRESS_781794] dose of study  intervent ion, wi th all sexual partners. Where a sexual partner of a 
male participant is a ‘wo man of childbearing potential’ who is not using effective 
contraception, male participants must use a condo m during the study  and f or [ADDRESS_781795] dose of study  intervent ion.
Female participants: Pregnancy tests on blood (screening) or urine (other ti me po ints) 
samples will be performed for women of childbearing potential prior to the start of study  
intervent ion, at the timepoints defined in the individual module SoA.
Women of childbearing potential must use enhanced contraception during the study , and for 
1month after the last dose of study  intervent ion, wit h all male sexual partners. Contraceptives 
that are prone to drug -drug interactions may not be effect ive due to a potential CYP3A4 
interact ion with study  intervent ion. Contracepti on used m ust there fore include a condom and 
one of:
Medroxy progesterone inject ions (eg, Depo -provera)
Intrauterine device
Levonorgestrol Intrauterine System ( eg, Mirena)
Tubal occlusio n
Vasectomised partner
Women who are breast feeding are excluded fro m the study .
5.4 Screen Fa ilures
Please refer to individual modules for screen failure definit ions. 
A minimal set of screen failure informat ion is required to ensure transparent reporting o f 
screen failure participants to meet the CONSORT publishing requirements and to respond to 
queri es fro m regul atory  authori ties. Minimal informat ion includes demography, screen failure 
details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened following c onsul tation wi th the sponsor .Rescreened participant s should be 
assigned the same participant number as for the initial screening , and re -sign the ICF.
[ADDRESS_781796] igator’s opi[INVESTIGATOR_3078] n, continue to 
benefit from receiving IP treatment.
Depending on what is available at t he time, the patients would be fo llowed ei ther:
Within the current study
Within a safety  expansi on study  if available
Within a  drug supply program (commercial or compassio nate use program) if 
applicable
In case of treatment continuat ion after the final D CO wi thin the current study :
Patients will  cont inue to attend site visits for safet y assessments.
There will be no more data collect ion except SAE reporting, overdosing and 
pregnancies. The clinical study  database will be closed.
SAEs , overdoses and pregnancies will be reported fo llowing a paper form process. All 
SAEs, overdose and pregnancies will be reported unt il [ADDRESS_781797] dose and 
recorded in the safet y database.
Drug dispensat ion and reconciliat ion will be handled by  [CONTACT_592726]’s visit.
Site will rem ain open until the last patient treatment discont inuat ion.
In case of treatment continuat ion after the final DCO within a safet y extensio n study , if
available:
Safety extensio n study  woul d have to be approved by  [CONTACT_592727]’s site .
Safety assessments would be performed as per the safet y extensi on study  protocol .
SAEs will be reported fo llowing a paper form  process. All SAEs, overdose and
pregnancies will be reported until 30 days after las t dose and recorded in the
safet y database.
Patients woul d be proposed to transit ion to the safety  study  and sign a new consent
form.
If the study  drug is m arketed for use in the disease under study  indicat ion:
Patients m ay discontinue study  and switch to marketed product.
7 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL -CORE
7.[ADDRESS_781798] of the study  at any  time, wi thout prej udice to 
further treatment. Procedures for withdrawal fro m the exploratory  research on collected 
samples are outlined in Appendix I2.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 22of 170Parti cipants may  be discont inued fro m study  intervent ion in the fo llowing si tuations:
Parti cipant or invest igator decisio n. The participant is at any  time free to withdraw his/her 
participat ion in the study.
AEs.
Severe non -compliance to this protocol (parti cipants or investigator) as judged by [CONTACT_592728]/or [COMPANY_008].
Disease progression.
Parti cipants incorrectly init iated on study  interventio n (Section 7.1.2 ).
When the reason does not impact safet y consider the risk/benefit to the participant of 
stoppi[INVESTIGATOR_056].
Life-threatening or other unacceptable toxicit y.
The discovery  of an unexpected, si gnificant, or unacceptable risk to the participants 
enrolled in the study .
Lack of evaluable and/or complete data.
Decisio n to m odify  the devel opment pl an of the drug.
A decisio n on the part of the sponsor to suspend or discont inue development of the drug.
Confirmed pregnancy in wo men of childbearing potential .
7.1.1 Temporary Discontinuation
Please refer to the relevant module.
7.1.2 Procedures for Handling Participants Incorrectly Initiated on Study 
Intervention
Participants who do not meet the inclusio n/exclusion criteria should not, under any  
circumstances, be enrolled or receive study  intervent ion. There can be no except ions to this 
rule.
When participants that do not m eet the inclusion/exclusion criteria are enrolled in e rror or 
incorrectly  started on study  intervent ion, or when participants subsequent ly fail to m eet the 
study  criteria post ini tiation, the invest igator should inform the sponsor Study  Physician 
immediately and these participants will be documented as protoc ol violations.
Any pa rticipant who is found to have failed to comply wit h all o f the select ion criteria, but has 
not started study intervent ion, will be removed from the study  following com pletion of safet y 
follow-up activit ies.
Any pa rticipant started on study interventi onin error, a ndhe/she has subsequent ly been found 
to have failed to comply wit h all o f the select ion criteria, will undergo a risk/benefit 
Clinical Study Protocol -Amendment [ADDRESS_781799] igator/sponsor ; if the partici pant is judged to be receiving clinical 
benef it, the invest igator may choose to continue to dose them with the study  intervent ion.
Every  effort shoul d be made to keep all participants in the study unt il completion of safet y 
follow-up activit ies.
The sponsor Study  Physician is to ensure all such conta cts are appropriately documented.
7.2 Participant Withdrawal from the Study
A participant may withdraw from  the study  at any  time at hi s/her own request, or may  be 
withdrawn at any  time at the di screti on of  the investi gator for safet y, behavioural ,
compliance, or administrative reasons .This is expected to be unco mmo n.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  
retain and cont inue to use any data collected before such a withdrawal o f consent.
If a parti cipant wi thdraws fro m the study , it shoul d be confirmed if he/she st ill agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested s hould be 
carried out in line with what was stated in the informed consent and local regulat ion. The 
investigator must document the decisio n on use of exist ing samples in the site study  
records and inform the Global Study  Team .
7.[ADDRESS_781800] be taken ifa participant fails to return to the clinic for a required
study  visit:
The site must attempt to contact [CONTACT_78778] m issed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or shoul d continue in 
the study .
Before a participant is deemed lost to f ollow-up, the invest igator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and ,
if necessary ,a certified letter to the participant ’s last known mailing address or local 
equivalent m ethods). These contact [CONTACT_13140] ’s 
medical record .
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants enrolled. Public sources 
may be searched for vital status informat ion. If vital status i s determined as deceased, this 
Clinical Study Protocol -Amendment [ADDRESS_781801] vital status information.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix B.
8 STUDY ASSESSMENTS AN D PROCEDURES -CORE
Please refer to the relevant individual modules for s tudy procedures and their timing s. 
Protocol waiver s or exem ptions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon 
occurrence or awareness to determine if the participant should contin ue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in individual 
module SoAs, is essent ial and requi red f or study conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al 
participant s meet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all partici pants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg,blood 
count) and obtained before signing of the ICF may be util ised for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the t imeframe defined in the individual module SoAs.
8.1 Efficacy Assessments
Please refer to individual modules for details.
8.2 Safety Assessments
Please refer to individual module SoAs for details on the timing/visits for safet y assessments.
8.2.1 Physical Exa minations
A co mpletephysical examinat ion with weight will be performed . Height will be recorded 
at screening only.
Examinat ion will  include general appearance, respi[INVESTIGATOR_696] , cardi ovascular, abdom en, skin, 
head and neck (including ears, ey es, nose and throat), lymph nodes, thy roid, 
musculoskeletal (including spi[INVESTIGATOR_271002]) and neurological systems. Investigators 
shoul d pay special attenti on to clinical signs related to previous serious illnesses. 
Situations in which physical examinat ion results should be repor ted as AEs are described 
in Section 8.3.5 .
8.2.2 Vital Signs
[IP_ADDRESS] Seated blood pressure and pulse rate
Blood pressure and pulse rate will be measured in the sitt ing position after at least [ADDRESS_781802] 5 minutes prior to times indicated. All ECGs should be recorded with the participant in 
the sam e physical posi tion. A standardised ECG machine should be used that autom atically 
calculates the heart rate and measures PR, QRS , and QT intervals, and the parti cipant shoul d 
be examined using the same machine throughout the study , where feasible.
For triplicate ECGs, 3 individual ECG tracings should be obtained in su ccessio n, no more 
than 2 minutes apart. The full set of triplicates should be completed within 5 minutes. Results 
from each replicate of the ECG should be recorded and an assessment of clinical significance 
recorded for each timepo int. Num erical  values (eg , QT, QTcF, PR interval) should be assessed 
based on an average of the triplicate readings, whilst qualitat ive findings (eg rhyt hm and 
overall evaluat ion) fro m all replicates should be taken into accoun t.
After paper ECGs have been recorded, the invest igator or desi gnated physician will review 
each of the ECGs and may refer to a local cardio logist if appropri ate. A paper copy  shoul d be 
filed in the participant’s medical records. If an abnormal ECG finding at screening is 
considered to be clinically signific ant by  [CONTACT_093], i t shoul d be reported as a concurrent 
condi tion. For all ECGs details o f rhythm, PR, R -R, QRS and QT cFinterval and an overall 
evaluat ion will be recorded.
8.2.4 Performance Status
Perform ance status will be assessed according to US ECOG criteria (Table 2).
These scales and criteria are used by [CONTACT_54124] a patient ’s 
disease is progressing, assess how the disea se affects the daily  living abilit ies o f the 
patient, and determine appropriate treatment and prognosis ( Oken et al , 1982 ). 
Table 2 Eastern Cooperative Oncology Group Performance Status
Grade ECOG
0 Fully  active, able to carry out all pre -disease activities without restrictions
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature eg, light housework, office work
2 Ambulatory and capable of self -care, but unable to carry out any work activities. Up and 
about more than 50% of waking hours
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D533 9C00001
CONFIDENTIAL AND PROPRIETARY 26of 170Grade ECOG
3 Capable of only limited self -care, confined to bed or chair more than 50% o f waking hours
[ADDRESS_781803] ion will be recorded in the appropriate 
eCRF.
Addit ional safet y samples may  be collected if clinically indicated at the discret ion of the 
investigator. The date, time of co llection and results (values, unit s and reference ranges) will 
be recorded on the appropriate eCRF.
Laboratory  values that m eet the cri teria for CTCAE Grade [ADDRESS_781804] changed significant ly 
from baseline and are considered to be of clinical concern will be repeated/confirmed within 
7days and fo llowed up as appropri ate.
8.[ADDRESS_781805] ion
The definit ions of an AE or SAE can be found in Appendix H.
AE will be reported by  [CONTACT_2299] (or, when appropriate, by  a caregiver, surrogate, or the 
participant ’s legally author ised representative) . 
The invest igator and any designees are responsible for detecting, document ing, and recording 
events that meet the definit ion of an AE .
8.3.[ADDRESS_781806] safet y follow-up 
visit and he/she considers there is a reasonable possibilit y that the event is rel ated to study 
intervent ion,the investigator should notify  [COMPANY_008].
If the invest igator becomes aware of a nSAE with a suspected causal relat ionship to the 
investigat ional medicinal product that occurs after the end of the clinical study in a participant
treated by  [CONTACT_198671], t he invest igator shall, wit hout undue delay, report the SAE to the 
sponsor.
8.3.2 Follow -up of AEs and SAEs
Any AEs that are unresolved at the participant ’s last AE assessment in the study are followed 
up by  [CONTACT_592729] l ong as medically  indicated, but wi thout further recording in the 
eCRF . [COMPANY_008] retains the right to request addit ional inform ation for any  participant with 
ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
Adverse event variab les
The fo llowing variables will be collected for each AE;
AE (verbat im)
CTCAEv5 grade
The date and time when the AE started and stopped
The date, time and new CTCAEv5 grade if this has changed
Whether the AE is serious or not
Invest igator causalit y ratingagainst the study  intervent ion(s) (y es or no)
Action taken with regard to study  intervent ion(s)
Outcom e.
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for seri ous AE
Date invest igator became aware of serious AE
AE is serious due to
Date of hospi[INVESTIGATOR_72913]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study procedure(s)
Causalit y assessment to other medicat ion
Clinical Study Protocol -Amendment [ADDRESS_781807] igator should assess causal relationship between study  interventi onand each AE, 
andanswer ‘yes’ or ‘no’ to the question ‘Do y ou consi der that there is a reasonable possibilit y 
that the event may have been caused by  [CONTACT_592730]?’
For SAEs, causal relat ionship shoul dalso be assessed for other medicat ion and study  
procedures . Note that for SAEs that could be associated with any study  procedure the causal 
relationship is implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in Appendix Hto the Clinical 
Study  Protocol .
8.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by  [CONTACT_592731]: ‘Have y ou had any heal th probl ems since the 
previous visit/y ou were l ast asked?’ , or revealed by  [CONTACT_487448] . When co llecting AEs, the record ing of diagnoses is preferred (when possible) to 
recording a list of signs and symptoms . However, if a diagnosis is known and there are other 
signs or symptom s that are not generally  part of  the di agnosis, the diagnosis and each sign or 
symptom  will be rec orded separately .
8.3.5 Adverse Events Based on Examinations and Tests
The results from the Clinical Study  Protocol -mandated l aboratory  tests , vital signs , and other 
safet y assessments will be summarised in the CSR . 
Deteri oration as com pared to baseline in prot ocol-mandated l aboratory  values, vital signs ,and 
other safet y assessments shoul d therefore only  be reported as AEs if they fulfil any of the SAE 
criteria, are the reason for concomitant therapy , and/or m odificati on or discontinuation o f 
treatm ent wi th thestudy  intervent ionor are considered to be clinically  relevant as j udged by 
[CONTACT_3170] (which may include but not limited to consideration as to whether treatment or 
non-planned visits were required or other action was taken with the study  treatment , eg,dose 
adjustm ent or drug interruption) unless clearly  due to progressi on of  disease under study  (see 
Disease progressi onSection8.3.7 ).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting invest igator
uses the clinical, rather than the laboratory  term  (eg,anaemia versus low haemoglo bin value) . 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in non -
mandated parameters should be reported as AE(s).
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 29of 170Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessme nt will be reported as an AE unless unequivocally 
related to the disease under study .
8.3.6 Hy’s Law
Cases where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion and occurrences of AST or ALT ≥3xULN together with total bilirubin ≥2xULN 
may need to be reported as SAEs . Please refer to Appendix Efor further instructi on on cases 
of increases in liver biochemistry  and evaluat ion of Hy’s Law .
8.3.7 Disease Progression
Disease progressi on can be considered as a worsening of a participant ’s condit ion attri butable 
to the di sease for which the study  intervent ionis being studied . It may be an increase in the 
severit y of the disease under study  and/or increases in the symptoms o f the disease . The 
development of new, or progression of exist ing metastasis to the primary cancer under study  
shoul d be considered as disease progression and not an AE . Events, which are unequivocally 
due to disease progression, should not be reported as an AE during the study.
[IP_ADDRESS] New cancers
The development of a new cancer should be regarded as an AE and will generally  meet at 
least one of the seri ous cri teria. New cancers are those that are not the primary  reason for the 
administration of the study  interventi on and have been ident ified after the participant’s 
inclusio n in this study . They  do not include metastases of the original cancer.
[IP_ADDRESS] Handling of deaths
All deaths that occur during the study , or wi thin the fo llow-up peri od after the administration 
of the l ast dose of study  interventi on, shoul d be reported as fo llows:
Death, which is unequivocally due to disease progressio n, should be co mmunicated to the 
study  monitor at the next m onitoring visit and should be documented in the eCRF 
module, but shoul d not be reported as a SAE during the study .
Where death is not clearly  due to disease progression of the disease under study  the AE 
causing t he death should be reported to the study mo nitor as an SAE wi thin 24 hours. The 
report should contain a comment regarding the co -involvement of progression of disease, 
if appropriate, and should assign a single primary  cause of death together with any 
contributory causes.
Deaths with an unknown cause should always be reported as a SAE but every  effort 
shoul d be made to establish a cause of death. A post -mortem may be helpful in the 
assessment of the cause of death, and if performed a copy  of the post -mortem resul ts 
Clinical Study P rotocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 30of 170(with transl ation of important parts into English) should be reported in an expedited 
fashio n to an [COMPANY_008] representative wit hin the usual timeframes.
8.3.[ADDRESS_781808] to be reported, whether or not considere d causally related to the study  
intervent ion, or to the study  procedure(s) . All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study , then investigator s or other site personnel inform 
the appropriate [COMPANY_008] representatives w ithin one day  ie,immediately but no later than 
[ADDRESS_781809] igator s or other site personnel indicate an AE is serious in the WBDC system , 
an autom ated email alert is sent to the designated Astr aZeneca representative.
If the WBDC system  is not available, then the investigator or other study  site staff reports a 
SAE to the appropriate [COMPANY_008] representative by [CONTACT_756].
The [COMPANY_008] representative will advise the investigator /study site st aff how to proceed .
The reference document for definit ion of expectedness is Secti on5 of theindividual study  
intervent ion IB.
8.3.9 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008] except for:
If the pregnancy  is discovered before the study  participant has received any study 
intervent ion
[IP_ADDRESS] Maternal Exposure
If a participant beco mes pregnant during the course of the study ,study  intervent ionshoul d be 
discontinued immediately .
Clinical Study Protocol -Amendment [ADDRESS_781810] iveness of a contraceptive medication . 
Congenital anomalies/birth defects and spontaneous miscarriages should be reported and 
handl ed as SAEs . Elective aborti ons wi thout com plicat ions should not be handled as AEs . The 
outcom e of all pregnancies (spontaneous miscarriage, elective terminat ion, ectopic pregnancy, 
norm al birth or congeni tal anomaly/birth defect ) shoul d be f ollowed up and documented even 
if the participant was di scontinued from the study .
If any pregnancy  occurs during exposure to study intervent ionor in the [ADDRESS_781811] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site wi thin 1 or 
5calendar days for SAEs (see Section 8.3.9 ) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
[IP_ADDRESS] Paternal Exposure 
Pregnancy of the participant ’s partners is not considered to be an AE. However, the outcome 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy, normal 
birth or congenital abnormalit y), occurring from the date of the first dose until 16weeks after 
dosing after the last dose and as indicated by [CONTACT_49808] (preclinical and clinical) should,
if possible, be fo llowed up and docum ented in the Pregnancy Report Form . Consent fro m the 
partner m ust be obtained before the Pregnancy  Report Form  is completed . 
8.3.[ADDRESS_781812] igator to ensure t hat all 
relevant informat ion is completed wi thin 1 (Init ial Fatal /Life -Threatening or follow -up 
Fatal /Life -Threatening)or 5 (other serious init ial and fo llow-up) cal endar days if there is an 
SAE associated with the medicat ion error (see Sectio n8.3.8 ) and within [ADDRESS_781813] dose but for longer duration.
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdo se eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an [COMPANY_008] study  intervent ionoccurs in the course of the study , the 
investigator or other site personnel inform appropriate AstraZe neca representatives 
immediately , but no later than [ADDRESS_781814] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site wi thin 1 or 5 
calendar day s for overdoses associ ated wi th an SAE (see Section 8.3.8 ) and within [ADDRESS_781815] confident iality. For further details on Handli ng of  Hum an Bi ological 
Sample see Appendix I.
Samples will  be stored for a m aximum  of 15 y ears fro m the date of the issue of the CSR in 
line with consent and local requirement s, after which they  will be destroyed /repatri ated. 
PK samples will be disposed of after the Bioanaly tical Report finali sation or 6months 
after issuance of the draft Bioanaly tical Report (whichever is earlier), u nless consente d 
for future analyses.
PKsamples may be disposed of or anonymised by [CONTACT_76435]. Addit ional analyses may 
be conducted on the anonymised, pooled pharmacokinet ic samples to further evaluate 
and validate the analyt ical method. Any  resul ts from such analyses m ay be reported 
separately  from the CSR.
8.5.[ADDRESS_781816] ion and shipment and destruction of these samples can be 
found ei ther in the appendices or in the Laboratory Manual. 
See Appendix Jfor further informat ion regarding the Geno mics Init iative genet ic sample .
8.8 Health Economic sorMedical Resource Utili sation and Health 
Economic s
Health Economics/Medical Resource Utili sation and Healt h Economics parameters are not 
evaluated in this study .
9 STATISTICAL CONSIDERATIONS -CORE
Please refer to individual modules for details.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 34of [ZIP_CODE] REFERENCES -CORE
Bryant et al, 2005
Bryant HE, Schul tzN, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of 
BRCA2 -deficient tum ours wi th inhibitors of poly(ADP -ribose) polymerase. Nature. 
2005 ;434:913 –917.
Coyne et al, 2017
Coyne GO, Takebe N, and Chen AP. Defining Precision: The Precisio n Medicine Init iative 
Trials NCI -MPACT and NCI-MATCH. Curr Probl Cancer. 2017;41(3):[ADDRESS_781817] CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. (2005). 
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy . Nature. 
2005;434:917 –921.
Feng et al, [ADDRESS_781818] Cancer 
Res. 2015 May  3;17:65.
Golan et al, 2019
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance 
Olaparib for Germline BRCA -Mutated Metastatic Pancreat ic Cancer. N. Engl. J. Med. 2019; 
381:317 –327.
Kaufma n et al, 2015
Kaufman B, Sharpi[INVESTIGATOR_20116] -Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaňa J et 
al. Olaparib mo notherapy  in pat ients with advanced cancer and a germline BRCA1/2 
mutati on. J Clin Oncol 2015;33(3):244 -251.
Kumar et al, 2016
Kumar A, Co leman I, Morri ssey C, Zhang X, True LD, Gulat i R et al . Substant ial 
interindividual and limited intraindividual genomic diversit y among tum ors from men wi th 
metastati c prostate cancer. Nat Med. 2016 Apr;22(4):[ADDRESS_781819] 
29;373(18):1697 -708.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 35of 170Moore et al, 2018. 
Moore K, Colo mbo N, Scambia G, Kim B -G, Oaknin A, Friedlander M, et al . Maintenanc e 
Olaparib in Pat ients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2018; 
379: 2495 –2505 .
Oken et al, 1982
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicit y And 
Response Criteria Of The Eastern Cooperative On cology Group. Am  J Clin Oncol  
1982:5;649 -655.
Robinson et al, 2015
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM et al. Integrative
clinical geno mics of advanced prostate cancer. Cell. 2015 May 21;161(5):[ADDRESS_781820] Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017;377:523 –
533.
Tan et al, 2016
TanW-L, Jain A, Takano A, Newell EW, Gopal akrishna Iyer N, LimW-T, et al . Novel  
Therapeut ic Targets on the Horizon for Lung Cancer. Lancet Oncol. 2016; 17(8):e347 -e362.
Zimmer et al, 2019
Zimmer K, Kocher F, Spi[INVESTIGATOR_69020] G, Salem M, Gastl G, Seeber A. Treatment According to 
Molecular Profiling in Relapsed/Refractory  Can cer Pati ents: A Review Focusing on Latest 
Profiling Studies. Comput Struct Biotechno l J. 2019;17:447 -453.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 36of [ZIP_CODE] MODULE 1: CERALASERTIB MONOT HERAPY IN ATM 
ALTERED ADVANCED SOL ID TUMOURS (AST) AND
PROSTATE CANCER
11.1 MODULE SUMMARY -MODULE 1
11.1.1 Synopsis
Rationale
Ataxia tel angiectasia m utated (ATM) i s a serine/threonine protein kinase that is recruited and 
activated by  [CONTACT_592732]. Ataxia 
Telangiectasia and Rad3 Related (ATR) is an api[INVESTIGATOR_592686] h a cri tical role in the DNA -
damage response. During normal DNA replicat ion, ATR is recruited at stalled replication 
forks which can progress to double strand breaks if left unrepaired. In norm al cells, there is a 
significant interpl ay between ATR and ATM as stalle d replicat ion forks can be converted into 
doubl e strand breaks through further DNA -damage and the resection of double strand breaks 
generates single stranded DNA.
Preclinical models have suggested that ATM -deficient cell lines are sensit ised to DNA 
damaging agents, including plat inum chemotherapy and ATR inhibitors. Ceralasert ib is an 
oral inhibitor of the serine/threonine protein kinase ATR, a member of the phosphoinosit ide-3-
kinase related kinase (PI[INVESTIGATOR_90290]) family. There are emerging data which are dem onstrating the 
anti-tumour activi ty of ATR inhibitors in patients with ATM mutation and/or protein loss.
In line with previous and ongoing studies, it is ant icipated that patients with ATM altered aST 
and m CRPC woul d benefit fro m treatm ent wi th ceral aserti b in this study .
Overall Design
Module [ADDRESS_781821] igating ceralasertib , previ ously  known as AZD6738, monotherapy  
administered orally, to participants with advanced/metastatic solid malignancies with ATM 
mutati on and/or protein loss .
Number of Participants
Cohort A (aST): A total of ~25 mo lecularly eligible and centrally confirmed participants will 
be enrolled into Cohort A.
Cohort B (mCRP C): A total  of ~27 molecularly eligible and centrally confirmed participants 
will be enro lled into Cohort B. Unfavourabl e CTC count requirement may be introduced for 
all participants to ensure an adequate (approximately  ≥50%) number of participants with CTC 
count ≥5/7.5 mL blood.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 37of 170At the time of protocol amendment 2, 8 pa rticipant shad been dosed at 240 mg BID in 
Cohort A, and 1 participant had been dosed at 2 40mg BID in Cohort B. Following the 
reducti on of  the starting dose from 240 mg BID to 160 mg BID in protocol amendment 2, the
intention is to enrol an addit ional total  of ~25 and ~[ADDRESS_781822] ics.
Cohort A (a ST)
Object ive response rate is defined as the percentage of participants who have at least one 
response of CR or PR prior to any  evidence of progressio n (as defined by [CONTACT_393] 1.1) that is 
confirmed at least 4 weeks later. Percentage of participants will be accompanied with a 2 -
sided 80% confidence interval as obtained from a Clopper -Pearson test.
Cohort B ( mCRP C)
Com posite response will be defined on the basis of the following outcomes; if any of these 
occur i n the absence of radio logical or PSA progressio n (according to RECIST 1.1 for soft 
tissue and visceral lesions, prostate cancer working group 3 (PCWG3) criteria for bone 
lesions, and PSA) parti cipants will be considered to have responded:
Invest igator assessed radio logical objective response by [CONTACT_393] 1.[ADDRESS_781823] 
to a protocol amendment.
Conversio n of CTC count fro m ≥ 5/7.5 m L blood (unfavourable) at baseline to < 5/7.5 
mL blood (favourable) confirmed by a second consecut ive value obtained 3 or more 
weeks later (as per PCWG3 criteria).
PSA decline o f > 50% confirmed by a second consecutive measurement at least 3 weeks 
later (based on PCWG1 criteria).
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 38of 170Percentage of participants will be acco mpanied wit h a 2-sided 80% confidence interval as 
obtained fro m a Clopper -Pearson test.
11.1.[ADDRESS_781824] except NSCLC and prostate cancer.2Ceralasertib administered twice a day between Days 1 to 14 in 28daycycle s.
Abbreviations: aST=advanced solid tumours; ATM=ataxia telangiectasia mutated; BID=twice daily; 
IHC=immunohistochemistry; NSCLC=non -small -cell lung carcinoma.

Clinical Study Protocol -Amendment [ADDRESS_781825] brain scan assessment (MRI where CT is contraindicated) applies to advanced solid tumour participants only (Cohort A 
[aST]). A CT brain scan will be performed if partici pant is not known to have brain metastases . If the participant has known brain metastases, a baseline 
MRI will be performed.
nCT scans of the chest, abdomen, and pelvis (or MRI where CT is contraindicated) and bone scans (Cohort B [mCRPC] only) should be conducted ever y 
8 weeks (±1 week) after the start of treatment (Cycle 1 Day 1) up to 1 year, then ever y 12weeks (±1 week) until objective disease progression as per 
RECIST 1.1 or PCWG3 criteria . In the event of treatment interruptions or delays, tumour assessments should proceed to schedule relative to Cycle 1 
Day 1. Bone progression observed by [CONTACT_15222] (Cohort B [mCRPC]) requ ires confirmation by [CONTACT_592733] 6 weeks later and preferably no later 
than the next scheduled scan (see Section [IP_ADDRESS] ). Soft tissue or vis ceral progression observed by [CONTACT_462], according to RECIST 1.1, does not 
require a confirmatory scan.
oClinical CTC counts and PSA levels (Cohort B [mCRPC] only) will be assessed ever y cycle up to Cycle 5 Day 1, then every 8 weeks (±1 week )up to 
1year, then every 12 weeks (±1 week), aligned with tumour assessments (except those aligned with C1D1, C2D1, and C4D1), until radiographic 
objective disease progression as per RECIST 1.1 or PCWG3 criteria or off -study . CTC count conversion, PSA res ponse by [CONTACT_43877]1 criteria, and PSA 
progression by [CONTACT_43877]3 criteria will need to be confirmed 4 weeks (±1 week) later unless a radiographic objective disease progression is registered
within 12 weeks of PSA progression in which case concurrent PSA progression w ill be regarded as confirmed. In the absence of radiographic 
progression, if confirmatory PSA sample is not taken in 4 weeks (±1 week), it should be taken as soon as possible before the next scheduled assessment.
Abbreviations: AE=adverse events; aST=advan ced solid tumour ; ATM=ataxia telangiectasia mutated; BP=blood pressure; CR=complete response; 
CSP=clinical study protocol; CT=computed tomography; CTC=circulating tumour cells; ; ECG=electroc ardiogram; d=day; 
DNA=deoxyribonuclei c acid; ECOG=Eastern Cooperative Oncology Group; G3=grade 3; ICF=informed consent form; IHC=immunohistochemistry; 
mCRPC=metastatic castration -resistant prostate cancer; MRI=magnetic resonance imaging; NGS=next generation sequencing; PCWG3=the prostate canc er 
working group 3; PGx=pharmacogenetic; PK=pharmacokinetic; PR=partial response; PSA=prostate specific antigen; RECIST=response evaluation criteria in 
solid tumours; SAE=serious adverse event; SD=stable disease; SoC=standard of care; WOCBP=women of childb earing potential.
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 44of [ZIP_CODE].2 INTRODUCTION -MODULE 1
Module 1 is testing ceralasert ib, previously known as AZD6738, in 2 participant populations 
(Cohort A and Cohort B) whose tumours contain deleteriousor suspected deleterious genet ic 
alterati ons in the ATM gene. Cohort A is recruit ing participants with ATM altered aST,
except participants with non-small -cell lung carcinom a and prostate cancer. Cohort B is 
recrui ting participants with ATM altered mCRPC. Molecularly eligible part icipants in 
Module [ADDRESS_781826] tumours containing alterations in ATM. A mo lecularly eligible participant 
is defined as a participant with deleteri ousor suspected deleterious ATM mutation in tum our 
or blood(germline or ctDNA) , tested in a locally accredit ed laboratory  using a validated test 
in line wit h local regulat ions (eg, CAP/CLIA laboratory , where available) . Definit ions of 
qualifying ATM mutations include deleterious/suspected deleterious, pathogenic/likely 
pathogenic, disease, or cancer -associ ated v ariants. Vari ants of unknown significance or benign 
variants are not eligible for enro lment. CohortA and Cohort B will each enrol participants 
with ATM IHC >5% and ≤5%. Prospective selectio n of patients with ATM IHC ≤5% m ay 
be introduced in each cohort based on emerging ATM protein deficiency prevalence and 
ceral asertib clinical act ivitydata.
11.2.1 Module Rationale
ATM is a serine/threonine protein kinase that is recruited and activated by [CONTACT_592734]. Ataxia telangiectasia and rad3 related 
protein (ATR) is an api[INVESTIGATOR_592687] a crit ical role in the DNA -damage response. During 
norm al DNA replicat ion, ATR is recruited at stalled replicat ion forks which can progress to 
doubl estrand break s if left unrepaired. In norm al cells, there i s a significant interplay  between 
ATR and ATM as stalled replicat ion forks can be converted into double strand breaks through 
further DNA -damage and the resection of double strand breaks generates single strand ed 
DNA ( Thuss et al , 2011 , and Toledo et al , 2011 ).
Preclinical models have suggested that ATM- deficient cell lines are sensit ised to DNA 
damaging agents, including plat inum chemotherapy and ATR inhibitors (Reaper et al, 2011 ). 
Ataxia tel angiectasia m utated protein loss of funct ion has been described in various tumour 
groups: up to 22% of metastatic tumours from pat ients with gastric cancer might have low or 
undetectable ATM expression, ( Kim et al, 2013 ), 8% in co lorectal  cancer. Synthet ic lethalit y 
between ATR inhibit ion and ATM deficiency was recent ly demo nstrat ed in gastric cancer 
warrant ing further clinical studies for ceralasert ib in ATM deficiency tumours (Min et al, 
2017 ).
[COMPANY_008] internal data for the prevalence of ATM mutation s and prevalence of ATM 
protein loss  is presented in Table 4. 
CCI
Clinical Study Protocol -Amendment [ADDRESS_781827] synthetic letha lity between ATR 
inhibit ion and ATM deficiency in gastric cancer cells ( Min et al , 2017 ).
Signs of preliminary efficacy (unpublished internal data) were observed in an ongoing study  
of ceral asertib combined wit h durvalumab in pat ients with NSCLC and ATM mutation or 
protein expressio n loss previously  treated wi th immune checkpo int inhibitors 
([STUDY_ID_REMOVED]).
[IP_ADDRESS] Prostate Cancer
The concept of synt hetic lethalityof DDR inhibitors in DDR -deficient backgrounds has been 
explored clinically in mCRPC: PARPi [INVESTIGATOR_592688]1/2 mutations and HRR 
mutati ons, including ATM mutations. The ongoing TRITON2 study of rucaparib in 
participants wi th DNA -Damage Repair -defic ient mCRPC associated with HRR gene 
alterati ons dem onstrated confirmed radiographic responses in 44.0% of participants with a 
deleterious BRCA1/2 alteration. In addit ion, male pati ents who had progressed on an 
androgen receptor directed therapy  and chem otherapy  dem onstrated confirmed PSA responses 
in 51.1% of participants with a deleterious BRCA1/2 alteration. Based on this data, the US 
FDA granted breakthrough therapy  designat ion for rucaparib as a monotherapy  for pati ents 
with BRCA1/2 -mutated m CRPC who ha ve received ≥1 prior androgen receptor directed 
therapy  and a taxane based chemotherapy ( Wassim Abida et al, 2018 ).
Interim results fro m the TALAPRO -[ADDRESS_781828] al terati ons who had previously  received taxane 
therapy  and NHT wi th confirmed overall ORR of 25.6%. 
Efficacy was most notable in pat ients whose tumours harboured BRCA1/2 alterations wit h a 
confirmed ORR of 50%. The composite response in patients with deleterious or suspected 
deleterious ATM m utations was reported to be 6.7% (1/15) and the PSA decline > 50% was 
reported in one pat ient out of 15 ( De Bono et al, 2020 ). 
The GALAHAD study  of niraparib in pat ients with mCRPC and DRD demo nstrated CTC0 
and CTC conversio n of 49% (45.5% in patients with measurable disease and 55.6% in patients 
with non-measurable disease) ( Smith et al , 2020 ). The CTC conversio n in pat ients with 
measurab le disease was similar to ORR per RECIST 1.1, concluding that in patients with 
measurable and non -measurable disease, CTC is correlated with longer time on  treatment and 
prolongati on of  survival. Hence CTC conversion should be considered as a validated en dpoint 
regardl ess of m easurable or non -measurable diseases.
Clinical Study Protocol -Amendment [ADDRESS_781829] interpatient mo lecular heterogeneit y and genomic 
aberrat ions that interfere wit h DNA repair which accounts for approximately 25 to 30% of all 
sporadi c, castrati on-resistant prostate cancers ( Grasso et al, 2012 ).For mCRPC, PCWG3 
strongly  recommends incorporating molecular profiling of tumours into clini cal study  
strategies for a better understanding of the disease bio logy to identify predictors of sensit ivity 
to a specific therapy. In line with the afore mentioned, we could anticipate that patients with 
ATM altered aST and mCRP Cwoul d benefit fro m treatm ent wi th ceral asertib in this study .
A detailed description o f the chemistry , pharmaco logy, efficacy , and safet y of ceralasertib is 
provi ded in the IB.
11.2.2 Background
[IP_ADDRESS] Role of ATR
During norm al DNA replicat ion, ATR is recruited at stalled replication forks whic h can 
progress to double strand breaks if left unrepaired. ATR is also recruited to single strand DNA 
coated wi th RPA foll owing single strand DNA -damage or the resection of double strand 
breaks. Recruit ment and activat ion of ATR leads to cell cycle arrest in the S phase while the 
DNA is repaired, and the stalled replication fork resolved, or nuclear fragmentation and entry  
into programmed cell death/apoptosis ( Cimprich a nd Cortez 2008 ).
Loss of ATR funct ion leads to the inabilit y to resolve stalled replication forks, the 
accumulat ion of DNA -damage and rapid cell death exemplified by  [CONTACT_592735]. 
ATR delet ion is embryo nic lethal in mice, however se vere ATR hypo morphism is tolerated in 
humans l eading to Seckel Syndrome. Normal cells from patients with Seckel Syndrome have 
reduced ATR funct ion and show extensive DNA breaks when subjected to replicat ion stress 
(Ajani et al, 2007 , and Alderton et al, 2004 ).
[IP_ADDRESS] Disease Linkage
Hum ans wi th loss of ATM function, typi[INVESTIGATOR_592689] m utation of  ATM, suffer 
from ataxia telangiectasia and have a 37-fold increased risk of cancer. Ataxia telangiectasia 
patients have approximately  a 10% risk of developi[INVESTIGATOR_592690] ( NCI 2006 ). 
There i s also a substantial risk of breast cancer, especially in wo men less than 50 years of age 
(relative ri sk=4.94), and an excess risk of colorectal cancer (rela tive risk=2.54) and stomach 
cancer (relat ive risk=3.39) ( Thom pson et al , 2005 ). Pati ents wi th ataxia tel angiectasia show 
hypersensit ivity to radi ation.
Sporadi c ATM deficiency  is reported in many  tumour ty pes, and ATM deficiency is expected 
to sensit ise tum our cells to ATR inhibit ion through their co mplementary  roles in DNA -
damage repair. Patients with ATM -deficient m alignancies can be clinically  identifi ed and, in 
most cases, are known to have a poor prognosis with current therapi[INVESTIGATOR_014].
Clinical Study Protocol -Amendment [ADDRESS_781830] ion (Murai  et al , 2012 and Murga et al, 2011 ).
A full descript ion of non -clinical and clinical studies are presented in the IB.
11.2.3 Benefit/Risk Assessment
[IP_ADDRESS] Risk Assessment
Data from non -clinical studies and emerging data from the clinical development programme 
has not i dentified any  risks that woul d precl ude investi gation of  ceral asertib in advanced 
cancer setting and shows that ceralasert ib has a manageable safety profile in an advanced 
cancer populat ion. 
Effects on bone marrow, particularly anaemia and thrombocytopenia, are anticipated in the 
clinic and may occur in the second or third week of dosing. These events are deem ed schedule 
limit ing, rather than dose limit ing toxicit ies as the main issue is a delayed recovery of the 
platelets. My elosuppressio n has been successfully managed wit h dose interruptions, dose 
reducti ons (dose and schedule) and supportive measures such as blood transfusio ns in the 
ongoing studies. Routine monitoring of haematology  and bi ochemistry  blood counts i s 
planned.
A number of other potential risks based on toxico logy data for ceral asertib and clinical 
findings when it is used with various co mbinati ons are being m onitored in ongoing clinical  
trials. For updates on the emerging safet y data and a detailed descript ion of all potential risks 
for ceral asertib please refer to the latest ceralasertib IB . 
[IP_ADDRESS] Benefit Assessment
Ceral asertib is considered to hav e a posi tive benefit -risk profile for patients with advanced 
cancer. Preclinical data suggest that, where tumour cells are dependent upon ATR for DNA 
repai r through defects in HR or other DNA repair pathways eg ATM or BRCA mutations, 
ceral asertib select ively increase stumour sensit ivity to therapy in advance cancer patients .
Early proof  of concept data from multiple studi es has shown evidence of efficacy from ATR 
inhibit ion patients whose tumours contain ATM mutations and ATM protein loss(see 
Secti on0).Participants in this study  will benefit from  the monitoring of all AEs ari sing during 
the clinical study , related or not related to the study  interventi on. In addition, they will be 
contributing to the development of new therapi[INVESTIGATOR_592691].
Clinical Study Protocol -Amendment [ADDRESS_781831] ion11.1.3.
Figure 3 Study Design –Cohort A
1All aST, excluding participants with NSCLC and prostate cancer.
2Ceralasertib administered twice a day between Days 1 to 14 in 28 day cycles.
Abbreviations: ATM=ataxia telangiectasia mutated; BID=twice daily; IHC=immunohistochemistry; 
NSCLC=no n-small -cell lung carcinoma.
[IP_ADDRESS] Cohort B
Cohort B is recrui ting participants with ATM al tered m etastati c mCRPC (Figure 4). A total  of 
~27 molecularly eligible and centrally  confirmed participants dosed at ceralasert ib 160mg 
BID will be enro lled into Cohort B . Unfavourable CTC count requirement may be introduced 
for all part icipants to ensure adequate (approximately ≥50%) number of participants with 
CTC count ≥5/7.[ADDRESS_781832] ion11.1.3.
Figure 4 S tudy Design –Cohort B
1Unfavourable CTC count requirement may be introduced for all participants to ensure adequate (approximately 
≥ 50%) number of participants with CTC count ≥ 5/7.5 mL blood. ATM ‘deficient’ is defined as ATM IHC ≤ 5% 
ATM -positive tu mour nuclei using the Ventana assay (VENTANA ATM (Y170) RPA Assay).
2Ceralasertib administered twice a day between Days 1 to 14 in 28 day cycles.
Abbreviations: ATM=ataxia telangiectasia mutated; BID=twice daily; IHC=immunohistochemistry.
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 53of [ZIP_CODE].4.1.3 Confirmation of ATM Protein Expression and ATM Mutation Status
Parti cipants wi th deleterious or suspected deleterious ATM tumour mutations (mono or 
biallelic) will be ident ified by [CONTACT_592736] -exist ing test results of mutations in tum our 
or blood(germline or ctDNA) . Definit ions of qualifying ATM alterations include 
deleterious/suspected deleterious, pathogenic/likely  pathogenic, di sease -or cancer -associ ated 
mutati ons/variants or equivalent wording. Variants of unknown significance or benign/like ly 
benign variants are not eligible. To assist the sites, rules for determining qualifying ATM 
mutati ons are attached in Appendix K. Central  prospect ive NGS testing to determine ATM 
mutati on status for participant eligibilit y into the study  may be introduced . Sites will be 
requi red to submit a blood sample and tumour tissu e to confirm centrally  ATM mutati ons 
from local pre-exist ing tests in blood/tumour and to assess tumour ATM IHC status. To ensure 
sufficient participants are recruited with ATM IHC deficiency , prospective testing for ATM 
status by  [CONTACT_592737].
For a pre -existing NGS ATM mutation test to be acceptable for assessment of eligibilit y, it 
shoul d meet the foll owing cri teria:
1Test i s validated and conducted in a CLIA -certified (for the US sites) or with local 
accreditation laboratory  (for sites outsi de of the US).
2Meets the acceptance criteria specified by [CONTACT_4530] (details o f proposed pre -
exist ing NGS test should be provided in the NGS testing laboratory quest ionnaire for 
sponsor approval).
3Inform ation from local test resul t is provi ded, includi ng locati on where i t was perform ed, 
methodol ogy, specimen t ype and minimal data on the analyt ical performance. 
4Site agrees to provide the minimum required tumour tissue samples for central 
confirmat ion of ATM status by  [CONTACT_592738].
Provisio n of an FFPE tumour tissue sample or slides is mandatory . The definit ion of ATM -
deficient is staining of ATM protein of 0 -5% of  tumour nuclei by  [CONTACT_592739] (Y170) RPA Assay.
For parti cipants wi tha local ATM mutati on test when ATM IHC testing is retrospective, 
participants m ay proceed to Screening Part [ADDRESS_781833] interests. 
Two-step consent procedure will be implemented for all participants. Part 1 consent 
(Screening Part 1) may be taken whilst the participant is receiving a prior line of treatment. 
However, if an ATM alteration is identified, this does not guarantee a reserved participant 
place in Part 2 (Screening Part 2). Test results (from Screening Part 1) will be disclo sed after 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 56of [ZIP_CODE].5.1 Inclusion Criteria (Cohort A [aST] and Cohort B[mCRPC] )
Thescreening will have [ADDRESS_781834] submit blood 
and FFPE tumour sam plesfor central confirmat ion of ATM mutation and ATM IHC testing. 
Parti cipants will then be asked to also consent for Part 2 allowing further assessments to 
confirm study  eligibilit y.
[IP_ADDRESS] Screening Part 1 (Molecular eligibility)
Screening Part [ADDRESS_781835] submit a FFPE tumoursample for central  
confirmat ion (NGS and IHC ).
Mandatory  ATM IHC protein l oss according to central testing may  be introduced.
Screening Part [ADDRESS_781836] (excluding NSCLC) 
or mCRPC tum our.
2Parti cipants must have adeleteriousor suspected deleterious ATM mutation in tum our or 
blood (germline or ctDNA) .Definit ions of qualifying ATM mutations may include 
deleterious/suspected deleterious, pathogenic/likely  pathogenic, di sease -or cancer -
associ ated variants, or equivalent wo rding. Variants of unknown significance, benign or 
likely  beni gn al terati ons are not qualifying. To assist the sites rules for qualifying ATM 
mutati ons are attached in the Appendix K. Testing must be performed in a locally 
accredited laboratory  using a validated test in line with local regulat ions (eg, CAP/CLIA 
laboratory  where available) . Submissio n of a copy  of local test resul t is m andatory  for 
eligibilit y. 
3All participants must submit a FFPE sample for central confirmat ion of ATM IHC and 
NGS status. If retrospective testing is used ,Screening Part [ADDRESS_781837] submit a FFPE tumour sample for central confirmat ion of ATM IHC 
and NGS status at Screening Part 1 and wait for the result before proceeding to Screening 
Part 2. For the specific tumour sample requirements please refer to the respective 
Screening Part 2 inclusio n criteria.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 57of [ZIP_CODE].5.1.2 Screening Part 2 (Study eligibility)
Parti cipants m ust m eet the eli gibili ty criteria described in the core module for all participants
(Secti on5.1)and those listed below . 
Type of Participant and Disease Characteristics
1Parti cipants who have no standard treatm ent opti onsavailable or in whom the standard 
treatm ent opti ons are contraindicated .
2Eastern Cooperative Oncology  Group perform ance status of 0 to 2.
3Life expectancy  ≥[ADDRESS_781838] dose 
of study  intervent ion as defi ned bel ow: 
(a)Haem oglobin ≥9.0g/dL with no blood transfusio ns (packed red blood cells) in the 
past [ADDRESS_781839] been receiving it for more than one 
month at the time study  intervent ion is started.
(b)Absolute neutrophil count ≥1.5 × 109/L.
(c)Platelet coun t ≥100 × 109/L with no platelet transfusions in the past  28days.
(d)Total  bilirubin ≤1.5 × institutional ULN unless the participant has document ed 
Gilbert’s Syndrome in which case it must be ≤ 3 × inst itutional ULN .
(e)Aspartate aminotransferase/alanine aminotransferase ≤2.5 × inst itutional ULN unless 
liver m etastases are present in which case they  must be ≤5 × ULN.
(f)Parti cipants m ust have creatinin e clearance of ≥45mL/min est imated or measured 
using standard methodology  at the investigating sit e (ie, Cockcroft -Gault, 
Modificat ion of Diet in Renal Disease, chronic kidney disease Epi[INVESTIGATOR_454832], ethylenediaminetetraacetic acid or 24 hour urine): 
Estimated CrCl= (140-age [y ears]) × wei ght (kg)(× 0.85)
serum  creat inine (mg/dL) × [ADDRESS_781840] be able to swallow tablets whole.
In addit ion, parti cipants are eligible to be included in Cohort A and Cohort B only if all o f the 
following criteria apply , respectively .
[IP_ADDRESS] Cohort A–aST
1Parti cipants m ust fulfil all  the core and Module [ADDRESS_781841] (excluding participants with NSCLC and 
prostate cancer ). 
4Measurable disease by [CONTACT_393] 1.1 criteria .
5Radiological evidence of disease progression on previous treatm ent prior to study  entry .
[IP_ADDRESS] Cohort B–mCRPC
1Parti cipants m ust fulfil all  the core and Module [ADDRESS_781842] one NHA (eg, abiraterone acetate , 
apalutamide, and/or enzalutamide) and at least one taxane regimen for the treatm ent of 
prostate cancer (unless the parti cipant has contraindi cations to taxanes) . 
4Parti cipants wi th histol ogically confirmed metastatic cas trate resi stant prostate cancer. 
Parti cipants whose di sease spread is limited to regional pelvic lymph nodes or local 
recurrence (eg, bladder, rectum ) are not eligible.
5Docum ented prostate cancer progression at study  entry  while on androgen deprivat ion or 
after bilateral  orchi ectomy as assessed by  [CONTACT_592740]:
Radiographic progressi on based on PCWG3 criteria.
PSA progression defined by a minimum o f 3 rising PSA l evels wit h an interval o f ≥1 
week between each determina tion. The PSA value at the Screening Part 2 visit should 
be ≥2ng/mL; participants receiving systemic gl ucoc orticoids for con trol of 
symptoms must have documented progression while on systemic glucocortico ids 
prior to commencing Cycle 1 Day 1 of study  intervent ion.
6One or both of the fo llowing:
Measurable disease according to RECIST 1.1 (except bone lesio ns).
Unfavourable CTC count ( ≥5/7.5 mL blood) according to local or central test. 
Submissio n of a copy  of the test resul t is m andatory  for eligibili ty. [Unfavourable 
CTC count requirement for all participants by [CONTACT_592741] (approximately ≥50%) number of participants with 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 59of 170CTC count ≥5/7.5 mL blood.]. If participant has no measurable disease, then 
prospect ive testing may be done in order for participant to enrol.
7Serum  testosterone levels ≤50ng/dL ( ≤1.75 nmol/L) within ( ≤) 28 day s before 
enrolment (not required for participants after bilateral orchiectomy) .
8Parti cipants wi thout pri or surgical  castrati on must be current ly taking for at least 4 weeks 
and willing to continue LHRH analog (agonist or antagonist) therapy  throughout the 
durati on of  study  intervent ion peri od.
11.5.2 Exclusion Criteria (Cohort A [aST] and Cohort B[mCRPC] )
Parti cipants m ust m eet the eli gibilit y criteria described in the core module for all participants 
(Secti on5.2)and those listed below .
Medical Conditions
1Any of the fo llowing ca rdiac diseases current ly or within the last 6 months:
Unstable angina pectoris.
Congest ive heart failure >Class 2 as defined by [CONTACT_89792] 
(see Appendix C).
Acute my ocardial  infarct ion.
Significant ventricular or supraventricular arrhy thmias (participants with chronic 
rate-controlled atrial fibrillat ion in the absence o f other cardiac abnormalit ies are 
eligible).
Mean resting corrected QT interval (QTc) > 470msec obtained fro m 
3electrocardi ograms (ECGs) in 24 hours using the Fredericia formula.
Any factors that increase the risk o f QTc prol ongati on or risk of arrhy thmic events 
such as heart failure, hypokalaemia, congenital long QT syndro me, immediate family 
history  of long QT syndrom e or unexplained sudden death under 40 y ears of age.
For Cohort B (m CRPC), surgery  or local prostatic intervent ion (excluding a prostatic 
biopsy) within [ADDRESS_781843] ions (ie, hepati tis B or C, tuberculosis, or COVID -
19).
3Parti cipants consi dered a poor m edical  risk due to a seri ous, uncontrolled medical 
disorder, non -malignant systemic disease or active, uncontrolled infection.
Examples include, bu t are not limited to, uncontrolled ventricular arrhy thmia, recent 
(within 3 months) my ocardial  infarcti on, uncontrolled major seizure disorder, 
unstable spi[INVESTIGATOR_53894] n, superior vena cava syndro me, extensive interstit ial 
bilateral  lung disease on high reso lution CT scan or any  psychiatri c disorder that 
prohibits obtaining informed consent, and any other medical condit ion that, in the 
opi[INVESTIGATOR_3078] n of the invest igator, places the participant at unacceptable risk of toxicit y.
Clinical Study Protocol -Amend ment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 60of 1704Parti cipants wi th symptom atic and/or uncontrolled brain metastases.
A contrast enhanced CT brain scan (MRI where CT is contraindicated), to confirm 
the absence of brain metastases is part of baseline disease assessment for participants 
with aST. If new asymptom atic brain metastases are discovered, an interval  scan 
(minimum 4 weeks) shoul d be conducted to confirm the new brain lesio ns are not 
progressing and do not require local CNS -directed therapy .If local treatm ent is 
necessary , this shoul d occur before study  entry . 
Parti cipants wi th spi[INVESTIGATOR_53894] n unless considered to have received 
definit ive treatment for this and evidence of clinically SD for 28 days.
Participants who have experienced a seizure or seizures within 6 mo nths of study  
intervent ion or who are currently  being treated wi th cytochrom e P450 enzyme 
inducing anti -epi[INVESTIGATOR_592692] (use of ant i-epi[INVESTIGATOR_592693]3A4 induct ion -phenytoin, carbamazepi[INVESTIGATOR_050], p henobarbital ).
Parti cipants wi th a history  of treated CNS metastases are eligible, provided they meet 
all of the following cri teria: Di sease outsi de the CNS is present. No clinical evidence 
of progressi on since com pletion of CNS -directed therapy. Minimum o f 3weeks 
between complet ion of radiotherapy  and Cycle 1 Day 1 and recovery  (Grade ≤1) 
from significant acute toxicit y with no ongoing requirement for > 10mg of 
prednisone per day  or an equivalent dose of other corticosteroid. If on corticosteroids, 
the participant should be receiving a stable dose of corticosteroids, started at least 
4weeks prior to study  interventi on.
4aParti cipants wi th INR ≥1.5 (e xcept those who receive vi tamin K antagoni stsand direct 
factor Xa inhibitors ) or with other evidence o f impaired hepat ic synt hesis funct ion.
Prior/Concomitant Therapy (see Appendix D)
5Previous therapy  with an ATR inhibitor.
6Any systemic ant i-cancer t herapy wit hin 14 days or 5 half -lives (whichever is longer) of 
Cycle 1 Day 1. For biological therapeut ics,including monoclonal ant ibodies and vaccines 
(eg,Sipuleucel -T),the minimum washout period shall be [ADDRESS_781844] 5 days prior to study intervent ion.
Agents such as 5α -reductase inhibitors (finasteride, dutasteride), oestrogen 
compound s (including estramustine) and megesterol are considered as ant i-cancer 
agent in prostate cancer and prohibited within 14 days or 5 half -lives (whichever is 
longer) prior to study  interventi on. Ongo ing treatment with LHRH analogs for 
prostate cancer are required in absence of prior bilateral orchiectomy .
7Exposure to a small mo lecule IP within 14 days or 5 half -lives (whichever is lo nger) prior 
to Cy cle1 Day 1.
Clinical Study Protocol -Amendment [ADDRESS_781845] dose 
of study  intervent ion, wi th the except ion of participants receiving radiat ion to m ore than 
30% of the bone marrow or with a wide field of radiat ion who should not start study  
intervent ion within 21 days after radiat ion.
9Concomitant use of known strong CYP 3A inhibit ors (eg i traconazol e, teli thromycin, 
clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, 
saquinavir, nelfinavir, boceprevir, telaprevir) ( Table 14). The required washout period 
prior to starting study  intervent ion is 2weeks. 
10Concomitant use of known strong CYP 3A inducers (eg phenobarbital, enzalutamide, 
phenyto in, rifampi[INVESTIGATOR_2513], rifabutin, rifapent ine, carbamazepi[INVESTIGATOR_050], nevirapi[INVESTIGATOR_3923] ’s 
Wort) (Table 14). The requi red washout peri od prior to starti ng study  interventi on is 
5weeks for enzalutamide or phenobarbita l and 3 weeks for other agents.
11.5.3 Lifestyle Considerations
[IP_ADDRESS] Meals and Dietary Restrictions
Parti cipants m ust fast (water to drink only) from at least [ADDRESS_781846] -dose for all doses.
Parti cipants shoul d avoi d conco mitant drugs, herbal supplements and/or ingest ion of foods 
known to modulate CYP3A4 activit y (See Section 11.6.5 and Appendix D).
[IP_ADDRESS] Skin
Study  intervent ion may increase the skin’s sensit ivity to sunlight, whi ch may  resul t in 
sunburn. Participants should therefore take appropriate precautions whe n out in the sun (eg 
limit exposure, wear appropriate clothing [hat and sunglasses] and use sunscreen).
[IP_ADDRESS] Contraception
Please refer to the core protocol (Section 5.3.1 ).
11.5.4 Screen Failures
Screen failures are defined as part icipants who consent to participate in Screening Part 1 
(molecular eligibilit y) and who are not subsequent ly entered in Screening Part 2 (study 
eligibilit y) or parti cipants who consent to parti cipate in Screening Part 2 (study  eligibilit y) but 
are not subsequent ly entered in the study .
Parti cipants will only  receive their central  molecular test results (from Screening Part 1) after 
they have been confirmed ineligible at Screening Part [ADDRESS_781847] concluded their participation 
in the study .
Please refer to the core protocol for further details (Secti on5.4).
Clinical Study Protocol -Amendment [ADDRESS_781848] igational intervent ion(s) or marketed product(s) 
intended to be administered to a study  parti cipant according to the study  protocol .
11.6.1 Study Intervention Administered
Eligible participants will receive study  intervent ion as described in Table 7. For both Cohort s
A and B, study  intervent ion will be administered by [CONTACT_592742] a day  between Day 1 and 
Day 14 in 28daycycles. Study  interventi on will  be di spensed and returned as shown in the 
SoA (Section 11.1.3 ).
Table 7 Investigational Products
ARM Name [CONTACT_99213]6738
Intervention Name [CONTACT_592781](s)AZD6738 tablets 20 mg or 80 mg
Dosage Level(s) 160mg twice daily *
Route of 
AdministrationOral
Use Experimental
Sourcing [COMPANY_008] R&D
Packaging and 
LabellingStudy intervention will be provided in high density polyethylene (HDPE) 
bottles. Each bottle will be labelled in accordance with Good Manufacturing 
Practice Annex 13 and per country regulatory requirements.
*[COMPANY_008] elected to reduce the starting dose of ceralasertib from [ADDRESS_781849] completed Cycle 1 and Cycle 2 without severe 
haematological toxicity or SAEs and are deemed to be benefitting from treatment, may continue on the current 
dose of 240 mg BD 2 weeks on /2 weeks o ff at the investigator’s discretion.
Abbreviations: BID=twice daily; SAE=serious adverse events.
11.6.2 Preparation/Handling/Storage/Accountability of Interventions
1Study  intervent ion will be supplied by [CONTACT_38227] R&D supply chain as individual 
bottles of tabl ets. Addi tional informat ion about study  intervent ion may be found in the 
Invest igator Brochure.
2Labels will be prepared in accordance wit h Good Manufacturing Practice and local 
regul atory  guidelines by  [CONTACT_38227] R&D supply chain. The labels will fulfil Good 
Clinical Study Protocol -Amendment [ADDRESS_781850] been 
maintained during transit for all study  intervent ion received and any  discrepancies are 
reported and resolved before use of the study  intervent ion.
4Only participants enro lled in the study  may receive study  intervent ion and only authorised 
site staff may supply or administer study  intervent ion(after instruct ion of medical team 
participants shoul d not take thei r study  intervent ion unt il authorised by [CONTACT_77947] ). All 
study  interventi on must be stored in a secure, environmentally  controlled, and m onitored 
(manual  or autom ated) area i n accordance with the labell ed storage condit ions wit h access 
limited to the investigator and authorised site staff.
5The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and reco rd maintenance 
(ie, recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi ded in the Pharmacy Manual.
11.6.3 Measures to Minimise Bias: Randomisation and Blinding
This is a modular, open -label study . Modul e1 is a non -rando mised, monotherapy , [ADDRESS_781851] questi oning 
and count ing of returned tablets during the site visits and documented in the source documents 
and eCRF. Deviat ion(s) fro m the prescribed dosage regimen should be recorded in the eCRF.
A record of the numb er of study  intervent ion tablets di spensed to and taken by  [CONTACT_37117] m ust be m aintained and reconciled wit h study  intervent ion and compliance 
records. Intervention start and stop dates, including dates for intervent ion delays and/or dose 
reducti ons will also be recorded in the eCRF.
Overdose is described in Section 8.4.
11.6.[ADDRESS_781852] abstain from  taking prescript ion or non -prescri ption drugs (including 
vitamins and di etary  or herbal  supplements) wi thin 7 days (or 14 day s if the drug is a potential 
enzyme inducer) or 5 half -lives (whichever is longer) before the start of study  intervent ion 
until completion of the fo llow-up visit, unless, in the opi[INVESTIGATOR_1649] o f the invest igator and sponsor, 
the medicat ion will not interfere with the study .
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 64of 170Any medicat ion or vaccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) that the participant is re ceiving at the time of enrolment or 
receives during the study  must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
The Medical Monitor should be contact[CONTACT_88451] e are any  questi ons regarding conco mitant or 
prior therapy .
If medically feasible participants taking regular medicat ion, wi th the excepti on of  potent 
inhibitors or inducers of CYP3A, should be maintained on it throughout the study  period.
Pre-medication
Anti -emetic treatment: No primary  prophylactic treatm ent wi th anti-emetics is advised. 
However, anti -emet ic treatm ent may be administered as secondary  prophylaxis or 
treatm ent according to the guidelines of the participating sites. Please note: aprepi[INVESTIGATOR_053] 
(Emend®) is a substrate, moderate inhibitor and inducer of CYP3A4 and also an inducer 
of CYP2C9.
Therefore, the use of aprepi[INVESTIGATOR_592694]. In general, drugs tha t interfere 
with CYP3A4 are not allowed in this study , and aprepi [INVESTIGATOR_592695]. For 
further informat ion about CYP3A4, CYP2C9 or prohibited/allowed medicat ion in this 
study , see Appendix D.
Supportive care
Parti cipants will be permitted to receive appropriate supportive care measures as deemed 
necessary  by [CONTACT_592743]:
Diarrhoea: Diarrhoea should be treated prompt ly with appropri ate supporti ve care, 
including administration of an anti -diarrheal  agent according to standard practice 
guidelines. Anti -diarrheal  agents shoul d not be taken prophylactically . Parti cipants shoul d
be instructed to begin taking ant i-diarrheal  medicati on at the first si gn of : 1) poorly 
formed or l oose stool , 2) occurrence of more bowel mo vements than usual in one day  or 
3) unusually  high vol ume of  stool . Ant i-diarrheal  agents shoul d be deferred if bl ood or 
mucus i s present in the stool or if diarrhoea is accompanied by  [CONTACT_411]. In thi s setting, 
appropriate diagnostic microbio logic specimens should be obtained to exclude an 
infect ious aeti ology. Parti cipants shoul d also be advised to drink liberal quant ities of clear 
fluids to hel p prevent dehydrat ion.
Nausea/vomiting: Nausea and vo miting should be treated adequately , and strong 
consideration should be given to the administration of secondary  prophylactic ant i-emet ic 
Clinical Study Protocol -Amendment [ADDRESS_781853] institut ional practice. Participants should be strongly  
encouraged to maintain liberal oral fluid intake. Supportive care with aprepi[INVESTIGATOR_053] (a 
CYP3A4 inhibitor / inducer / substrate) according to institutional guidelines in the 
context of standard of care chemothera py is NOT allowed. See Appendix D.
Anaemia: Transfusio ns and/or ery thropoi etin may be utilised as clinically indicated for 
the treatment of anaemia but shoul d be clearly  noted as concurrent medicat ions. No bl ood 
transfusio ns in the [ADDRESS_781854] dose is allowed .
Neutropaenia: Colony-stimulat ing factors including G -CSF, pegylated G -CSF or GM -
CSF according to Institutional Standards, fo llowing discussio n with the Principal 
Invest igator and [COMPANY_008] .
Blood transfusio ns are allowed at any  time during the study .
Avoid conco mitant m edicat ions, herbal supplements and/or ingestion of foods that 
significant ly modulate CYP3A4 or Pgp activit y (see Appendix D). Note these include 
commo n azo le antifungals, macrolide ant ibiotics, etc. For participants receiving study 
intervent ion in the absence of d iscont inuat ion criteria, if the invest igator feels that 
concomitant administration o f medications, herbal supplements or foods that significant ly 
modulate CYP3A4 act ivity is necessary based upon medical judgement, such products 
may be administered with cau tion following discussion between the invest igator and the 
sponsor Study  Physician.
Concomitant medicat ion may be given as medically indicated with the fo llowing exceptions.
[IP_ADDRESS] Therapy that may NOT be administered
No other anti -cancer therapy  (chem otherapy , immunotherapy , horm onal therapy  [LHRH 
analogues in prostate cancer and hormone replacement therapy  are acceptable ], biological  
therapy  or other novel  agent) for the disease under study is to be permitted while the 
participant is receiving study  intervent ion.
Live attenuated virus and bacterial vaccines should not be administered, eg yello w fever, 
measles, influenza, rubella, mumps, ty phoid, mycobacteri um tubercul osis (BCG), Yersinia 
pestis (EV). An increased risk of infection by [CONTACT_592744] h conventional chemotherapy and the effects with ceralasertib are unknown. The 
administration of killed vaccines is allowed. Examples of killed vaccines are cho lera, bubonic 
plague, polio vaccine, hepatit is A and rabies.
[IP_ADDRESS] Drug -Drug Interaction Between Ceralasertib and Other Drugs
Ceral asertib i s an invest igational drug for which no data on in vivo interactions are currently 
available. Potential interaction and guidelines belo w are considered on the basis of preclinical 
in vitro data only. 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 66of 170The lists of CYP and transporter inhibitors/inducers, and CYP and transporter substrates are 
available in Appendix D. They  are not exhaust ive and the absence o f a drug from these lists 
does not imply that its combinat ion with ceralasertib is safe. If ceralasert ib is being 
administered in combinat ion, potenti al interact ions of the combinat ion partner should also be 
considered.
Restrictions regarding drugs affecting CYP metabolism 
The principal enzyme for metabo lising ceralasertib is CYP3A4. Participants should avo id 
concomitant drugs, herbal supplements, and/ or ingestion o f foods known to modulate 
CYP3A4 act ivity from  the time they  enter the screening period unt il [ADDRESS_781855] 
dose of study  intervent ion.
Prior to study  intervent ion, use of potent inducers or inhibitors of CYP3A are not 
permitted . Forparticipants taking any o f these drugs (examples provided in 
Appendix D) the requi red washout periods before starting ceralasert ibis five 
half-lives; except for St. John’s wort, which is 3 weeks.
On study  intervent ion, if there is no suitable alternative conco mitant m edicati on other 
than a potent inhibitor of CYP3A, the invest igator must interrupt ceralasert ibfor the 
durati on of  the potent CYP3A inhibitor and wait for the required washout period 
(five half -lives) before dosing ceralasertib again. If potent CYP3A inducers are 
considered necessary  for the participant’s safet y and welfare, this may diminish the 
clinical efficacy o f ceral asertib and the participant should be monitored carefully for 
any change in the efficacy  of study intervent ion. Refer to Appendix Dfor addi tional 
guidance.
The use of any  herbal supplements or ‘fo lk remedies’ (and medicat ions and foods 
that significantly modulate CYP3A activit y) should be discouraged. If deemed 
necessary , such products m ay be administered with caut ion and the reason for use 
docum ented in the eCRF.
In vitro data also suggest that ceralasertib may be metabo lised by [CONTACT_097]2C8 but a lesser 
extent, therefore caution should be applied wit h co-administration o f potent i nhibitors or 
inducers o f CYP2C8 (examples provided in Appendix D).
Drugs known to be inhibitors or inducers of Pgp and/or BCRP, undertake 
appropriate monitoring if co -administration is necessary 
-Ceral asertib i s also a P -gp substrate. Co -administration of P -gp inhibitors or inducers 
may affect exposure to ceralasert ib and therefore should not be co -administered with 
ceral asertib. If the use of any inhibitors or inducers of P -gp are c onsidered necessary  
for the parti cipant’s safet y and welfare, the invest igator must contact [CONTACT_592745] a decisio n to allow the participant to continue in the study  will be made on a case -
by-case basis.
Clinical Study Protocol -Amendment [ADDRESS_781856] exposure to ceralasert ib; therefore, it is recommended that the invest igators 
must interrupt ceralasert ib for the duration of the BCRP inhibitor or inducer and wait 
for the requi red washout period of the BCRP modulator (five half -lives) before dosing 
ceral asertib again. 
Drugs known to be substrates of CYP3A4 and/or CYP2B6, undertake appropriate 
monitoring if co -administration is necessary 
Ceral asertib is a potential inducer of CYP3A4 and CYP2B6. Caution shoul d be applied 
with co-administration of drugs that are either co mpletely metabo lised by [CONTACT_097]3A4 and/or 
CYP2B6, or that are CYP3A4 and/or CYP2B6 substrates and also have a narrow 
therapeuti c index. Invest igators should be aware that the exposure of othe r drugs 
metabo lised by [CONTACT_097]3A4 and/or CYP2B6 may be reduced.
Drugs known to be substrates of OATP1B1 and BCRP, undertake appropriate 
monitoring if co -administration is necessary 
Ceral asertib is an inhibitor of OATP1B1 and BCRP. Co -administration of substrates of 
OATP1B1 and/or BCRP may affect exposure to ceralasertib ; therefore, it is 
recommended that caution should be applied when such drugs are to be administered with 
ceral asertib .
Anticoag ulation therapy
Parti cipants on warfarin may  parti cipate in thi s study  but i t is recommended that their INR 
is monitored m ore frequently.
11.6.6 Dose Modification
[IP_ADDRESS] General Guidance
Any clinically  significant and/or unacceptable toxicit y observed during the course of the study  
shoul d be managed by [CONTACT_592746] , dose 
reducti ons if necessary ,and administration of supportive therapy .
If the toxicit y reso lves or reverts to ≤ CTCAEv5 Grade 1 or 2 (depending on the toxicity, see 
Table 8) treatm ent wi th study  interventi on may be restarted using the rules in Table 8and 
Table 9for dose m odificat ions. Parti cipants who have their dose previously reduced to the 
lowest possible dose and who have demonstrated an acceptable response to the dose 
interrupti on may  be permitted to restart at the lowest dose level at the discret ion of the 
investi gator.  
If the toxi city does not resolve to ≤ CTCAEv5 Grade 1 or 2 ( depending on the toxicit y)or the 
participant is not showing clinical benefit, then the participant should be discont inued from 
study  interventi on and observed until resolut ion of the toxicit y.
Clinical Study Protocol -Amendment [ADDRESS_781857] not be adjusted under any  other ci rcumstances unless 
prior agreem ent is given by  [CONTACT_456]. 
All dose modificat ions and interruptions (including any missed doses) and the reasons for the 
modificati ons/interrupti ons are to be r ecorded in the eCRF.
[IP_ADDRESS] Guidance for Dose Modification and Interruption
Refer to Table 8and Table 9for dose modificat ion and stoppi [INVESTIGATOR_33084]. Once dose is 
reduced, escalat ion is not permitted.
Parti cipants wi th ≥ G3 anaemia , neutropeni a, thrombocy topenia during Cycle 1 and Cycle 2 
will be requi red to attend for addi tional Day  8 and Day  14 assessments unt il there is no 
evidence of ≥ G3 anaemia , neutropeni a, thrombocy topenia for at l east 2 cy cles. Parti cipants 
who develop a ≥ G3 anaemia , neutropeni a, throm bocy topeni a later in their treatment , will also 
need to have addit ional Day  8 and Day  14 assessments unt il there is no evidence of ≥ G3 
anaemia , neutropeni a, thrombocy topeni a for at l east 2 cy cles.
Table 8 Guidance for Dose Modifications , Interruption s and Discontinua tions
for Ceralasertib
Event Action
Grade 1 neutropenia and/or thrombocytopenia Ceralasertib dosing may continue if neutrophil count 
is ≥1500/mm3 and/or platelet count is ≥75,000/mm3. 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 69of 170Event Action
Grade 1 -2 toxicities (except neutropenia and 
thrombocytopenia)Investigator decision whether to interrupt ceralasertib 
(max 28 days) or continue treatment. Treatment may 
be resumed at the same dose level or with a dose 
reductio n by 1 level. For prolonged (>2 weeks) or 
persistent Grade 2 toxicity (>28 days) that does n ot 
respond to supportive treatment, ceralasertib should 
be interrupted and restarted at lower dose.
Grade 2 neutropenia or 
Grade 3 anaemiaInterrupt ceralasertib (max 28 days) and give 
appropriate supportive treatment e.g. transfusion, 
until AE improves to at least neutrophil count 
≥1500/mm3and haemoglobin ≥8.0 g/dL, then restart 
reducing the dose of ceralasertib by [ADDRESS_781858] occurrence
Interrupt ceralasertib (max 28 days) and give 
appropriate supportive treatment until platelets 
improve to at least ≥100,000/mm3. At resolution, it 
is not mandatory to lower the dose as blood counts 
may recover during the “off period” on the 
intermittent schedule. If blood counts do not recover 
by [CONTACT_592747], ceralasertib 
should be restarted with a dose reduction by 1 level 
for ceralasertib.
Subsequent occurrences
Interrupt ceralasertib (max 28 days ) and give 
appropriate supportive treatment. Treatment may be 
restarted with a reduced dose of ceralasertib when the 
toxicity is resolved or investigator discretion to stop 
treatment.
Grade 4 thrombocytopenia Interrupt ceralasertib (max 28 days) and give 
appropriate supportive treatment; investigator 
discretio n on whether to restart treatment with a dose 
reductio n by 1 dose leve lceralasertib when the 
platelet count has recovered to ≥100,000/mm3or 
stop treatment.
If a second Grade [ADDRESS_781859] be stopped.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 70of 170Event Action
Grade 3 -4 toxicity
(including Grade 3 -4 neutropenia or
Grade 4 anaemia)
Excludes Grade 3 anaemia or
Grade 3 -4 thrombocytopenia (see above )First occurrence
Interrupt ceralasertib (max 28 days) and give 
appropriate supportive treatment; restart treatment 
with a dose reduction by 1 level for ceralasertib when 
the toxicity is resolved (Grade 1 or 2 depending on 
the toxicity or returns to baseline).
Subsequent occurrences
In case of haematological toxicity or Grade 3 non 
haematological toxicity, i nvestigator discretion on 
whether to interrupt ceralasertib (max 28 days) or to 
stop treatment. Restart treatment with a dose 
reductio n by [ADDRESS_781860] tablets can be counted. Resume with the 
following schedul ed dose.
Missed dose Allowed to take the scheduled dose up to 2 hours 
after the scheduled dose time. If greater than 2 hours, 
the missed dose should not be taken, and participant 
should continue with next dose at allotted time.
1This table is for guidance. Therefore, for example, it may be deemed appropriate by [CONTACT_592748].
Table 9 Dose Reduction Leve ls for Ceralasertib
Initial dose 160 mg BID days 1 -14
Level 1 dose reduction 120 mg BID days 1 -14
Level 2 dose reduction 80 mg BID days 1 -14
Level 3 dose reduction Stop treatment
*[COMPANY_008] elected to reduce the starting dose of ceralasertib from 240 mg B ID to 160 mg B ID with protocol 
amendment 2. For any pa rticipant continuing at 240 mg BID 2 weeks on / 2 weeks off at the investigator ’s 
discretio n), the ceralasertib dose should be reduced to 160 mg BID days 1 -14 (‘initial dose ’) and thereafter 
follow the dose reduction levels as tabulated.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 71of 170Abbreviations: BID=twice daily; SAE=serious adverse events.
[IP_ADDRESS] Individual Stoppi[INVESTIGATOR_592696] 
20mmHg in systolic BP to below [ADDRESS_781861] or ALP* > [ADDRESS_781862] or ALP* > [ADDRESS_781863] with the appearance o f symptoms ass ociated wi th a clinical 
diagnosis of hepat itis including right upper quadrant pain or tenderness, fever, rash or 
eosinophilia (> 5%).
[ALT or AST > [ADDRESS_781864]] and [total bilirubin > [ADDRESS_781865] or INR+> 1.[ADDRESS_781866] ion of the liver].
* In the presence of bone metastases bone specific iso form of raised ALP in the presence of a 
raised gamma -GT (to ensure the ALP change is specific to the liver).
+Unless participant is receiving warfarin or other vi tamin K antagoni sts,or direct factor Xa 
inhibitors .
Please refer to Appendix E“Acti ons Requi red in Cases of Increases in Liver Biochemistry  
and Evaluat ion of Hy’s Law.”
11.6.7 Intervention after the Final DCO
Patients still receiving IP at the time of final analysis DCO may  continue to receive study
treatm ent wi thin the study . Pati ents will  continue to attend study  visits as per SoA, section 
11.1.3,  Table 3,witha reduced number of assessments :
Physical Examinat ion including weight
Vital signs
Com plete bl ood count and other clinical safet y laboratory  assessments 
Pregnancy test (WOCBP only)
Dosing wit h Ceralasert ib
Adverse events (AE)
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 72of 170TheInvesti gator will continue to monitor the patient’s safet y laboratory  resul ts pri or to and
periodically  during treatm ent in order to manage AEs in accordance with the dose
modificati on and stoppi[INVESTIGATOR_592697] (see sect ion 11.6.6 ). 
All data f rom thesafet y assessments willbe recorded in the patient’s medical records with the
following being reported to Astra Zeneca , as applicable :
SAEs and AESIs
Pregnancy
Overdos es
For these patients ongoing at the time of final analysis DCO, tumour assessment and bone 
scans will be perfo rmed as per standard of care frequency , but as wi th safet y assessments ,
these data will not be reported to [COMPANY_008] .
11.7 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL -
MODULE 1
Please refer to the core protocol (Section 6.1). 
Patients m ay receive study  intervent ionuntil objective disease progression, or as long as they 
are conti nuing to show clinical benefit, as judged by [CONTACT_093], or treatment 
discontinuat ion criteria are m et.
Any participant who permanently discont inues study  intervent ion shoul d be f ollowed up till 
the safet y follow-up visit (see fo llow-up Secti on7.3) and unt il radiographic disease 
progression is registered and confirmed where necessary according to the protocol 
requi rements.
The SoA (Section 11.1.3 ) details the data to be collected at the time of study  intervent ion 
discontinuat ion, and for any  further evaluat ions that need to be completed.
11.8 MODULE ASSESSMENTS AND PROCEDURES -MODULE 1
Study  procedures and their timing are summarised in the SoA ( Table 3).
The m aximum  amount of  blood collected from  each parti cipant over the d uration of the study , 
including any  extra assessments that may be required, will not exceed 300mL (over a 1 -
month peri od). Repeat or unscheduled samples may be taken for safet y reasons or for 
technical issues wit h the samples.
11.8.1 Efficacy Assess ments
In Cohort A ( aST) any tumour lesions will be assessed by [CONTACT_393] 1.1 criteria.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D533 9C00001
CONFIDENTIAL AND PROPRIETARY 73of 170In Cohort B (prostate cancer) soft tissue and visceral lesio ns will be assessed by  [CONTACT_393] 1.[ADDRESS_781867] 1.1
soft tissue assessment.
[IP_ADDRESS] Tumour Assessments
RECIST 1.[ADDRESS_781868] scan, assessment of the brain should be included. Follow-up assessments should 
be perform ed every  8 weeks (± 1 week) for 1year and thereafter every 12 weeks (± 1 week) 
after the start of study  intervent ion unt il objective disease progression by [CONTACT_393] 1.1 (in 
Cohort B RECIST 1.1 for soft tissue and visceral lesio ns and by [CONTACT_43877]3 cri teria for bone 
lesions) or withdrawal of consent.
If a participant discont inues study  intervent ion (and/or receives a subsequent ant i-cancer 
therapy ) prior to obj ective radiographic disease progressi on regi stered according to the 
protocol  requi rements , then the participant should sti ll continue to be fo llowed unt il object ive 
radiographic disease progressi on.
Any other sites at which new disease is suspected should also be appropriately imaged. If an 
unscheduled assessment is performed and the participant has not progressed, every atte mpt 
shoul d be made to perform  subsequent assessments at the scheduled visits whilst the 
participant rem ains on study  intervent ion.
Categorisat ion of object ive tumour response assessment will be based on the RECIST 1.1 
guidelines for response: CR, PR, SD, a nd PD.
For parti cipants who only have non -measurable disease at baseline, categorisat ion of objective 
tumour response assessment will be based on the RECIST 1.1 guidelines for response for 
NTLs: CR, PD and Non -CR/Non -PD.
If the invest igator is in doubt as to whether progression has occurred, particularly wit h 
response to NTLs or the appearance o f a new lesio n, it is advisable to continue study  
intervent ion and reassess the participant’s status at the next scheduled assessment or sooner if 
clinically indicat ed.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 74of 170To achieve ‘unequivocal progression’ on the basis of non -target di sease, there m ust be an 
overall level o f substant ial worsening in non -target disease such that, even in presence of SD 
or PR in target disease, the overall tumour burden has increased su fficient ly to merit 
discontinuat ion of therapy . A modest ‘increase’ in the size of one or more NTLs is usually not 
sufficient to qualify for unequivocal disease progressio n status.
Frequency will be adjusted after 56weeks of treatment if the tumour is not changing in size 
(SD, PR or CR) and will occur every 12 weeks (±1 week). 
It is important to follow the assessment schedule as closely  as possible. Pl ease refer to the 
SoAs (Secti on11.1.3 ) and Appendix F.
[IP_ADDRESS] Cohort B
Bone lesions assessment in Cohort B (mCRPC) (Based on PCWG3 Criteria)
Object ive tumour response criteria for bone lesio ns using PCWG3 criteria are presented in 
Appendix Gof this Clinical Study Protocol .
Bone lesions will be assessed by [CONTACT_592749]-99 
(bone scans). Bone lesio ns will be assessed by [CONTACT_592750] 
1.1 m alignant soft ti ssue assessment. The definit ion for bone progression is bas ed on PCWG3 
criteria. Posi tive hot spots on the bone scan should be considered significant and unequivocal 
sites of  malignant di sease to be recorded as metastatic bone lesio ns.
Progression on a bone scan is defined as:
At the 8 -week scan:
If [ADDRESS_781869] 8 -week scan, the 
confirmatory  scan perform ed (at l east 6 weeks l ater), m ust show 2 or more 
additional new metastatic bone lesio ns (for a total of 4 or more new metastati c bone 
lesions since the baseline ass essment). 
Note -The first bone scan completed after baseline will be considered the ‘8 -week 
scan’ regardless if taken at Week8 or at an unscheduled assessment. 
After the 8 -week scan:
For participants without progression at the [ADDRESS_781870] 8 -week assessment (compared to Week8 scan), a 
confirmatory  scan perform ed at least [ADDRESS_781871] scan document ing the 2 new lesio ns. If the 
investi gator i s in doubt as to whether progression has occurred, it is advisable to continue 
study  interventi on and reassess the bone lesio n status at the next sche duled assessment, or 
sooner if clinically  indicated.  
The requi rements for determinat ion and confirmat ion of radiographic progression by [CONTACT_592751] (bone progression) or CT/MRI (soft tissue progression) are summari sed in 
Table 10.
Table [ADDRESS_781872] 1.1.
No confirmation scan required.
Abbreviations: C T=computed tomography; MRI=magnetic resonance imaging; RECIST=Response Evaluation 
Criteria in Solid tumours .
It is important to follow the assessment schedule as closely  as possible. Please refer to the 
SoA (Section 11.1.3 )and Appendix G.
Prostate Specific Antigen
Blood sam ple will  be taken as det ailed in the SoA (Section 11.1.3 ). For informat ion on sample 
processing, handling and shipment refer to the Laboratory  Manual .
For storage, re -use and destruction of bio marker samples see Section 8.5.
Circulating Tumour Cell Clinical Samples
A who le blood sample will be taken as detailed in the SoA (Section 11.1.3 ). Circulat ing 
Tumour Cell  Clinical samples will be shipped under ambient condit ions on the day  of 
acquisit ion so as to be received at an [COMPANY_008] approved laboratory  within 72 hours of 
blood sam pling. Local  or central  CTC count assessments will be used for screening and 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 76of 170subsequent testing for CTC count will be performed centrally. For information on sample 
processing, handling and shipment refer to the Laboratory  Manual .
For storage, re -use and destruction of bio marker samples see Section 8.5.
11.8.2 Safety Assessments
Planned time p oints for all safet y assessments are provided in the SoA (Section 11.1.3 ).
For all participants, results of all safet y assessments must be available and must be reviewed 
by [CONTACT_592752] y prior to start of each dosing cycle. Samples can be co llected 
the day  before dosing cycle start.
Prior to di scharge from  each in -patient and clinic visit, the Invest igator or their deputy will be 
responsible for reviewing all available safet y data, including vital signs and ECGs.
[IP_ADDRESS] Physical Examinations
A co mplete physical examinat ion with weight will be performed at the visits as indicated 
in the SoA and clinically indicated (Section 11.1.3 ). Hei ght will be recorded at screening 
only.
Please refer to the core protocol (Section 8.2.1 ).
[IP_ADDRESS] Vital Signs
Seated blood pressure and pulse rate
Blood pressure and pulse rate will be measured in the sitt ing position after at least [ADDRESS_781873]. Assessments will be performed at the v isits as shown in the SoA (Section 11.1.3).
Body temperature
Body  temperature will be measured in degrees Celsius at the visits indicated in the SoA 
(Secti on11.1.3 ).
[IP_ADDRESS] Electrocardiograms
Resting 12 -lead ECG
Triplicate 12-lead ECG swill be performed as shown in the SoA (Section 11.1.3 ).
Please refer to the core protocol (Section 8.2.3 ).
[IP_ADDRESS] Performance Status
Perform ance status will be assessed at the visits as indicated in the SoA (Section 11.1.3 ) 
according to US ECOG criteria.
Please refer to the core protocol (Section 8.2.4 ).
Clinical Study P rotocol -Amendment [ADDRESS_781874] 
(MRI where CT is contraindicated) scans of the brain (Cohort A only) , chest, abdomen and 
pelvis (including liver and adrenal glands) and should enco mpass all areas o f known 
predilect ion for metastases in the disease under evaluat ion, and should addit ionally invest igate 
areas that m ay be invo lved based on signs and symptoms of individual part icipants. Follow -up 
CT or MRI assessments will cover chest, abdomen and pelvis wit h any  other regi ons imaged 
at baseline where disease was present. Any other sites at which new disease is suspected 
shoul d also be appropri ately imaged. A CT scan o f the brain shoul d be perform ed in all 
participants in Cohort A at baseline if the participant is not known to have brain metastases. If 
the participant is known to have brain metastases then an MRI will be performed.
A contrast enhanced CT brain scan (MRI where CT i s contraindicated) forms part of the 
baseline disease assessment in Cohort A only as indicated in the SoA (Section 11.1.3 ).
[IP_ADDRESS] Clinical Safety Laboratory Assessments
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, coagulation,
and urinalysis will be taken at the visits indicated in the SoA (Section 11.1.3 ).
Please refer to the core protocol (Section 8.2.5 ).
The clinical chemistry , haematol ogy and urinalysis will be performed at a l ocal laboratory  at 
or near to the invest igator site. Sample tubes and sample sizes may vary depending on 
laboratory  method used and routine practice at the site.
The fo llowing l aboratory  variables will be measured.
Table 11 Laboratory safety variables
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
Blood (B) -Haemoglobin Serum (S)/Plasma (P) -Albumin
B-Leukocy te count S/P-Alanine transaminase (ALT)
B-Leukocy te differential count (absolute count)aS/P-Aspartate transaminase (AST)
Neutrophils S/P-Alkaline phosphatase
Lymphocy tes S/P-Bilirubin, total
Monocytes S/P-Calcium, total
Basophils S/P-Creatinine
Eosinophils S/P-Glucose
B-Platelet count S/P-Magnesium
B-ReticulocytesbS/P-Phosphate
CoagulationcS/P-Potassium
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 78of 170Table 11 Laboratory safety variables
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
B-INR S/P-Sodium
APTT S/P-Urea nitrogen or U rea
Urinalysis (dipstick)cS/P-C -reactive protein
U-Protein S/P-Thyroid stimulating hormone (TSH)d
U-Glucose
U-Blood
Other screening tests
Serum (screening) and urine (other time points) human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)
aIf absolute differentials not available please provide % differentialsbIf absolute particle counts not available please provide relative particle countcCoagulation and urinalysis are only scheduled for baseline and as clinically indicated post -baselinedFree triiodothyronine (T3) or free thyroxine (T4) will only be measured if TSH is abnormal or if there is 
clinical suspi[INVESTIGATOR_454833].
NB. In case a participant shows an AST orALT ≥3xULN together with total  bilirubin 
≥2xULN pl ease refer to Appendix E. Act ions requi red in cases of increases in liver 
biochemistry  and eval uation of  Hy’s Law’, for further instructions.
Addit ionally , a serum  (screening) or urine (other time points) sample will be collected from all 
wom en of childbearing potential at the visits indicated in the SoA (Section 11.1.3 ).
11.8.3 Adverse Events and Serious Adverse Events
Please refer to the core protocol (Section 8.3).
11.8.4 Overdose
Please refer to the core protocol (Section 8.4).
11.8.5 Human Biological Samples
[IP_ADDRESS] Pharmacokinetics
Venous blood samples for determinat ion of concentrations of study  intervent ion in plasma 
will be taken at the times specified in the SoA (Section 11.1.3 ). The date and time o f 
collect ion of each sample will be recor ded.
Samples may  be collected at addi tional time points during the study  if warranted and 
agreed upon between the invest igator and the sponsor eg for safety reasons. The timing of 
sampling may  be al tered during the course of the study  based on newly available data to 
ensure appropriate monitoring. The total vo lume of blood taken from each participant will 
not exceed that presented in Section 11.8.1 .
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 79of 170Plasma bl ood sam ples will  be used to analyse the PK of the study  intervent ion. Samples 
collected for analyses of study  intervent ion concentration may also be used to evaluate 
safet y or efficacy  aspects rel ated to concerns arising during or after the stu dy.
Samples will  be collected, l abelled, stored, and shipped as detailed in the Laboratory  
Manual.
Determination of Drug Concentration
Samples for determination of study  interventi on in pl asma will be assayed by [CONTACT_415536] o f [COMPANY_008], using an appropriately validated 
bioanalyt ical method. Full details of the analy tical method used will be described in a separate 
Bioanaly tical Report.
Incurred sample reproducibilit y analysis, if any , will  be perform ed al ongside the bioanalysis 
of the test samples. The results from the evaluation, if performed, will be reported in a 
separate Bioanaly tical Report.
[IP_ADDRESS] Pharmacodynamics
 will be used to info rm the extent and duration of ATR target 
inhibit ion following treatm ent wi th study  interventio n.  will also be 
used to ob tain assessment of the ceralasert ib  relationship in parti cipants and 
determine any  retrospective correlat ions wi th ATM status and response to study  intervent ion.
The collection of blood based  sampl es will  provide assessment of downstream 
effects of ceral asertib administration in participants . Addit ional  
 may be assessed .  will be collected and processed as detailed in the 
SoA (Section 11.1.3 ).This sample may  also be used to assess .
Addit ional details o f blood, archival and fresh frozen tissue collect ion, shippi[INVESTIGATOR_592698].
For storage, re -use and de structi on of   see Secti on  8.5and Appendix I.
11.8.6 Human Biological Sample Biomarkers
[IP_ADDRESS] Collection of Archival Tumour Samples
Formalin fixed tumour tissue embedded in paraffin blocks are to be requested for all 
participants. Archival samples from eit her primary or metastatic tumour will be acc epted but 
tissue from  the primary  tumour is preferred. However, t issue from the most recent biopsy  
woul d be preferred where a participant has archival t issue samples from mult iple time points.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 80of 170Approximately  30freshly cut (within 30 days) unstained s ections from the archival tum our 
block are accepted if tumour blocks cannot be submitted, however tumour tissue blocks are 
preferred. Specimens with insufficient tumour content orfine needle aspi[INVESTIGATOR_592699] y. Where available, provisio n of a copy  of the pathol ogy report 
associ ated wi th the tum our sam ple is also required.
Details o f sample collection, processing, shippi[INVESTIGATOR_592700]/or the Pathology  and Genomic Testing manual .
[IP_ADDRESS] Collection of Plasma Samples for 
A peripheral blood sample will be collected to provide plasma for  
 
, 
 
Section 11.1.3 ).
 
 
.
Details o f sample collection, processing, shippi[INVESTIGATOR_592701].
[IP_ADDRESS] Collection of
 
.
For storage, re -use and destruction of  see Section 8.5.
11.8.7 Optional Genomics Initiative Sample
Please refer to c ore m odule for details.
11.9 STATISTICAL CONSIDERATIONS -MODULE 1
11.9.1 Statistical Hypotheses
No formal stati stical hypotheses are being conducted for this study .
11.9.2 Sample Size Determination
Cohort A (a ST): A total of ~25 molecularly eligible and centrally confirmed participants 
dosed at ceralasertib 160mg BID will be enrolled into Cohort A .  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 81of 170Cohort B (prostate cancer): A total of ~27 molecularly  eligible and centrally confirmed 
participants dosed at ceralasert ib 160mg BID  will be enrolled into Cohort B. Unfavourabl e 
CTC count requirement may be introduced for all participants to ensure adequate 
(approximately ≥50%) number of participants with CTC count ≥5/7.5 mL blood.
At the time of protocol amendment 2, 1 participant had been dosed at 240 mg BID in 
Cohort A, and 8 parti cipants had been dosed at 240 mg BID in Cohort B. Following the 
reducti on of  the starting dose from 240 mg BID to 160 mg BID in protocol amendment 2, th e
intention is to enrol an addit ional total  of ~25 and ~[ADDRESS_781875] ive response 
rate (Cohort A) and composite response rate (Cohort B) of study  intervent ion. The number of 
participants has been based on the desire t o obtain adequate response, tolerabilit y, safet y, 
pharmacokinet ic and PDc data while exposing as few participants as possible to study  
intervent ion and procedures. In Cohort A, the sample size of ~[ADDRESS_781876] imate of the ORR.  
 In Cohort B, the sample size of ~[ADDRESS_781877] to an approved protocol 
amendment .
11.9.3 Populations for Analyses
The fo llowing popul ations are defined:
Tabl e 12 Populations for Analysis
Population/Analysis set Description
Enrolled Analysis Set All study participants who signed the ICF (including screening failures).
Evaluable for Response Set Cohort A: All study participants with measurable baseline disease who 
received at least 1 dose of study intervention.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 82of 170Population/Analysis set Description
Cohort B: All study participants with measurable disease and/or 
unfavourable CTC count at baseline who receive dat least 1 dose of study  
interventio n.
'Molecularly Eligible Centrally  
ConfirmedaEvaluable for 
Response Se tCohort A: All molecularly eligible and centrally confirmed study 
participants with measurable baseline disease who received at least 1 dose 
of study intervention.
Cohort B: All molecularly eligible and centrally confirmed study 
participants with measurable disease and/or unfavourable CTC count at 
baseline who receive at least [ADDRESS_781878] 1 dose of study intervention.
aParticipants with any or both of the following conditions will be considered molecularly eligible centrally 
confirmed:
1) Centrally confirmed deleterious or suspected deleterious ATM mutation by [CONTACT_077] .
2) Centrally confirmed ATM IHC ≤ 5%.
11.9.[ADDRESS_781879] important endpoints including primary 
and key  secondary endpoints. Any deviat ions fro m the planned analysis will be described in 
an SAP addendum and justified in the final integrated CSR.
Data that will be analysed at each timepo int is presented  Table 13.
Table 13 Summary of Analyses and Data Cut -off Triggers
Analysis Trigger Data Type Included
Interim Cohort AApproximately 4 months after 18 
molecularly eligible centrally  
confirmed evaluable for response 
participants are enrolled .At a minimum, key efficacy and 
safety data for Cohort A, Details to 
be provided in the SAP
CCI
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 83of 170Analysis Trigger Data Type Included
Interim Cohort BApproximately 6 months after 12 
molecularly eligible centrally  
confirmed evaluable for response
participants are enrolled .At a minimum, key efficacy and 
safety data for Cohort B, Details to 
be provided in the SAP
Primary  analy sis Cohort AApproximately 6 months after 25 
molecularly eligible centrally  
confirmed evaluable for response 
participants are enrolled .All data for Cohort A
Primary  analy sis Cohort BApproximately 6 months after 27 
molecularly eligible centrally  
confirmed evaluable for response 
participants are enrolled.All data for Cohort B
Abbreviations: ATM=ataxia telangiectasia mutated; RECIST=response evaluation criteria in solid tumours. 
[IP_ADDRESS] General Considerations
All statistical analysis will be performed by [CONTACT_592753], under the direct ion of the Biostatist ics Group, [COMPANY_008]. 
Further detail will be provided in the SAP . All statist ical analysis will be performed using the 
latest available versio n of SAS®(SAS Inst itute Inc., Cary , North Carolina, US), versio n 9.4 or 
higher. Exploratory  analyses may  be reported outside of the CSR.
Safety data will be presented separately  by [CONTACT_76681] (and total) for each cohort of 
participants wi thin Modul e 1. Summari es of  efficacy  data will only  be presented for 
participants receivi ng [ADDRESS_781880] ings will include all participants 
(240 mg BID and 160 mg BID starting dose).
Cohort A: aST except NSCLC and prostate cancer
Cohort B: Metastatic castration -resistant prostate cancer
No formal stati stical analys es will be carried out for this study  and the data will be 
summarised using standard summary statist ics.
Deviat ions from  the protocol  will be assessed as “important” or “not -important”. Deviat ions 
will be defined before database lock to determine the impact o n any planned analyses. 
Important devi ations will be defined in a separate protocol deviat ion docum ent.
All important protocol deviations will be listed by [CONTACT_592754]. 
Further details will be described in the SAP.
Demographic data
Clinical Study Protocol -Amendment [ADDRESS_781881] ics at 
baseline will be listed for each participant and summarised by [CONTACT_9084].
Reasons for discont inuat ion of study  intervent ion will be listed including the study  day of 
treatm ent discont inuat ion and will be summarised by [CONTACT_9084].
Exposure
Exposure to study  intervent ion will be listed for all participants by [CONTACT_9084].
[IP_ADDRESS] Safety
Safety and tol erabilit y will  be assessed in term s of AEs, l aboratory  data, vi tal signs, and 
physical examinat ion. These will be collected for all part icipants. Appropriate summaries of 
these data will be presented.
During the evaluat ion of AE data, an [COMPANY_008] medically qualified expert will review the 
list of AEs that were not reported as SAEs a nd AEs l eading to di scontinuat ion of study  
intervent ion. Based on the expert’s judgement, AEs of particular clinical importance may, 
after consul tation wi th the Gl obal Safety  Physician, be considered other significant adverse 
events and reported as such in the CSR. A similar review o f laboratory  values, vi tal signs, 
ECGs and other safet y assessments will be performed for ident ificat ion of other significant 
AEs.
Examples of these are marked haematological and other laboratory  abnorm alities, and certain 
event s that l ead to intervention (other than those already  classified as serious), dose reduction 
or significant addit ional treatment.
[IP_ADDRESS] Pharmacokinetic Variables
A stati stical summary  of ceralasertib concentration per the nominal t ime point and a list ing of 
individual  concentrati ons of  ceralas ertib will be generated.
[IP_ADDRESS] Pharmacodynamic Variables
, 
[IP_ADDRESS] Efficacy
Cohort A
Primary Endpoint(s)
Determinat ion of objective response rate is the primary object ive. The primary analysis will 
occur approximately [ADDRESS_781882] one 
response of CR or PR prior to any  evidence of progressio n (as defined by [CONTACT_393] 1.1) that is 
confirmed at least 4 weeks later. The primary analysis o f objective response rate will be based 
upon the ‘mo lecularly eligible centrally confirmed evaluable for response’ populat ion. 
Addit ionally , object ive response rate will also be provi ded for the 'evaluable for response' 
popul ation.Percentage of participants will be accompanied wit h a 2 -sided 80% confidence 
interval  as obtained from  a Cl opper -Pearson test.
Secondary Endpoint(s)
Duration of Response
Durati on of  response will be defined as the time from the date of first documented response 
until date of docum ented progressi on or death in the absence of disease progression, the end 
of response shoul d coincide wi th the date of progressio n or death fro m any cause used for the 
PFS endpo int. The time of the init ial response will be defined as the latest of the dates 
contributing towards the first visit response of PR or CR.
If a participant does not progress fo llowing a response, then their duration of response will use 
the PFS censoring time.
Descript ive data will be provided for the duration of response in responding participants, 
including the associated Kaplan -Meier estimate of median duration of response, where there 
are sufficient number of responders.
Percentage Change in Tumour Size 
The percentage change in TL tumour size fro m baseline will be sum marised using descript ive 
statist ics by [CONTACT_765]. Waterfall plots showing the best percentage change from baseline in sum o f 
the diameters of TLs will be produced. Spi[INVESTIGATOR_592702] m 
baseline in tumour size for each subject over t ime will be produced.
Progression Free Survival
Progression free survival is defined as the time from start of study  interventi on until the date 
of objective disease progression or death (by  [CONTACT_72999]) 
regardl ess of whether th e participant withdraws from therapy or receives another ant i-cancer 
therapy  prior to progressi on. Parti cipants who have not progressed or died at the time of 
Clinical Study Protocol -Amendment [ADDRESS_781883] baseline da ta, they  will be censored 
at 0 days unless they  die wi thin 2 visits of baseline.
The PFS time will always be derived based on scan/assessment dates not visit dates.
For further details see Appendix Fof this Clinical Study  Protocol .
Analyses of PFS will be based upon the 'mo lecularly  eligible centrally  confirmed ' populat ion. 
Kaplan -Meier pl ots of  PFS will be presented. Summaries will include the median PFS wi th 
respective CIs calculated using the Kaplan -Meier technique. Summaries will also provide the 
number and percentage of participants experiencing a PFS event, and the ty pe of  event 
(progression or death).
Cohort B
Primary Endpoint(s)
Determinat ion of composite response rate is the primary object ive. The primary analysis will 
occur approximately [ADDRESS_781884] been enro lled intothe cohort.
Composite Response Rate
Com posite response will be defined on the basis of the following outcom es; if any of these 
occur i n the absence of radio logical or PSA progressio n (according to RECIST 1.1 for soft 
tissue and visceral lesions, prostate cancer working group 3 (PCWG3) criteria for bone 
lesions, and PSA) parti cipants will be considered to have responded:
Invest igator assessed radio logical objective response by [CONTACT_393] 1.[ADDRESS_781885] 
to a protocol amendment.
Conversio n of CTC count fro m ≥5/7.5 mL blood (unfavourable) at baseline to 
<5/7.5 mL blood (favourable) confirmed by a second consecutive value obtained 3 or 
more weeks later (as per PCWG3 crit eria).
PSA decline o f >50% confirmed by a second consecutive measurement at least 3 weeks 
later (based on PCWG1 criteria).
Overall radio logical visit assessment in prostate cancer is provided in Appendix G.
The primary  analysis of com posite response rate will be based upon the ‘molecularly  eligible 
centrally  confirmed evaluable for response’ population. Addit ionally, co mposite response rate 
willalso be provided for the 'evaluable forresponse' populat ion. Percentage of participants 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 87of 170will be accompanied with a 2 -sided 80% confidence interval as obtained from a Clopper -
Pearson test.
Secondary Endpoint(s)
Radiological Objective Response Rate
Radiological ORR is defined as the percentage of participants with a confirmed response of 
CR or PR in their so ft tissue and visceral lesio ns assessed by [CONTACT_393] 1.[ADDRESS_781886] ive radio logic disease progression or 
death. Descript ive data will be provided for the duration of response in responding 
participants, including the associated Kaplan -Meier estimate of median durat ion of  response, 
where there are sufficient number of responders .
Percentage change in tumour size
Percentage change in tumour size will be summarised descriptively, as described for 
Cohort A.
CTC Count conversion
Conversio n of CTC count are defined as a co nversio n from unfavourable at baseline 
(≥5/7.5 mL blood) to favourable post -baseline (< 5/7.5 mL blood). Post -baseline result should 
be confirmed with a second consecut ive value obtained 3 or more weeks l ater. The percentage 
of parti cipants wi th CTC count conversio n based on those wi th unfavourable CTC at baseline, 
will be presented for this study .
Confirmed PSA Decline
Proporti on of  parti cipants wi th a PSA decline of >50% confirmed by a second consecutive 
measurement at least 3 weeks later.
Radiological PFS (rPFS) 
rPFS is defined as the time fro m the start of treatment until the date of object ive radiographic 
disease progressi on or death.
Clinical Study Protocol -Amendment [ADDRESS_781887] not progressed (ie, who have a CR, PR or SD by  [CONTACT_393] 1.1, and non -
progressive disease by  [CONTACT_43877] -3) at the time of analysis will be censored at the time o f the 
latest date of their last evaluable RECIST 1.[ADDRESS_781888] 
baseline data, he will be censored at Day1 unless he dies wit hin 2 visits of baseline (in which 
case the pa rticipant ’s date of death will be used). The rPFS time will always be derived b ased 
on scan/assessment dates, not visit dates. When the invest igator is in doubt as to whether 
progressive disease has occurred and therefore reassesses the patient at a later date, the date of 
the init ial scan should be declared as the date of progressio n if the repeat scans confirm 
progression.
Analyses of rPFS will be based upon the 'mo lecularly  eligible centrally confirmed ' popul ation. 
Kaplan -Meier pl ots of  rPFS will be presented. Summaries will include the median rPFS with 
respective CIs calculated us ing the Kaplan -Meier technique. Summaries will also provide the 
number and percentage of participants experiencing a rPFS event, and the ty pe of event 
(progression or death).
[IP_ADDRESS] Biomarker Variables
The analyses of bio marker variables include, but are not limi ted to, . Change 
from baseline and percent change from baseline for bio marker variables will be calculated for 
all participants.
11.9.5 Interim Analyses 
[IP_ADDRESS] Cohort A
An administrative interim analysis will be conducted approximately [ADDRESS_781889] anned adapt ions to the study.
[IP_ADDRESS] Cohort B
A futility interim analysis will also be conducted approximately  [ADDRESS_781890] been 
enrolled dosed at ceralasertib 160mg BI D.The fut ility stoppi[INVESTIGATOR_592703], com positeresponse .[COMPANY_008] may decide to cease 
recrui tment for the prostrate cohort at the interim analysis if there are ≤2 responders out of 12 
molecularly  eligible and centrally confirmed participants. This stoppi[INVESTIGATOR_592704] -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 89of 170only, and any  decisi on to cease recrui tment will be based on sponsor review of all safet y and 
efficacy  clinical  data available. Further d etails will be provided in the SAP.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage respons e agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 90of [ZIP_CODE].10 REFERENCES -MODULE 1
Ajani et al, 2007
Ajani JA, Moiseyenko VM, Tjulandin S, Majilis A, Constenla M, Boni C et al. Qualit y of life 
with docetaxel  plus cisplat in and fluorouracil co mpared with cisplat in and fluorouracil fro m a 
phase III trial for advanced gastric or gastroesophageal adenocarcino ma: the V -325 study  
group. J Clin Onco l 2007; 25(22):3210 -3216.
Alderton et al, 2004
Alderton GK, Joenje H, Varon R, Børglum AD, Jeggo PA, and O’Drisco ll M. Seckel  
syndro me exhibits cellular features demonstrating defects in the ATR -signalling pathway . 
Hum an Mo lec Gen 2004;13(24):3127 -3138.
Cimprich a nd Cortez 2008
Cimprich KA, Cortez D. ART: an essent ial regulator of geno me integrity. Nat Rev Mol  Cell 
Biol 2008;9:616 -27.
De Bono et al, 2020
TALAPRO -1: A Phase 2 Study  of Talazoparib in Men Wit h DNA Damage Repair Mutations 
and Metastatic Castrati on-resistant Prostatae Cancer –June 2019 Interim Analysis. ASCO GU 
2020.
Dillon et al, 2017
A Phase I dose -escalat ion study  of ATR inhibitor mo notherapy  with AZD6738 in advanced 
solid tumors (PATRIOT Part A). AACR 2017.
Dillon et al, 2019
A Phase I study  of ATR inhibitor, AZD6738, as monotherapy  in advanced solid tumours 
(PATRIOT Part A, B). ESMO 2019.
Eder et al, [ADDRESS_781891] A080: Olaparib and the A TR inhibitor AZD6738 in relapsed, refractory  cancer 
patients wi th homologous recombinat ion (HR) re pair mutations –OLAPCO; AACR -NCI-
EOR TC International Conference on Molecular T argets and Cancer .
Grasso et al, [ADDRESS_781892], Cao X, Dhanasekaran SM, Khan AP, et al. The 
mutati onal landscape of l ethal castrati on-resistant prostate can cer. Nature. 2012 Jul 
12;487(7406):239 -43.
Kim et al, 2013
Kim HS, Kim MA, Hodgson D, Harbron C, Wellings R, O'Connor MJ, et al. Concordance of 
ATM (ataxia telangiectasia mutated) immunohistochemistry  between bi opsy or m etastati c 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 91of 170tumor sam ples and primary  tumors in gastri c cancer patients. Pathobio logy. 2013;80(3):127 -
37.
Min et al, 2017
Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, et al. AZD6738, A Novel Oral Inhibitor of 
ATR, Induces Synt hetic Lethalit y with ATM Deficiency in Gastric Cancer Cells. Mo l Cancer 
Ther. 2017 Apr;16(4):566 -577.
Murai et al, 2012
Murai  J, Huang SYN, Das BB, Renaud A, Zhang Y, Doroshow JH et al. Trappi[INVESTIGATOR_48817]1 
and PARP2 by [CONTACT_182674]. Cancer Res 2012;72:[ADDRESS_781893]. Mol Bio l 2011;18(12):1331 -1335.
NCI 2006
https://www.cancer.gov/about -cancer/causes -prevent ion/gene tics/ataxia -fact-sheet
Prostate Cancer Treatment, 2020
Prostate Cancer Treatment (PDQ) –Health Professio nal Versi on. Nati onal Cancer Insti tute. 
2002 -2020 Jan 29.
Prostate Cancer Treatment, 2019
Prostate Cancer Treatment (PDQ) –Patient Version. National C ancer Inst itute. 2002 -2019 Jun 
12.
Reaper et al, 2011
Reaper PM, Griffit hs MR, Long JM, Charrier JD, Maccormick S, Charlton PA et al. Selective 
killing of ATM -or p53 -deficient cancer cells through inhibit ion of ATR. Nat Chem Bio l 
2011;7(7):[ADDRESS_781894] Sheets: Prostate Cancer. National Cancer Inst itute. 
https://seer.cancer.gov/statfacts/ht ml/prost.html 
Smith et al, 2020
Niraparib in Pat ients Wit h Metastati c Castrati on-resistant Prostate Cancer (mCRPC) and 
Biallelic DNA -repai r Gene Def ects (DRD): Correlative Measure of Tumor Response in the 
Phase [ADDRESS_781895] 2005;97(1 1):[ADDRESS_781896] supportive care as second -line chemotherapy in gastric 
cancer –A rando mised phase III study  of the Arbeitsgemeinschaft Internist ische Onko logie 
(AIO). European J Cancer 2011;47:[ADDRESS_781897]. Mol Bio l 2011;18:721 -727.
Wassim Abida et al, 2018
ESMO 2018, Preliminary  resul ts from triton2: a phase 2 study  of rucaparib in patients (pts) 
with metastati c castrati on-resistant prostate cancer (MCRPC) associated with ho mologous 
recombinat ion repair (HRR) gene alterat ions.
World Cancer Report, 2014
Chapter 1.1. World Cancer Report. World Healt h Organizat ion. 2014. ISBN 978 -[PHONE_12285].
Yap TA et al, [ADDRESS_781898] -in-Human Tri al of the 
Oral Ataxia Tel angiectasia and RAD3 -Related (ATR) Inhibitor BAY 1895344 in Patients with 
Advanced Solid Tumors. Cancer Discov 2021;11:80 -91.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 93of [ZIP_CODE] SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 94of 170Appendix AChanges Related to Mitigation of Study Disruptions Due to 
Cases of Civil Crisis, Natural Disaster, or Public Health 
Crisis
Note: Changes below should be implemented only during study disruptions due to any of or a 
combinat ion of civil crisis, natural disaster , or public healt h crisis (eg, during quarant ines and 
resul ting site closures, regional travel restrictions and considerat ions if site personnel or study  
participants beco me infected with SARS -CoV -2or similar pandemic infection) during which 
participants may not wi sh to or m ay be unable to visit the study  site for study visits. These 
changes should only be implemented if allowable by [CONTACT_271133]/regi onal guidelines and following 
notification fro m the sponsor and instructions on how to perform these procedures w ill be 
provi ded at the time of implementation.
Please note that during civil crisis, natural disaster, or public healt h crisis, some study  
assessments and procedures may  not be conducted due to internat ional or local po licies or 
guidelines, hospi[INVESTIGATOR_592705]’s safet y. If in doubt, pl ease contact [CONTACT_941] A straZeneca Study  Physician.
A1 Reconsent of Study Participants During Study Interruptions
During study  interrupti ons, i t may not be possible for t he participants to com plete study  visits 
and assessments on site and alternat ive means for carrying out the visit s and assessments may  
be necessary, eg, remote visits. Reconsent should be obtained for the al ternative m eans of 
carrying out visits and assess ments and should be obtained prior to performing the procedures 
described in Section 11.1.3 and Sections 11.8.1 to 11.8.7 . Local  and regi onal regulat ions 
and/or guidelines regarding recons ent of study  participants shoul d be checked and followed. 
Reconsent m ay be verbal  if allowed by [CONTACT_244943] (note, in the case of 
verbal reconsent the ICF should be signed at the participant’s next contact [CONTACT_72953]). 
Visiting the study  sites for the sol e purpose of obtaining reconsent should be avoided. 
A2 Rescreening of Participants To Reconfirm Study Eligibility
Addit ional rescreening for screen failure due to study  disrupti on can be performed in 
previously screened part icipants . The invest igator should confirm this with the designated 
[COMPANY_008] study  physician.
In addit ion, during study  disrupt ion there may be a delay between confirming eligibilit y of a 
participant and ei ther enro lment into the study  or commencing of dosing wi th IP. If  this delay 
is outsi de the screening window specified in Sect ion11.1.[ADDRESS_781899] On -site Visit (where applicable)
A qualified healt hcare professio nalfrom the study  site or third party  vendor service will visit 
the participants home/or other remote location as per local standard of procedures , as 
applicable. Supplies will be provided for a safe and efficient visit. The qualified healt hcare 
professio nalwill be expected to collect informat ion per the CSP.
A4 Telemedicine Visit to Replace On -site Visit (where applicable)
In thi s appendix, the term telemedicine vis it refers to rem ote contact [CONTACT_592755], virtual or video visit s, and 
mobile health devices.
During a civil crisis, natural disaster, or public healt h crisis, on -site visi ts may  be replace d by 
a telemedicine visit if allowed by  [CONTACT_5737]/regional guidelines. Having a telemedicine contact 
[CONTACT_592756], conco mitant m edicat ion to be reported and 
docum ented.
A5 At-home or Remote Location IP Administration Instruction s
If a site visit is not possible, at -home or remote location administration of IP may be 
perform ed by  a qualified healt hcare professio nal, provi ded thi s is acceptable within lo cal 
regul ation/guidance, or by  [CONTACT_325417]/her caregiver. The option of at-home or 
remote locati on IP administrati on ensures participants safet y in cases of a pandemic where 
participants may be at increased risk by [CONTACT_122652]/clinic. This will also minimize 
interrupti on of  IP administration during other study  disrupt ions, eg, site closures due to natural 
disaster.
A5.1 At-home or Remote Location IP Administration by [CONTACT_122653]/Her Caregiver
Prior to at -home or remote location IP administration the investigator must assess the 
participant or his/her caregiv er to determine whether they  are appropri ate for at -home or 
remote locati on administrati on of  IP. Once the participant or his/her caregiver i s deemed 
appropriate for at -home or remote location administration, he/she must receive appropriate 
training. All n ecessary  supplies and instructions for administration and d ocum entati on of  IP 
administration will be provided. More informat ion related to the visit can be obtained via a 
telemedicine or hom e / rem ote visit.
A6 Data Capture During Telemedicine or Home / Remote Visits
Data collected during telemedicine or home/remote visits will be captured by [CONTACT_592757], or by  [CONTACT_592758].
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 96of 170Appendix BRegulatory, Ethical, and Study Oversight C onsiderations
B1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council fo r Internati onal Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relev ant 
docum ents (eg, adverti sements) m ust be submitted to an Institutional Review Boards 
(IRB)/Independent Ethics Co mmittees ( IEC)by [CONTACT_41428]/IEC before the study  is init iated.
Any amendments to the protocol will requi re IRB/IEC and applicable Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
[COMPANY_008] will be responsible for obtaining the requi red authori sations to conduct the 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO but the accountabilit y remains wi th [COMPANY_008].
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_592759] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the local regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulat ory authorit y, IRB/IEC, and invest igators.
For all studies except those utilising medical devices investigator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regul atory  requi rements and sponsor policy and forwarded to invest igators as necessary.
An invest igator who receives an invest igator safety report describing a SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the sponsor will review 
and then file it and will no tify the IRB/IEC, if appropri ate accordi ng to l ocal 
requi rements.
B2 Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and acc urate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 97of 170are responsible for providing information on financial interests during the course of the study 
and for 1 y ear after com pletion of  the study .
B3 Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorised representative and answer all quest ions regarding 
the study .
Parti cipants m ust be inform ed that thei r participat ion is vo luntary and they  are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason 
during the study . Partici pants or thei r legally  authori sed representative will be required to 
sign a statem ent of  inform ed con sent that m eets the requirements of [ADDRESS_781900] 
(HIPAA) requirements, where applicable, and the IRB/IEC or study  centre.
The m edical  record m ust include a statem ent that written inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorised person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
authori sed representative.
Please refer to individual modules for specific details.
For Module 1, the screening will have [ADDRESS_781901] ion and use of 
any mandatory  and/or opti onal human bio logical  sam ples. The invest igator or authorised 
designee will explain to each participant the objectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that they are free to refuse to 
participate in any optional samples or the future use and may wit hdraw their consent at any  
time and for any  reason during the retention period. 
B4 Data Protection
Parti cipants will be assigned a uni que i dentifier by [CONTACT_456]. Any part icipant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable will not be 
transferred.
The parti cipant m ust be inform ed that hi s/her personal  study -related data will  be used by  
[CONTACT_456] i n accordance with local data protection law. The level of disclo sure and use 
of their data m ust al so be explained to the participant in the informed consent 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 98of 170The pa rticipant m ust be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other authorised personnel appo inted by  [CONTACT_103], by  [CONTACT_6667]/IEC members, and by [CONTACT_32857].
B5 Committees Structure
The safet y of all [COMPANY_008] clinical studies is clo sely monitored on an on -going basis by  
[CONTACT_96784] y. Issues ident ified will be 
addressed; for instance, this could invo lve amendments to the CSP and letters to investigators.
B6 Dissemination of Clinical Study Data
A descript ion of this clinical study  will be available on http://astrazenecaclinicaltrials.co mand 
http://www.clinicaltrials.gov as will the summary  of the m ain study  resul ts when they  are 
available. The clinical study  and/or summary  of main study  resul ts may also be available on 
other websites according to the regulat ions of the countries in which the main study  is 
conducted.
B7 Data Quality Assurance
All participant data relat ing to the s tudy will be recorded on eCRF unless transmitted to 
the sponsor or designee electronically (eg, laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_592760].
Theinvest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect access to source data documents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y 
such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, incl uding handling of 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  including 
qualit y checking of the da ta.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (eg, 
Contract Research Organisat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_156083] e accurate, com plete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, an d all applicable regulatory  requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by [CONTACT_41176] 20years after study  com pletion unless local 
regul ations or inst itutional policies requ ire a longer retenti on peri od. No records m ay be 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 99of 170destroy ed during the retention period without the written approval of the sponsor. No 
records m ay be transferred to another location or party  without wri tten notificat ion to the 
sponsor.
B8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the eCRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained. The invest igator may need to request previous medical records or transfer 
records, depending on the study . Also, current m edical records must be available.
Source data may include, but is not limited to: medical history  and physical examinat ion 
notes, hospi[INVESTIGATOR_44458] , autopsy  report when available, results of relevant 
diagnosti c tests com pleted.
B9 Study and Site Start and Closure
The study  start dat e is the date on which the clinical study will be open for recruit ment of 
participants.
The first act of recruitment is the first participant enro lled and will be the study start date.
The sponsor designee reserves the right to close the study  site or term inate the study  at any  
time for any  reason at the sole discret ion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study site closur e visi t has been perform ed.
The invest igator may init iate study  site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_17095]:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by [CONTACT_17062]
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investigators, the IECs/IRBs, the regulatory  authorit ies, and any contract research 
organisat ion(s) used in the study  of the reason for terminat ion or suspensio n, as specified by 
[CONTACT_122644]. The invest igator shall pro mptly inform the participant 
and should assure appropriate participant therapy  and/or foll ow-up.
Clinical Study Protocol -Amendment [ADDRESS_781902] the opportuni ty to be transferred to another site to 
continue the study .
B10 Publication Policy
The results of this study  may be published or presented at scient ific meet ings. If this is 
foreseen, the invest igator agr ees to submit all manuscripts or abstracts to the sponsor 
before submissio n. This allows the sponsor to protect proprietary  information and to 
provi de comments.
The sponsor will co mply wit h the requirements for publication o f study  resul ts. In 
accordance w ith standard editorial and ethical practice, the sponsor will generally support 
publicat ion of mult icentre studies only  in thei r entirety  and not as individual site data. In 
this case, a co -ordinat ing invest igator will be designated by [CONTACT_11402].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 101of 170Appendix C[LOCATION_001] Heart Association
C1 [LOCATION_001] Heart Association Functional Classification
NYHA Symptoms 
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
palpi[INVESTIGATOR_226367] n, dy spnoea (sho rtness of breath).
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in 
fatigue, palpi[INVESTIGATOR_332], dyspnoea ( shortness of breath).
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, 
palpi[INVESTIGATOR_226367] n, or dy spnoea.
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest . If any 
physical activity is undertaken, discomfort increases.
Abbreviation: NYHA=[LOCATION_001] Heart Association.
C2 References
Criteria Committee of the [LOCATION_001] Heart Association, 1994
The Cri teria Co mmit tee of  the [LOCATION_001] Heart Association. (1994). Nomenclature and 
Criteria for Di agnosis of Diseases of the Heart and Great Vessels (9th ed.). [LOCATION_011]: Little, 
Brown & Co. pp. 253 –256.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 102of 170Appendix DGuidelines Regarding Potential Interactions of Ceralasertib 
with Concomitant Medications
Restrictions regarding drugs af fection CYP3A metabolism
There are currently no data confirming that there is a pharmacokinet ic (PK) interaction 
between these agents and ceralasert ib; a potential interaction is considered on the basis of 
preclinical and in vitro data only. Ceralasert ib is predominant ly eliminated via CYP3A 
metabo lism, therefore CYP3A inhibitors or inducers may increase or decrease exposure to 
ceral asertib, respect ively. Potent inhibitors or inducers of CYP3A should not be combined 
with ceralasert ib. In vitro data also sug gest that ceralasertib may  be m etabo lised by [CONTACT_097]2C8 
but a l esser extent, therefore caution should be applied with co -administration of potent 
inhibitors or inducers of CYP2C8.
These lists are not intended to be exhaust ive, and similar restrict ions will app ly to other agents 
that are known to modulate CYP3A or CYP2C8 activit y. Please contact [CONTACT_588107] h any 
queri es you have on this issue. Please refer to full prescribing information for all drugs prior to 
co-administration with ceralasert ib. 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 103of 170Table 14 Drugs Known to be Inhibitors of CYP3A4
Potent CYP3A inhibitors Potent CYP3A inducers
Boceprevir
Ceritinib
Clarithromycin
Cobi cistat (GS-9350)
Conivaptan
Danoprevir / RIT
Elvitegravir / RIT
Grapefruit juicea
Idelalisib
Indinavir
Indinavir /RIT
Itraconazole
Ketoconazole
LCL161
Lopi[INVESTIGATOR_054] / RIT
Mibefradil
Mifepristone
Nefazodone
Nelfinavir
Posaconazole
Ribociclib
Ritonavir
Saquinavir
Saquinavir / RIT
Telaprevir
Telithromy cin
Tipranavir /RIT
Troleandomycin
VIEKIRA PAK2b
VoriconazoleApalutamide
Avasimibe
Carbamazepi[INVESTIGATOR_592706]'s Wort extract
aDouble -strength grapefruit juice. Participants should abstain from eating large amounts of grapefruit and 
Seville oranges (and other products containing these fruits e.g., grapefruit juice or marmalade) during the 
study (e.g., no more than a small glass of grapefruit juice [120 mL ] or half a grapefruit or 1 -2 teaspoons 
[15g] of Seville orange marmalade daily ).bVIEKIRA PAK = 150/100 mg paritaprevir/ritonavir + 25 mg ombitasvir + [ADDRESS_781903] created using the University of Washington Drug -Drug Interaction Database July 2019.  
RIT=Ritonivir. Ritonavir has dual effects of simultaneous CYP3A inhibition and induction, and the net 
pharmacokinetic outcome during chronic ritonavir therapy is in hibitio n of CYP3A activity 
Clinical Study Protocol -Amendment [ADDRESS_781904] created using the University of Washington Drug -Drug Interaction Database Jan 2020.
Drugs known to be inhibitors or inducers of Pgp and/or BCRP, undertake appropriate 
monitoring if co -administration is necessary
Ceral asertib i s a substrate of Pgp and BCRP. Co -administration of Pgp inhibitors/inducers or 
BCRP inhibitors/inducers may  affect exposure to AZD6738 therefore it is recommended that 
these are not co -administered with ceralasertib.
These lists are not intended to be exhaust ive, and similar restrict ions will apply to other agents 
that are known to modulate Pgp activit y or BCRP activit y. Please contact [CONTACT_592761] y ou have on this i ssue. Pl ease refer to full prescribing informat ion for all drugs 
prior to co -administration with ceralasert ib.
Table 16 Drugs Known to be Inhibitors or Inducers of P -gp
Drugs Known to be Inhibitors of Pgp Drugs Known to be Inducers of Pgp
Alogliptin
Amiodarone
Asian ginseng (Panax ginseng)
Asunaprevir
AZD5672
azithromycin
Canagliflozin
Captopril
Carvedilol
Clarithromycin
Clopi[INVESTIGATOR_592707] /asunaprevir/beclabuvir
Diltiazem
Diosmin
DronedaroneApalutamide
Avasimibe
Carbamazepi[INVESTIGATOR_592708] (Salvia miltiorrhiza)
Efavirenz
Genistein
Green tea
Phenytoin
Quercetin
Rifabutin
Rifampin
Ritonavir
St. Jo hn's wort extract 
Tivantinib
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 105of 170Drugs Known to be Inhibitors of Pgp Drugs Known to be Inducers of Pgp
Elagolix
Eliglustat
Erythromycin
Felodipi[INVESTIGATOR_592709]-flavor berry (schisandra chinensis)
Flibanserin
Fluvoxamine
Fostamatinib
Ginkgo
Glecaprevir/pi[INVESTIGATOR_592710]/ritonavir
Isavuconazole
Itraconazole
Ivacaftor
Ketoconazole
Lapatinib
Lopi[INVESTIGATOR_054]/ritonavir
Mibefradil
Mifepristone
Milk thistle
Mirabegron
Nelfinavir
Neratinib
Nifedipi[INVESTIGATOR_592711]/ritonavir/ombitasvir
Paroxetine
Pi[INVESTIGATOR_592712]/ritonavir
Sarecycline
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 106of 170Drugs Known to be Inhibitors of Pgp Drugs Known to be Inducers of Pgp
Simeprevir
Sofosbuvir/velpatasvir/voxilaprevir
St. Jo hn's wort extr act
Surfactant TPGS
Suvorexant
Talinolol
Telithromycin
Telaprevir
Telmisartan
Tezacaftor/ivacaftor
Ticagrelor
Tipranavir/ritonavir
Tolvaptan
Valbenazine
Valspodar (PSC 833)
Vandetanib
Velpatasvir
Vemurafenib
Verapamil
Voclosporin
Vorapaxar
Table [ADDRESS_781905] created using http://dmd.aspetjournals.org/content/dmd/43/4/490 full.pdf
Note: Although BCRP is involved in a number of clinically relevant drug-drug interaction , none of the ci ted 
inhibito rs above is truly specific for this transporter
Drugs known to be substrates of CYP3A4 and/or CYP2B6, undertake appropriate 
monitoring if co- administration is necessary 
Ceral asertib i s a potential inducer of CYP3A4 and CYP2B6. Therefore, caution should be 
applied wit h co-administration of drugs that are either completely metabo lised by [CONTACT_097]3A4 
and/or CYP2B6, or that are substrates of CYP3A4 and/or CYP2B6 and also have a narrow 
therapeuti c index. Invest igators should be aware that the exposu re of other drugs metabo lised 
by [CONTACT_097]3A4 and/or CYP2B6 may  be reduced.
Table 18 Drugs Known to be Metabolised by [CONTACT_097]3A4 and/or CYP2B6 and Have 
a Narrow Therapeutic Index
Metabolised by [CONTACT_097]3A4
andwith a narrow therapeutic indexMetab olised by [CONTACT_097]2B6
andwith a narrow therapeutic index
Alfentanil Bupropi[INVESTIGATOR_592713] -Amendment [ADDRESS_781906] created using the University of Washington Drug -Drug Interaction Database October 2019.
Note: This is not an exhaustive list.
Drugs known to be substrates of OATP1B1 and BCRP, undertake appropriate 
monitoring if co -administration is necessary 
Ceral asertib is also an inhibitor of OATP1B 1 and BCRP. Caution should be applied wit h 
co-administration of substrates of OATP1B1 and/or BCRP as ceralasertib may increase their 
exposure.
These lists are not intended to be exhaust ive and appropriate medical judg ement is required. 
Please contact [CONTACT_592762] y ou have on this i ssue. Pl ease refer to full 
prescribing information for all drugs prior to co -administration with ceralasert ib.
Table 19 Drugs Known to be Substrates of OATP1B1
Docetaxel
Enalapril
Olmesartan 
Phalloidin
Repaglinide
Statins* 
Temocaprilat
Valsartan
* all statins 
List created using https://www.solvobiotech.com/transporters/OATP1B1, latest access Nov [ADDRESS_781907] created using https://www.solvobiotech.com/transporters/bcrp, latest access Nov 2019
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage respo nse agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 110of 170Appendix EActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E1 Introduction
This Appendix describes the process to be fo llowed in order to ident ify and appropriately 
report Potential Hy’s Law (PHL) cases and Hy’s L aw (HL) cases. It is not intended to be a 
comprehensive gui de to the m anagement of el evated liver biochemistries. 
During the course of the study  the invest igator will remain vigilant for increases in liver 
biochemistry . The invest igator is responsible for determining whether a participant meets 
potenti al PHL cri teria at any  point duri ng the study.
All sources of l aboratory  data are appropri ate for the determinat ion of PHL and HL events; 
this includes samples taken at scheduled study  visits and other vi sitsincluding central and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL 
criteria coul d be m et by  [CONTACT_96724]  a central  laboratory  and/or elevated TBL fro m 
a local laboratory . 
The invest igator will a lso review Adverse Event data (for example, for AEs that may indicate 
elevations in liver biochemistry ) for possible PHL events.
The invest igator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases me eting PHL criteria to agree whether HL criteria are met. HL 
criteria are met if there is no alternat ive explanation for the elevat ions in liver biochemistry  
other than Drug Induced Liver Injury  (DILI) caused by  [CONTACT_244993] 
(IMP). 
The invest igator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Serious Adverse Events (SAEs) and Adverse Events (AEs) according to the 
outcom e of the review and assessment in line wit h standard safet y reporting processes.
E2 Definitions
Potential Hy’s Law (PHL)
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥3x Upper Limit of 
Norm al (ULN) together with Total Bilirubin (TBL) ≥2xULN at any po int during the study  
following the start of study  intervent ionirrespect ive of an increase in Alkaline Phosphatase 
(ALP).
Hy’s Law (HL)
AST or ALT ≥3xULN together with TBL ≥2xULN, where no other reason, other than the 
IMP, can be found to explain the combinat ion of increases, eg, elevated ALP indicating 
cholestasis, viral hepat itis, another drug. 
Clinical Study Protocol -Amendment [ADDRESS_781908] precede or be coinci dent wi th (ie, on the 
same day ) the el evati on in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
E3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL i t is important to perfo rm a com prehensive review of 
laboratory  data for any  parti cipant who m eets any of the fo llowing identificat ion criteria in 
isolation or in combinat ion:
ALT ≥3xULN
AST ≥3xULN
TBL ≥2xULN
Local laboratories being used:
The invest igator will wit hout delay review each new laboratory  report and if the ident ificat ion 
criteria are met will:
Determine whether the participant meets PHL criteria (see Section E2Definit ions 
within this Appendix for definit ion) by [CONTACT_244995] m all 
previous visits
Prom ptly enter the laboratory  data into the l aboratory  eCRF
E4 Follow -up
E4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL criteria the investigator will:
Perform  follow-up on subsequent laboratory  resul ts according to the guidance 
provi ded in the Clinical Study  Protocol .
E4.2 Potential Hy’s Law Criteria met
If the participant does meet PHL criteria the investigator will:
 Dete rmine whether PHL criteria were met at any  study  visit prior to starting study  
intervent ion (See Section E6)
Notify  the [COMPANY_008] representative who will then inform the central Study  Team  
Within [ADDRESS_781909] igator will report the case as an SAE of 
Potenti al Hy’s Law; seri ous cri teria ‘Im portant m edical event’ and causalit y asses sment 
‘yes/related’ according to CSP process for SAE reporting
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 112of 170For parti cipants that met PHL criteria prior to starting IMP, the invest igator is not 
requi red to submit a PHL SAE unless there is a significant change #in the participant’s 
condi tion
The Study Physician contacts the investigator, to provide guidance, discuss and agree an 
approach for the study  parti cipants’ fo llow-up (including any further laboratory  testing) 
and the continuous review of data
Subsequent to this contact [CONTACT_33157]:
Monitor the parti cipant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE Form as required.
Invest igate the aetiology o f the event a nd perform diagnostic investigat ions as 
discussed wi th the Study  Physician. For studies using a central laboratory  add: This 
includes deciding which the tests available in the Hy’s Law lab kit should be used .
Com plete the 3 Liver eCRF Modules as informat ion becom es available 
#A ‘significant’ change in the participant’s conditio n refers to a clinically  relevant 
change in any  of the individual liver biochemistry  param eters (ALT, AST or total bilirubin) in 
isolation or in combinat ion, or a clinically  releva nt change in associated symptoms. The 
determinat ion of whether there has been a significant change will be at the discret ion of the 
investigator, this may  be in consul tation wi th the Study  Physician if there is any  uncertaint y.
E5 Review and Assessment of Pot ential Hy’s Law Cases
The instructions in this Section should be fo llowed for all cases where PHL criteria are met.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the Study  
Physician contacts the invest igator in order to rev iew available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL criteria other than DILI caused by [CONTACT_86184], to ensure timely analysis and reporting to healt h authorit ies wit hin [ADDRESS_781910] and TBL elevations, 
a determination of whether the alternat ive explanatio n is an AE will be made and 
subsequent ly whether the AE meets the criteria for a SAE:
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 113of 170If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate eCRF
If the alternat ive explanat ion is an AE/SAE: update the previously submitted Potential 
Hy’s Law SAE and AE eCRFs accordingly wit h the new informat ion (reassessing event 
term; causalit y and seri ousness cri teria) fo llowing the [COMPANY_008] standard processes.
If it is agreed that there is no explanat ion that would explain the ALT or AST and TBL 
elevations other than the IMP:
Send updated SAE (report term ‘ Hy’s Law’) according to [COMPANY_008] standard 
processes. 
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious 
criteria apply
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay, of over 15 calendar day s in obtaining the informat ion 
necessary  to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such time as an inf ormed decisio n can be made:
Provi des any  further update to the previously submitted SAE of Potential Hy’s Law, 
(report term now ‘Hy’s Law case’) ensuring causalit y assessment i s related to study  
intervent ion and seriousness criteria is medically important, according to CSP process for 
SAE reporting.
Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previ ously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternat ive explanat ion for the liver biochemistry  
elevations is determined.
E6 Actions Required When Potential Hy’s Law Criteria are Met 
Before and After Starting Study Treatment 
This sect ion is applicable to participants with liver metastases who m eet PHL cri teria on study  
treatm ent, having previously met PHL criteria at a study  visit prior to starti ng study  treatment.
At the first on study  treatm ent occurrence of PHL cri teria being met the invest igator will 
determine if there has been a significant change in the participants’ condit ion#compared wi th 
the last visit where PHL criteria were met#
If there is no significant change no action is required
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 114of 170If there is a significant change, notify the [COMPANY_008] representative, who will 
inform  the central  Study  Team , then foll ow the subsequent process described in 
Secti on E4.2
E7 Actions Required for Repeat Epi[INVESTIGATOR_33099]’s Law
This sect ion is applicable when a participant meets PHL criteria on study  treatm ent and has 
already met PHL cri teria at a previous on study  treatm ent visi t.
The requi rement to conduct fo llow-up, revi ew and assessment of a repeat occurrence(s) of 
PHL i s based on the nature of the alternat ive cause identified for the previous occurrence. 
The invest igator should determine the cause for the previous occurrence of PHL criteria being 
met and answer the fo llowing quest ion:
Was the alternat ive cause for the previous occurrence o f PHL cri teria being met found 
to be the di sease under study  eg, chronic or progressing malignant disease, severe 
infection or liver disease or did the participant meet PHL criteria prior to starting study  
treatm ent and at their first on study  treatm ent visi t as described in sect ion 6 of this 
Appendix?
If No: follow the process described in Sect ion E4.2for reporting PHL as an SAE
If Yes: Determine if there has been a significant change in the participant’s condit ion#
compared wi th when PHL cri teria were previously met
If there is no significant change no action is required
If there is a significant change fo llow the process described in Section E4.2for report ing 
PHL as an SAE
# A ‘significant’ change in the part icipant’s condit ion refers to a clinically relevant change in 
any of the individual liver biochemistry  param eters (ALT, AST or total bilirubin) in iso lation 
or in co mbination, or a clinically relevant change in associated symptoms. The determinat ion 
of whether there has been a significant change will be at the discretion o f the invest igator, this 
may be in consultat ion with the Study  Physician if there is any uncertaint y.
E8 References
Aithal et al, 2011
Aithal et al 2011, Clinical Pharmaco logy and Therapeuti cs 89(6):806 -815.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 115of 170FDA Guidance for Industry, July 2009
FDA Guidance for Industry  (issued July  2009) ‘Drug -induced liver injury: Premarket ing 
clinical evaluat ion’. Available from; https://www.fda.gov/re gulatory -informat ion/search -fda-
guidance -docum ents/drug -induced -liver-injury -premarket ing-clinical -evaluati on
Clinical Study Protocol -Amendment [ADDRESS_781911] 1.1 (Response Evaluation Criteria in Solid 
Tumours)
Introduction
This appendix details the implementation of RECIST (Response Evaluat ion Cri teria in Solid 
Tumours) 1.1 gui delines ( Eisenhauer et al , 2009 ) for the study  with regards to invest igator 
assessment of tumour burden including protocol -specific requirements for this study .
Assessment of Disease using RECIST 1.[ADDRESS_781912] one lesio n (measurable and/or non -measurable) that can be 
accurately assessed at baseline by  [CONTACT_592763]  (CT), m agnetic resonance 
imaging (MRI) or plain X -ray should be included in this study .
Measurable lesions
A lesio n, not previously irradiated, that c an be measured accurately at baseline as ≥10mm in 
the longest diameter (except lymph nodes which must have a short axis ≥15mm with CT or 
MRI and which is suitable for accurate repeated measurements).
Non-measurable lesions
All other lesio ns, including small lesio ns (lo ngest di ameter < 10mm or pathological 
lymph nodes with ≥10mm to < 15mm short axi s at baseline). Nodes with < 10mm short 
axis are considered non -pathol ogical and shoul d not be recorded as non -target lesio ns 
(NTLs)
Truly non -measurable lesions include the following: bone lesions, leptomeningeal 
disease, ascites, pleural / pericardial effusio n, inflammatory  breast di sease, lymphangit ic 
involvement of skin or lung, abdominal masses/abdominal organo megaly ident ified by 
[CONTACT_592764] m easurable by [CONTACT_462]
Previously  irradiated l esions as l ocalised post -radiation changes, which affect lesio n sizes, 
may occur. Therefore, lesio ns that have been previously irradiated will not be considered 
measurable and should be selected a s NTLs at baseline and fo llowed up as part of the 
NTL assessment
Skin l esions assessed by [CONTACT_198278] 
Brain metastasis
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 117of 170Special cases
Lytic bone lesio ns or mixed ly tic–blast ic lesio ns, with ident ifiable so ft tissue com ponents, 
can be considered me asurable if the soft tissue component meets the definit ion of 
measurabilit y. Blast ic lesio ns are considered non -measurable.
Cystic metastases can be considered measurable lesions if they meet the criteria for 
measurabilit y from a radi ological  point of view , but if non -cystic lesions are present in the 
same parti cipant, these non -cystic lesio ns shoul d be sel ected as the target lesio ns (TLs).
Target lesions
A maximum of 5 measurable lesio ns (with a maximum o f 2 lesions per organ), representative 
of all lesio ns invo lved suitable for accurate repeated measurement, should be identified as TLs 
at baseline.
Non-target lesions
All other lesio ns (or sites of disease) not recorded as TLs should be ident ified as NTLs at 
baseline.
Methods of Measurement
The same method of assessment and the same technique should be used to characterise each 
ident ified and reported lesio n at baseline and during fo llow-up.
The m ethods to be used for RECIST assessment are summarised in Table 21and those 
excluded for tumour assessments in this study  are di scussed below, with the rationale 
provi ded.
Table [ADDRESS_781913] (preferred) CT (preferred) CT (preferred)
MRI MRI MRI
Plain X -ray (includes chest X -ray)Plain X -ray (includes chest X -ray)
Clinical examination Clinical examination
Ultrasound
Bone scan
FDG -PET
Clinical Study Protocol -Amendment [ADDRESS_781914] examinat ions will be used to assess tumour burden at 
baseline (including assessment of brain lesio ns at baseline in participants with no known brain 
metastases) and fo llow-up visit s. CT examinat ion with intravenous contrast media 
administration is the preferred method. MRI should be used where CT is not feasible, or it is 
medically contraindicated, for pre -existing brain metastases, and when there is a clinical 
suspi[INVESTIGATOR_24510] n of brain metastases.
Clinical examination
Clinical examinat ion will not be used for assessment of TLs. Clinically d etected l esions can be 
selected as TLs if they  are then assessed by [CONTACT_76480]. Clinical examinat ion can be 
used to assess NTLs in participants that also have other lesio ns assessable by  [CONTACT_4654], MRI or 
plain X -ray and to i dentify the presence of new lesio ns.
X-rays
Plain X -ray
Plain X -rays may  be used as a m ethod of assessment for bone NTLs and to ident ify the 
presence of new bone lesio ns.
Chest X -ray
Chest X -rays will  not be used for assessment of TLs as they  will be assessed by [CONTACT_592765]. Che st X-rays can, however, be used to assess NTLs and to ident ify the presence 
of new lesio ns.
Ultrasound
Ultrasound examinat ion will not be used for assessment of TLs and NTLs as it is not a 
reproducible method, does not provide an accurate assessment of tum our si ze and i t is 
subjective and operator dependent. Ultrasound examinat ion can, however, be used to ident ify 
the presence o f new lesio ns. If new clinical symptoms occur and an ultrasound is performed, 
then new lesio ns should be confirmed by [CONTACT_592766].
Clinical Study Protocol -Amendment [ADDRESS_781915] ic origin of any effusio n that appears or worsens 
during treatment is required when the measurable tumour has m et cri teria for response or 
stable disease (SD). In such circumstances, the cy tology is necessary  to differentiate between 
response / SD (an effusio n may be a si de effect of the treatment) and progressive disease (if 
the neopl astic origin of th e fluid is confirmed). Where cy tology findings are not available, any  
effusio n that significant ly worsens (from trace to large) or the appearance of a clinically 
significant effusio n (requi ring change in drug therapy ) during the study  treatm ent will  be 
considered to be progression o f NTLs or disease progression due to new lesions.
Isotopic bone scan
Bone l esions i dentified on an isotopic bone scan at baseline and confirmed by [CONTACT_4654], MRI or 
X-ray at baseline should be recorded as NTLs and fo llowed by [CONTACT_63931] m ethod as per 
baseline assessment.
Isotopi c bone scans m ay be used as a method of assessment to ident ify the presence of new 
bone lesio ns at follow -up visi ts. New l esions will  be recorded where a positive hot -spot that 
was not present on the baseline bone s can assessment is ident ified on a bone scan performed 
at any  time during the study . The invest igator should consider the posit ive hot-spot to be a 
significant new site of malignant disease and represent true disease progression in order to 
record the new l esion. Confi rmation by [CONTACT_4654], MRI and X -ray is recommended where bone scan 
findings are equivocal.
FDG -PET scan
FDG -PET (fl uorodeoxy glucose posi tron emissio n tomography ) scans may  be used as a 
method for ident ifying new lesio ns, according with the fo llowing a lgori thm: New lesi ons will  
be recorded where there is posit ive FDG uptake (defined as when an uptake greater than twice 
that of the surrounding tissue is observed) not present on baseline FDG -PET scan or in a 
location corresponding to a new lesio n on CT/MR I at the same fo llow-up visi t. If there i s no 
baseline FDG -PET scan available, and no evidence of new lesio ns on CT/MRI scans then 
Clinical Study Protocol -Amendment [ADDRESS_781916]/MRI assessments should be cont inued, scheduled as per protocol or clinical 
indicated, in order to confirm new le sions.
Tumour response evaluation
Schedule of evaluation
Baseline tumour assessments should enco mpass all areas of known predilect ion for metastases 
in the disease under evaluation and should addit ionally  invest igate areas that may be invo lved 
based on sig ns and symptoms of individual part icipants and should be performed according to 
the respective schedule of activit ies unt il objective radiographic disease progression is 
registered according to the protocol requirements or withdrawal of consent. Any other sites at 
which new disease is suspected should also be adequately imaged at follow -up.
Target lesions
Documentation of target lesions
A maximum of 5 measurable lesio ns, with a maximum o f 2 lesions per organ (including 
lymph nodes), representative of all le sions involved, should be identified as TLs at baseline. 
Target l esions shoul d be selected on the basis of their size (longest diameter for non -nodal  
lesions or short axis for nodal lesio ns) but in addit ion should be those that lend themselves to 
reproduci ble repeated measurements. It may be the case that, on occasion, the largest lesio n 
does not l end i tself to reproducible measurement in which circumstance the next largest 
lesion, which can be measured reproducibly, should be selected.
The site and locat ion of each TL should be documented as well as the longest diameter for 
non-nodal  lesions (or short axis for lymph nodes). All measurements should be recorded in 
millimetres. At baseline, the sum of the diameters for all TLs will be calculated and reported 
as the baseline sum of diameters. At follow -up visits the sum  of diameters for all TLs will be 
calculated and reported as the follow -up sum  of diam eters.
Special cases:
For TLs m easurable in [ADDRESS_781917] diameter. For 
pathol ogical lymph nodes measurable in 2 or 3 dimensions, always report the short axis.
If the CT/MRI slice thickness used is > 5mm, the minimum size of measurable disease at 
baseline should be twice the slice thickness of the baseline scan.
If a lesio n has co mpletely disappeared, the longest diameter should be recorded as 0 mm.
If a TL split s into [ADDRESS_781918] the sum of the diameters of those parts.
If 2 or more TLs merge, then the sum of the diameters of the combined lesion should be 
recorded f or one of the lesio ns and 0 mm recorded for the other lesio n(s).
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 121of 170If a TL i s believed to be present and is faint ly seen but too sm all to measure, a default 
value of 5 mm should be assigned. If an accurate measure can be given, this should be 
recorded, even if it is below 5 mm.
If a TL cannot be measured accurately due to it being too large, provide an est imate of the 
size of the lesio n.
When a TL has had any intervent ion eg, radi otherapy , embo lisation, surgery  etc., during 
the study , the si ze of the TL shoul d still be provi ded where possible.
Evaluation of target lesions
Table 22provides the definit ions of the cri teria used to determine objective tumour vi sit 
response for TLs.
Table 22 Overall Visit Response for Target Lesions
Complete Response (CR) Disappearance of all TLs since baseline. Any pathological lymph 
nodes selected as TLs must have a reduction in short axis to < 10mm.
Partial Response (PR) At least a 30% decrease in the sum of diameters of TLs, taking as
reference the baseline sum of diameters.
Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify  for PD.
Progressive Dis ease (PD) At least a 20% increase in the sum of diameters of TLs, taking as
reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 
20%, the sum must also demonstrate an absolute increase of at least 
5mm.
Not Evaluable (NE) Only relevant if any of the TLs were not assessed or not evaluable or 
had a lesion intervention at this visit.
Note: If the sum of diameters meets the progressive disease criteria, 
progressive diseas e overrides not evaluable as a TL response.
Non-Target lesions
Evaluation of non -target lesions
All other lesio ns (or sites of disease) not recorded as TLs should be ident ified as NTLs at 
baseline. Measurements are not required for these lesio ns, but their status should be fo llowed 
at subsequent visits. At each visit, an overall assessment of the NTL response should be 
recorded by  [CONTACT_3170]. Table 23provi des the definit ions of the criteria used to determine 
and record overall response for NTL s at the invest igational site at each visit.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 122of 170Table 23 Overall Visit Response for Non -Target Lesions
Complete Response (CR) Disappearance of all NTLs since baseline. All lymph nodes must be 
non-pathological in size (< 10mm short ax is).
Non-CR/Non -PD Persistence of one or more NTLs.
Progressive Disease (PD) Unequivocal progression of existing NTLs. U nequivocal pro gression 
may be due to an important progression in one lesion only or in several 
lesions. In all cases the progression M UST clinically significant for the 
physician to consider changing or stoppi[INVESTIGATOR_7374].
Not Evaluable (NE) Only relevant when one or some of the NTLs were not assessed and in 
the investigator’s opi[INVESTIGATOR_592714].
Note: For participants without TLs at baseline, this is relevant if any of 
the NTLs were not assessed at this visit and the progression criteria 
have not been met.
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall level o f 
substant ial worsening in non -target disease such that, even in presence of SD or PR in TLs, 
the overall tumour burden has increased sufficient ly to merit discont inuat ion of therapy . A 
modest ‘increase’ in the size of one or mor e NTLs is usually not sufficient to qualify for 
unequivocal progression status.
New Lesions
Details o f any new lesio ns will also be recorded with the date of assessment. The presence of 
one or m ore new l esions is assessed as progression.
A lesio n identified at a follow -up assessment in an anatomical locat ion that was not scanned at 
baseline is considered a new lesio n and will indicate disease progression.
The finding of a new lesio n shoul d be unequivocal: ie, not attributable to differences in 
scanning technique, change in imaging modalit y or findings thought to represent something 
other than tumour.
If a new lesio n is equivocal, for example because of its small size, the treatment and tumour 
assessments should be cont inued unt il the new lesion has been confirmed. If repeat scans 
confirm there is a new lesio n, then the progression date should be declared using the date of 
the init ial scan.
Symptomatic deterioration
Symptom atic deteri oration is not a descriptor of an object ive response: it is a reason for 
stoppi[INVESTIGATOR_45806] .
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 123of 170Tumour response data for participants with ‘symptomat ic deterioration’ which required 
discontinuat ion of study  treatm ent and wi thout objective radiographic disease progression 
according to the protocol requirements will be cens ored at the date of their last RECIST 
assessment.
Evaluation of Overall Visit Response and Best Overall Response
The overall visit response will be derived using the algorithm shown in Table 24.
Table 24 Overall Visit Response
Target Lesions Non-target lesions New Lesions Overall response
CR CR No CR
CR NA No CR
NA CR No CR
CR Non-CR/Non -PD No PR
CR NE No PR
PR Non-PD or NE No PR
SD Non-PD or NE No SD
NA Non-CR/Non -PD No SD (Non -CR/Non -PD)
NE Non-PD or NE No NE
NA NE No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Abbreviations: CR=complete response; IR=incomplete response; NA=not applicable (relevant when no 
TLs/NTLs at baseline); NE=not evaluable; PD=progressive disease; PR=partial response; SD=stable disease.
Specifications for Radiological Imaging
These notes are recommendations for use in clinical studies. The use of standardised protocols 
for CT and MRI allows co mparabilit y both within and between different studies, irrespect ive 
of where the examinat ion has been undertaken.
CT Scan
CT scans of the chest, abdomen, and pelvis should be cont iguous throughout all the 
anatomical regio ns of interest. 
Clinical Study Protocol -Amendment [ADDRESS_781919] administration
Optimal visualisat ion and m easurement of m etastases in so lid tumours requires consistent 
administration (dose and rate) of intravenous contrast as well as t iming o f scanning. Ty pi[INVESTIGATOR_897], 
most abdo minal imaging is performed during the portal venous phase and (optimally ) about 
the sam e time frame after inject ion on each examinat ion. An adequate v olume of a suitable 
contrast agent should be given so that the metastases are demonstrated to best effect and a 
consistent method is used on subsequent examinat ions for any  given part icipant. It is very  
important that the same technique be used at baseline and on follow -up examinat ions for a 
given participant. For participants who develop contraindicat ions to contrast after baseline 
contrast CT is done, the decisio n as to whether non -contrast CT or MRI (enhanced or non -
enhanced) should be performed should also be based on the tumour ty pe, anatomic location o f 
the disease and should be optimised to allow for comparison to the prior studies if possible. 
Each case should be discussed with the radio logist to determine if substitution of these other 
approaches i s possible and, if not, the participant should be considered not evaluable fro m that 
point forward. Care must be taken in measurement of TLs on a different modalit y and 
interpretati on of  non-target di sease or new l esions, since the same lesion may appear t o have a 
different size using a new modalit y. Oral  contrast is recommended to help visualise and 
different iate structures in the abdo men.
If iodine contrast m edia is medically  contraindicated at baseline or at any  time during the 
course of the study , then the recommended methods are: CT thoracic examinat ion without 
contrast and abdominal and pelvic MRI with contrast. If MRI cannot be performed then CT 
without intravenous contrast is an option for the thorax, abdomen and pelvic examinat ions. 
Clinical Study Protocol -Amendment [ADDRESS_781920] itutions may  perf orm medically acceptable scans at 
slice thi cknesses greater than 5 mm. If this occurs, the minimum size of measurable lesions at 
baseline should be twice the slice thickness of the baseline scans.
All window settings should be included in the ass essment, parti cularly in the thorax where 
lung and soft tissue windows should be considered. When measuring lesio ns, the TLs should 
be measured on the same window setting for repeated examinat ions throughout the study . All 
images from each examinat ion shou ld be included in the assessment and not “selected” 
images of the apparent lesio n.
MRI Scan
MRI has excellent contrast, spatial and temporal resolut ion; however, there are many  image 
acquisit ion variables invo lved in MRI, which greatly impact image quali ty, lesion conspi[INVESTIGATOR_72922] y 
and measurement. Furthermore, the availabilit y of MRI i s variable gl obally. The m odali ty 
used at follow -up shoul d be the same as was used at baseline and the lesio ns should be 
measured/assessed on the same pulse sequence. Genera lly, axial  imaging of the abdom en and 
pelvis wit h T1 and T2 weighted imaging along wit h gado linium -enhanced imaging should be 
perform ed. The field of view, matrix, number of excitat ions, phase encode steps, use of fat 
suppressio n and fast sequences should be optimised for the specific body  part being imaged as 
well as the scanner utilised. It is bey ond the scope of this appendix to prescribe specific MRI 
pulse sequence parameters for all scanners, body  parts and diseases. Ideally , the same t ype of 
scanner s hould be used, and the image acquisit ion protocol should be fo llowed as closely  as 
possible to prior scans. Body  scans shoul d be perform ed wi th breath -hold scanning techniques 
if possible.
For these reasons, CT is the imaging modalit y of choi ce.
FDG -PET sc ans
FDG -PET has gained acceptance as a valuable tool for detecting, staging and restaging several 
malignancies. If FDG -PET scans are included in a protocol, an FDG uptake period of [ADDRESS_781921] ion. PET camera specificat ions are variable and 
manufacturer specific, so every  attem pt shoul d be made to use the same scanner, or the same 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 126of 170model scanner, for seri al scans on the sam e participant. Who le-body  acquisit ions can be 
perform ed in eit her 2 -or 3-dimensio nal mode wi th attenuati on correcti on, but the m ethod 
chosen should be consistent across all part icipants and serial scans in the clinical study .
PET/CT scans
At present, low dose or attenuation correction CT portions of a combined PET –CT are of 
limited use in anatomically based efficacy  assessments and it i s therefore suggested that they  
shoul d not be subst ituted for dedicated diagnostic contrast enhanced CT scans f or tum our 
measurements by  [CONTACT_393] 1.1. In except ional situations, if a si te can docum ent that the CT 
perform ed as part of a PET –CT is o f ident ical diagnostic qualit y to a diagnost ic CT (with IV 
and oral contrast) then the CT portion of the PET –CT can be use d for RECIST m easurements. 
However, this is not recommended because the PET portion of the CT introduces addit ional 
data that may bias an invest igator if it is not routinely or serially performed.
F1 REFERENCES
Eisenhauer et al, [ADDRESS_781922] R et al. New response 
evaluat ion criteria in solid tum ours: Revised RECIST guideline (versio n 1.1). European 
Journal  of Cancer 2009;45:228 -247.
Clinical Study Protoc ol-Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 127of 170Appendix GGuidelines for Evaluation of Objective Tumour Response 
Using PCWG3 (P rostate Cancer Working Group Criteria 3) 
in Bone Lesions
Introduction
This appendix details the implementation o f PCWG3 guidelines ( Scher et al 2016 ) forthe 
study  with regards to assessment of tumour burden including protocol -specific requirements 
for this study .
Assessment of Bone Lesions Progression Using PCWG3 Criteria
Bone l esions will be assessed by [CONTACT_592750] v1.[ADDRESS_781923] 1.1 (soft 
tissue) or PCWG3 (bone). 
If an unscheduled assessment was performed and the participant has not progressed, every  
attem pt shoul d be made to perform the subsequent assessments at their originally scheduled 
visits. Thi s schedule is to be fo llowed in order to minimise any  unintent ional bias caused by 
[CONTACT_592767] a different frequency than other participants.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 128of 170Docum entati on of  lesions
All bone l esions (or si tes of  disease) shoul d be ident ified at baseline. Their status should be 
followed at subsequent visits. At each visit an overall assessment of the bone lesio n 
progression should be recorded by  [CONTACT_3170]. This section provides the definit ions of the 
criteria used to determine and record bone progression at the investigat ional site at each visit.
Progression on a bone scan is identified using PCWG3 as fo llow:
At the 8 week scan:
[ADDRESS_781924] 6 weeks l ater and 
preferably no later than the next scheduled visit for a bone scan (ie, Week 16), must show 
2 or m ore addi tional new m etastati c bone lesio ns (for a total of 4 or more new metastatic 
bone lesio ns since the baselin e assessment) for progressio n to be documented.
Note -The first bone scan completed after baseline will be considered the ‘8 -week scan’ 
regardl ess if taken at week 8 or at an unscheduled assessment.
After the 8 week scan:
[ADDRESS_781925] documents the second lesion.
Evaluation of bone progression status
Table 25provides the definit ions for the visit bone progression status for bone lesio ns.
Table 25 Bone Progression Status
Non-Progressive Disease (Non -PD) No evidence of progression, or appearance of one new bone lesion, 
or non-fulfilment of the progression criteria including new lesions 
without confirmation of progression.
Progressive Disease (PD) Bone lesions fulfilling the requirements for at least 2 new lesions 
and confirmation of progression.
Not Evaluable (NE) Only relevant if a follow -up bone scan is not performed.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 129of 170Overall radiological visit assessment in prostate cancer. 
Table 26provides the definit ions for how the visit responses for soft tissue (according to 
RECIST 1.1 criteria) and bone progression status (according to PCWG3 criteria) are 
combined to give an overall radio logical object ive visit response.
Table 26 Overall Radiological Visit Response
Overall visit soft 
tissue response 
(RECIST 1.1)Bone progression 
status (PCWG3)Bone lesions at visit 
Present/AbsentOverall radiological 
visit response
CR Non-PD Absent CR
CR Non-PD Present PR
CR NE - PR
PR Non-PD or NE Any PR
SD Non-PD or NE Any SD
NED Non-PD or NE Any Non-PD
NE Non-PD or NE Any NE
PD Any Any PD
Any PD Any PD
Abbreviations: CR=complete response; IR=incomplete response; NE=not evaluable (only relevant if a follow -up 
bone scan is not performed), NED=No Evidence of Disease (only relevant when there is no TL and NTL from 
baseline); PD=progressive disease; PR=partial response; SD=stable disease.
Confirmation of response
In thi s study , imaging for confirmat ion of response (CR or PR) shoul d be perform ed at the 
next scheduled RECIST and PCWG3 assessment (and must not be less than 4 weeks later) 
following the date the criteria for response were first met.
Table [ADDRESS_781926] overall response
PR PR PR
PR SD SD
PR PD SD or PD
PR NE SD or NE
NE NE NE
Abbreviations: CR=complete response; NE=not evaluable; PD=progressive disease; PR=partial response; 
SD=stable disease.aif a CR is truly met at first time point, then any disease seen at subsequent time point, even disease meeting 
PR criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after 
CR). Best response would depend on whether minimum duration for SD was met. However, sometimes 
‘CR’ may  be claimed when subsequent scan suggest small lesions were likely still present and in fact the 
participant had PR, not CR at the first time point. Under these circumstances, the origina l CR should be 
changed to PR and the best response is PR.
G1 REFERENCES
Scher et al [ADDRESS_781927] ives for castration -resistant 
prostate cancer: Updated recommendations from the Prostate Cancer Clinical Tr ials Working 
Group 3. J Clin Onco l 34 (2016).
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 131of 170Appendix HAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
H1 Definition of adverse events
An adverse event is the development of any untoward medical occurrence in a participan t or 
clinical study  parti cipant administered a medicinal product and which does not necessarily 
have a causal relat ionship with this treatment. An AE can therefore be any unfavourable and 
unintended sign (eg, an abnormal laboratory  finding), symptom (for e xample nausea, chest 
pain), or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of a pre -exist ing medical occurrence. An AE may  occur at any  time, including 
run-in or washout periods, even if no Study treatment has been administered.
H2 Definitions of serious adverse event
A serious adverse event is an AE occurring during any study  phase (ie, run -in, treatment, 
washout, follow -up), that fulfils one or more of the fo llowing cri teria:
Results in death
Is immediately life -threatening
Requi res in -partici pant hospi [INVESTIGATOR_122568] n of exist ing hospi[INVESTIGATOR_72913] 
Results in persistent or significant di sabili ty or incapaci ty
Is a congenital anomaly or birth defect
Is an important medical event that may jeopardise the participant or may require medical 
treatm ent to prevent one of the outcomes listed above
Adverse Events (AEs) for malignant tumours reported during a study  shoul d generally  be 
assessed as Serious AEs. If no other seriousness criteria apply, the ‘Important Medi cal Event’ 
criterion shoul d be used. In certain situat ions, however, medical judgement on an individual 
event basis shou ld be applied to clarify that the malignant tumour event should be assessed 
and reported as a Non-Serious AE. For example, if the tumour is included as medical history  
and progression occurs during the study , but the progressi on does not change treatment a nd/or 
prognosi s of the m alignant tum our, the AE m ay not fulfil the attributes for being assessed as 
Serious, al though reporting of the progression of the malignant tumour as an AE is valid and 
shoul d occur. Also, some types of malignant tumours, which do n ot spread remotely after a 
routi ne treatm ent that does not require hospi[INVESTIGATOR_72913], may be assessed as Non -Serious; 
examples in adults include Stage [ADDRESS_781928] ion is a new 
malignant tumour (ie, it is notthe tum our f or whi ch entry  into the study  is a cri terion and that 
is being treated by  [CONTACT_592768] ). Malignant tum ours that –as part of normal, if 
rare, progression –undergo transformat ion (eg, Richter's transformat ion of B cell chronic 
lymphocy tic leukaemia into diffuse large B cell lymphoma) should not be consid ered a new 
malignant tumour.
Life-threatening
‘Life -threatening’ means that the participant was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
participant’s death. ‘Life -threatening’ does not m ean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepatic failure).
Hospi[INVESTIGATOR_72917] a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema). Hospi[INVESTIGATOR_2144]/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the participant was enrolled in the study , provi ded that i t did not deteri orate in 
an unexpected way  during the study .
Important medical event or medical treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life -threatening or resul t in 
death, hospi [INVESTIGATOR_72913], disabili ty or incapaci ty but may jeopardise the participant or may  
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgement must be used.
Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
Hepatotoxicit y caus ed by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_72913]
Development of drug dependency or drug abuse
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 133of 170Intensity rating scale:
mild (awareness of sign or symptom, but easily tolerated)
moderate (di scomf ort sufficient to cause interference with normal act ivities)
severe (in capacitat ing, with inabilit y to perform norm al activities)
It is important to dist inguish between serious and severe AEs. Severit y is a measure of 
intensity whereas seri ousness is defined by [CONTACT_73010]  H 2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it mee ts the cri teria 
shown in Appendix H 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild str oke but would be a SAE when it satisfies the criteria 
shown in Appendix H 2.
The grading scales found in the revised National Cancer Inst itute CTCAE latest versio n will 
be utilised for all events with an assigned CTCAE grading. For those events without assigned 
CTCAE grades, the recommendation in the CTCAE criteria that converts mild, moderate and 
severe events into CTCAE grades should be used. A copy  of the CTCAE can be downloaded 
from the Cancer Therapy  Evaluat ion Program websi te (http://ctep.cancer.gov ).
H 3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by [CONTACT_33641].
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug?  Di d the AE occur i n a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated f rom its pharmacol ogical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause. The AE cannot be reasonably explained by [CONTACT_73011], other drugs, other host or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the suspected drug was reintroduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a re-
challenge .
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 134of 170In difficult cases, other factors could be considered such as:
Is this a recogni sedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related’ is made if following a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case. The expressio n 
‘reasonable possibilit y’ of acausal relationship is meant to convey, in general , that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgement. With no available facts or arguments to suggest 
a causal relat ionship, the event(s) will be assessed as ‘not related’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
H4 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study  intervent ion that either causes harm to the 
participant or has the potential to cause harm to the participant. 
A medicat ion error is not lack o f efficacy  of the drug, but rather a human or process related 
failure while the drug is in control of the study  site staff or parti cipant.
Medicat ion error includes situat ions where an error. 
occurred
was i dentified and intercepted before the participant received the drug
did not occur, but circumstances were recognised that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error eg, medication prepared incorrectly , even i f it was not actually  given to 
the participant
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated eg, tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed eg, kept in the fridge when it should be at room temperature 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 135of 170Examples of events that do not require reporting as medicat ion errors in clinical studies:
Parti cipant acci dentally  missed drug dose(s) eg, forgot to take medication
Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open -label studi es, even if an [COMPANY_008] product 
Medication errors are not regarded as AEs but AEs may occur as a consequence of the medication 
error .
Clinical Study Protocol -Amendment [ADDRESS_781929] igator at each centre keeps full traceability of co llected bio logical sam ples f rom the 
participants while in storage at the centre until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples whilst at site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
[COMPANY_008] or delegated representatives w ill keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders.
Samples retained for further use will be stored in the AstraZenec a-assigned bi obanks or other 
sample archive facilit ies and will be tracked by  [CONTACT_592769].
I2 Withdrawal of Informed Consent for donated biological samples 
If a participant withdraws study  conse nt samples collected fro m the parti cipant will be 
disposed of/destroy ed/repatri ated, and the action documented. If samples are already analysed ,
[COMPANY_008] is not obliged to destroy  the resul ts of this research.
[COMPANY_008] ensures the organisat ion(s) ho lding the sam ples is/are inform ed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action documented and study  site notified.
I3 International Airline Transportation Association (IATA) 6.[ADDRESS_781930] SAMPLES
International Airline Transportation Associat ion (IATA) 
(https://www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal  disease in 
otherwi se healt hy humans or animals. 
Category A pathogens are eg, Ebol a, Lassa fever virus. Infectious substances meet ing these 
Clinical Study Prot ocol -Amendment [ADDRESS_781931] be assigned to UN 
2900:
Category B In fectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are eg, Hepatit is A, C, D, and E viruses. They  
are assigned the fo llowing UN number and proper shippi[INVESTIGATOR_72919]
UN 3373 –Biological Substance, Category  B
are to be packed in accordance with UN3373 and IATA [ADDRESS_781932] to these regulat ions unless they 
meet the criteria for inclusio n in another class.
Clinical study  samples will fall into Category  B or exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 compliant packaging
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf).
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry  ice content
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 138of 170Appendix JOptional Genomics Initiative Sample
J1 Use/analysis of DNA
[COMPANY_008] intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o f diseases, and the response 
to medicat ions. This genetic research may lead to better understanding of d iseases, better 
diagnosis of diseases or other improvements in healt h care and to the discovery o f new 
diagnosti cs, treatm ents or m edicat ions. Therefore, where local regulat ions and IRB/IEC 
allow, a blood sample and t issue samples will be collected for DNA analysis fro m 
consent ing participants.
This optional genet ic research may consist of the analysis o f the structure of the 
participant´s DNA, i e, the enti re genom e. 
The results of genet ic analyses may be reported in a separate study summary.
The sponsor w ill store the DNA samples in a secure storage space with adequate 
measures to protect confident iality.
The samples will be retained while research cont inues but no longer than 15 years or 
other period as per local requirements.
J2 Genetic research plan and p rocedures
Selection of genetic research population
All participants will be asked to participate in this genet ic research. Participat ion is 
voluntary and if a participant declines to participate there will be no penalt y or loss of 
benefit. The participant will not be excluded fro m any aspect of the main study .
Inclusion criteria
For inclusio n in this genet ic research, participants must fulfil all of the inclusio n criteria 
described in the main body  of the Clinical Study  Protocol  and: Provi de informed conse nt for 
the Geno mics Init iative sampling and analyses.
Exclusion criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in 
the main study  or any  of the f ollowing:
Previous allogeneic bone marrow transplant
Non-leuko cyte depl eted whole blood transfusio n in [ADDRESS_781933] ion
Healthy Vol unteers and paediatric participant samples will not be collected for the 
Geno mics Init iative.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 139of 170Withdrawal of consent for genetic research:  
Parti cipants may  withdraw from this genet ic research at any t ime, independent of any 
decisio n concerning participation in other aspects of the main study . Vol untary  
withdrawal  will not prej udice further treatment. Procedures for withdrawal are outlined in 
section 7.2of the m ain Clinical Study  Protocol .
Collection of samples for genetic research
The blood sample for this genetic research will be obtained fro m the parti cipants at on 
Cycle [ADDRESS_781934] ion is preferred to avoid 
introducing bias through excluding participants who may  withdraw due to an adverse 
event (AE). If for any  reason the sample is not drawn on Cycle [ADDRESS_781935] study visit. Only one sample should be collected per participant 
for genet ics during the study .
Details o f sample collection, processing, shippi[INVESTIGATOR_592715].
Coding and storage of DNA samples
The processes adopted for the coding and storage of samples for genet ic analysis are 
important to maintain participant confident iality. Sam ples will  be stored for a m aximum  
of 15years, from the date of last participant last visit, after which they will be destroy ed. 
DNA is a finite resource that is used up during analyses. Samples will be stored and used 
until no further analyses are possible or the maximum storage time has been reached.
An addit ional second code will be assigned to the sample either before or at the time of 
DNA extraction replacing the informat ion on the sample tube. Thereafter, the sample will 
be ident ifiable only by [CONTACT_33160], unique number. This number is used to identify the 
sample and corresponding data at the [COMPANY_008] genet ics laboratori es, or at the 
designated organisation. No personal details ident ifying the individual will be available to 
any person ([COMPANY_008] emplo yee or desi gnated organi sations working with the DNA).
The link between the participant enrolment co de and the second number will be 
maintained and stored in a secure environment, with restricted access at [COMPANY_008] or 
designated organisations. The link will be used to ident ify the relevant DNA samples for 
analysis, facilitate correlat ion of genoty pic resul ts wi th clinical  data, all ow regulatory  
audit, and permit tracing of samples for destruction in the case of withdrawal of consent.
Ethical and regulatory requirements
The principles for ethical and regulatory  requi rements for the study , incl uding thi s 
genet ics research component, are outlined in Appendix B.
Informed consent
The genetic component of this study  is opti onal and the parti cipant m ay part icipate in 
other components of the main study  without parti cipating in this genet ic component. To
participate in the genet ic component of the study the participant must sign and date both 
Clinical Study Protocol -Amendment [ADDRESS_781936] be given to the participant an d the 
original  filed at the study  centre. The Principal investigator(s) is responsible for ensuring 
that consent is given freely  and that the parti cipant understands that they  may freely 
withdrawal  from the genet ic aspect of the study at any time.
Partici pant data protection
[COMPANY_008] will not provide individual genoty pe resul ts to parti cipants, any  insurance 
company, any emplo yer, thei r family members, general physician unless required to do so 
by [CONTACT_2371].
Extra precautions are taken to preserve confident iality and prevent genetic data being 
linked to the ident ity of the parti cipant. In except ional circumstances, however, certain 
individuals might see both the genet ic data and the personal ident ifiers of a participant. 
For example, in the case of a medical e mergency , an [COMPANY_008] Physician or an 
investigator might know a participant’s ident ity and al so have access to his or her genetic 
data. Regul atory  authori ties may requi re access to the rel evant files, though the 
participant’s m edical  information and the genet ic files would remain physically separate.
Data management
Any genet ic data generated in this study will be stored at a secure system at [COMPANY_008] 
and/or designated organisat ions to analyse the samples.
[COMPANY_008] and its designated organisat ionsmay share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with 
other researchers, such as hospi[INVESTIGATOR_600], academic organisations or healt h insurance 
companies. This can be done by [CONTACT_89982] r esults in scientific databases, where they  can 
be co mbined with the results of similar studies to learn even more about health and 
disease. The researchers can only  use thi s inform ation for heal th-related research 
purposes. Researchers may  see summary  resu lts but they  will not be able to see individual 
participant data or any  personal ident ifiers. 
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic 
data in a suitable secure environment separate from the clinical database .
The results of this pharmacogenetic research will be reported separately and will not form 
part of the CSR.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 141of 170Appendix KATM Alterations Classification Guidance
ATM Classification Algorithm
for Definition of Qualifying Alterations
(based on Lynparza HRR Classificat ion Algori thm v2)
K1 Introduction
This appendix describes the geno mic alterat ions in the ATM gene that will be classified 
qualifying for the PLANETTE study  (“A Modul ar Phase 2a Mult icenter Open -Label Study  to 
Invest igate DNA -damage Response Agents (or Combinat ions) in Patients With Advanced 
Cancer Whose Tumo urs Contain Mo lecular Alterations”). These rules are based on Lynparza 
HRR classificat ion algorithm (used in [COMPANY_008] clinical trials).
The appendix is made available for information purposes only. Use of this guidance outside 
the PLANETTE study  is enti rely at the invest igator’s discretion.
This document contains 3 sections.  
Secti on K1.1describes the generic rules for determining qualifying mutations in ATM 
(EntrezID 472; RefSeq NM_000051).
Secti on K1.2describes a look -up list of qualifying mutations that do not meet the generic 
rules in sect ion K1.1.
Secti on K1.3describes the rationale and process for arriving at the qualifying mutations 
listed in sect ion K1.2.
K1.1 Instructions for generic eligibility criteria for ATM 
Classificat ion of variants will be conducted in accordance wit h the principles published in 
the American College of Medical Genet ics and Geno mics (ACMG) standards and 
guidelines for the interpretation of sequence variants ( Richards et al 2015 ).
For cl arificati on, only pat ients with “deleteri ous” or “suspected deleterious” variants will 
be considered q ualifying wit hin the PLANETTE study . Pati ents wi th variants of uncertain 
significance (VUS) will not be eligible .
The fo llowing al gorithm implements the cri teria specified above. If the variant meets any  of 
the following cri teria the pati ent is considered eligible for the study :
Mutati ons that resul t in truncati on of  the protein product, including:
Any nonsense mutations
Any frameshift indels
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 142of 170Any mutations in the consensus splice donor and acceptor sequence (5’ 
GT……intron…..AG 3’) that disrupts the consens us, including insert ions and 
deletions
Large -scale geno mic deletions (affect ing at least one who le exon), insertions or 
rearrangements
Any homozygous delet ion
Any missense, splice, nonsense, or short in frame delet ions not captured by  [CONTACT_592770], pathogenic, clinically  important, suspected del eterious or 
suspected pathogenic in the BIC or ClinVar database, or by  a validated Dx device, or 
known to be founder mutations in a given local regio n.
Any mutations not captured above but spec ified in the lookup table fro m Secti on K1.2.
K1.[ADDRESS_781937] the variant look -up lists for special variants. If the variant is pr esent in the 
separate look -up lists, the alteration is considered qualifying.
The current resultant lists are given below as Table 28and Table 29with numbering based on 
NM_000051 (ATM) transcript.
Table [ADDRESS_781938] for Deleterious Intronic Variants

Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C000 01
CONFIDENTIAL AND PROPRIETARY 143of 170K1.3 Procedures used to generate the look -up tables in Section K1.2
The fo llowing procedures were used to generate the static look -up tables wit h informat ion 
ClinVar to complement the generic rules fro m Sectio n K1.1. The tabl es were l ocked down on 
11Jan2016 (based on a November [ADDRESS_781939] from ClinVar).
The ClinVar database for variants in ATM was used with the fo llowing incl usion criteria:
In “Clinical significance”, with entries “pathogenic” or “likely pathogen ic”.
And variant specified as missense, or synonymous, or intronic .
And in “Review status”, with the entry  “expert panel”, which corresponds to the 3 
star rating as discussed with [COMPANY_008], or 2 star rating with mult iple consistent 
submissio n. The 4 sta r rating is a category called ‘Practice guideline’ that wasn’t 
available for any  missense m utations in these genes .
K2 References
Richards et al 2015
Richards S, Azi z N, Bale S, Bi ck D, Das S, Gasti er-Foster J, et al. Standards and guidelines 
for the interpr etation of  sequence variants: a jo int consensus recommendat ion of the American 
College o f Medical Genet ics and Geno mics and the Associat ion for Molecular Pathology . 
Genet Med. 2015;17(5):405 -24.
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 144of 170Appendix LAbbreviations
Abbreviation or special 
termExplanation
AE Adverse event
ALP Alkaline phosphatase
ALT Alanine transaminase
ANC Absolute neutrophil count
ANSM Agence Nationale de Sécurité du Médicament et des Produits de Santé (French 
Natio nal Agency for Medicines and Health Products Safety)
ARID1A AT-Rich Interaction Domain 1A
aST Advanced Solid Tumours
AST Aspartate transaminase
ATM Ataxia telangiectasia mutated
ATR Ataxia telangiectasia and rad3 related protein
BCRP Breast cancer resistance protein
BICR Blinded independent central review
BID Twice daily
BMI Body mass index
BP Blood pressure
BRCA1 BReast CAncer gene [ADDRESS_781940]
HIV Human immunodeficiency virus
HL Hy’s Law
HR Homologous recombination
HRR Homologous recombination repair
IATA International Airline Transportation Association
IB Investigator’s Brochure
ICF Informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IgG Immunoglobulin G
IHC Immuno histochemistry
IMP Investigational Medicinal Product
IND Investigational New Drug
Clinical Study Pr otocol -Amendment [ADDRESS_781941]
IVRS Interactive Voice/Web Response System
LHRH Luteinizing hormone -releasing hormone
mCRPC Metastatic castration -resistant prostate cancer
MRI Magnetic resonance imaging
NE Not evaluable
NGS Next generation sequencing
NHA Novel hormonal agent
NTRK Neurotrophic tyrosine receptor kinase
ULN Upper limit of normal
NSCLC Non-small -cell lung carcinoma
NTL Non-target lesions
OATP1B1 Organic anion transporter protein B1
ORR Objective response rate
OS Overall survival
PARP Poly (ADP -ribose) poly merase
PCWG3 Prostate Cancer Working Group 3
PD Progressive disease
PDc Pharmacodynamic
PET Positron emission tomography
PFS Progression free survival
PHL Potential Hy’s Law
Pgp P-glycoprotein
PI [INVESTIGATOR_592716] -Amendment [ADDRESS_781942]
QTcF The corrected QT interval (QTc) according to Fridericia's formula
WBDC Web Based Data Capture
WHO World Health Organization
WOCBP Women of childbearing potential
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-dama ge response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 150of 170Appendix MProtocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment 3 (04 -Apr-2022 )
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n. 
Overall Rationale for the Amendment:
Preliminary data (Yap et al. Can cer Discov. 2021;11(1):80 -91.) showed that patients with 
either ATM mutati on, or ATM protein loss, or both had benefit on an ATR inhibitor. In 
Module 1 we used an arbitrary  60% threshol d for the minimum number of patients with ATM 
protein loss. However, th ere is no robust justificat ion for this thresho ld, and it is impeding 
recrui tment, therefore we propose to remove the 60% thresho ld for both cohorts A and B. This 
amendment will not impact the primary  analysis, and the subgroup analysis will st ill be 
condu cted and pati ents’ tum or sam ples tested retrospect ively .
Section # and Name [CONTACT_415588]/Non -
Substantial
MODULE 1 (Section 11) 
Ceralasertib Monotherapy in ATM Altered Advanced Solid Tumours (aST) and Prostate Cancer
8.3.1 Time Period and 
Frequency for Collecting 
AE and SAE InformationDeletion of the text “a participant has 
completed the study” and addition of 
text “last safety follow up visit"to clarify  
collection of 
SAEs 
discontinues 
after safety 
follow up visit.Non-substantial
11.1.1 M1 Synopsis, 
Number of Participants 
Cohort ADeletion of text “ensuring at least 60% 
of participants with ATM IHC ≤ 5% ”Please see 
overall rationaleSubstantial 
11.1.1 M1 Synopsis, 
Number of Participants 
Cohort BDeletion o f text “ensuring at least 60% 
of participants with ATM IHC ≤ 5%”Please see 
overall rationaleSubstantial
11.1.2 M1 Study Design Deletion of footnote 2 “2A minimum 
of 60% participants will be ATM IHC 
≤ 5% (ie n=15) in addition to having a 
deleterious or suspected deleterious (or 
pathogenic/likely pathogenic) mutation 
in the ATM gene. ATM ‘deficient’ is Please see 
overall rationaleSubstantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 151of 170defined as ATM IHC ≤ 5% ATM -
positive tumour nuclei using the 
Ventana assay (VENTANA ATM 
(Y170) RPA Assay)”
11.1.3 Schedule of 
Activities (SoA) Table 3, 
Footnote AAddition of the text “If prospective 
central ATM NGS testing is 
introduced” and “must submit a 
sample”Clarification 
that this relates 
to prospective 
NGS testing 
onlyNon-substantial
11.1.3 Schedule of 
Activities (SoA) Table 3, 
Footnote EAddition of the text “scheduled” Clarification 
that  is 
only taken at 
scheduled 
assessments and 
at progressionNon-substantial
11.1.3 Schedule of 
Activities (SoA) Table 3, 
Footnote LAddition of the text “All safety 
assessments and laboratory results 
must be reviewed by [CONTACT_592771]”Clarification Non-substantial
11.2 M1 Introduction Deletion of the text “ensuring at least 
60% of participants with ATM IHC ≤ 
5%” and addition of text “Prospective 
selection of patients with ATM IHC ≤ 
5% may  be introduced in each cohort 
based on emerging ATM protein 
deficiency prevalence and ceralasertib 
clinical activity”Please see 
overall rationaleSubstantial
[IP_ADDRESS] Module Rationale, 
Prostate CancerDeletion of text “evaluating rucaparib 
in patients”Typo Non-substantial
[IP_ADDRESS] Study Design 
Cohort AAddition of the text “dosed at 
ceralasertib 160mg BID”Clarification Non-substantial
[IP_ADDRESS] Study Design 
Cohort ADeletion of the text “with prospective 
selection, if necessary, to ensure at 
least 60% of participants with ATM 
IHC ≤ 5%”Please see 
overall rationaleSubstantial
[IP_ADDRESS] Study Design 
Cohort A (Figure 3)Deletion of foot note 2 “2A minimum 
of 60% participants will be ATM IHC 
≤ 5% (ie n=15) in addition to having a see overall 
rationaleSubstantial
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 152of 170deleterious or suspected deleterious (or 
pathogenic/likely pathogenic) mutation 
in the ATM gene. ATM ‘deficient’ is 
defined as ATM IHC ≤ 5% ATM -
positive tumour nu clei using the 
Ventana assay (VENTANA ATM 
(Y170) RPA Assay)”
[IP_ADDRESS] M1 Design, Cohort 
BAddition of the text “dosed at 
ceralasertib 160mg BID”Clarification Non-substantial
[IP_ADDRESS] Study Design 
Cohort BDeletion of t he text “ensuring at least 
60% of participants with ATM IHC ≤ 
5%”see overall 
rationaleSubstantial
[IP_ADDRESS] Study Design 
Cohort B (Figure 4)Deletion of the text “A minimum of 
60% participants will be ATM IHC ≤ 
5% (ie n=16) in addition to having a 
deleterious or suspected deleterious (or 
pathogenic/likely pathogenic) mutation 
in the ATM gene”see overall 
rationaleSubstantial
[IP_ADDRESS] Confirmation of 
ATM Protein Expression 
and ATM Mutation StatusDeletion of the text “To ensure that a 
minimum of 60% participants will be 
ATM IHC ≤ 5% for each disease 
cohort (ie n=[ADDRESS_781943] and n=16 prostate) 
by [CONTACT_592772], an additio nal enrolment 
criteria of ATM loss may be 
implemented. To enable this”
Additional text added to clarify that 
prospective testing may be introduced. 
The decision to trigger prospective 
participant selection may be based on 
preliminary  data f rom subgroup 
analy sis”see overall 
rationaleSubstantial
[IP_ADDRESS] Inclusion Criteria 
Screening Part 1 (Molecular 
Eligibility)Deletion of the text “if required to 
ensure a minimum 60% enrolled 
participants are ATM IHC deficient 
(defined as ATM protein staining ≤ 5% 
of tumour nuclei) by [CONTACT_592773].
Prospective selection by [CONTACT_592774] a maximum 
number of participants with ATM see overall 
rationaleSubstantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 153of 170protein staining of > 5% by [CONTACT_592775]”
[IP_ADDRESS] Inclusion Criteria, 
Screening Part 1 (Molecular 
Eligibility)Addition of the text “if prospective 
ICH ATM testing is triggered, local 
ATM NGS test report must be 
provided”
Deletion of the text “Prospective ATM 
NGS central testing may be 
introduced”Correction 
around 
provision of 
local ATM 
NGS testsNon-substantial
[IP_ADDRESS] Inclusion Criteria, 
Screening Part 1 (Molecular 
Eligibility)Inclusion criterion #2 –Addition of the 
text to clarify details around ATM 
mutationClarification Non-substantial
[IP_ADDRESS] Inclusion Criteria, 
Screening Part 2 (Study 
Eligibility), Type of 
Participant and Disease 
CharacteristicsInclusion criterion #4(a) -Addition of 
the text “Participants already receiving 
erythropoietin at the time of screening 
for the study may continue it providing 
they have been receiving it for more 
than one month at the time study 
interventio n is started” This text was 
moved from 
Section, 11.6.5, Concomitant Therapy, 
Supportive CareClarification Non-substantial
[IP_ADDRESS] Inclusion Criteria, 
Other, Cohort A -aSTInclusion criterion #2 –Deletion of text 
“Specimens from bone biopsies”Details to be 
added to lab 
manual 
allowing bone 
biopsies post 
validationNon-substantial
[IP_ADDRESS] Inclusion Criteria, 
Other, Cohort B -mCRPCInclusion criterion #2 –Deletion of text 
“Specimens from bone biopsies”Details to be 
added to lab 
manual 
allowing bone 
biopsies post 
validationNon-substantial
11.5.2 Exclusion Criteria 
(Cohort A and Cohort B), 
Medical ConditionsExclusion criterion #1, 7th bullet point 
-Addition of text “28 days”Correction of 
typo in CSP 
Amendment 02. 
Correct wording 
was in CSP 
Amendment 01Non-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 154of [ZIP_CODE].5.2 Exclusion Criteria 
(Cohort A and Cohort B), 
Medical ConditionsExclusion criterion #4 –Addition of 
the text “if new asymptomatic brain 
metastases are discovered, an interval 
scan (minimum 4 weeks) should be 
conducted to confirm the new brain 
lesions are not progressing and do not 
require local CNS -directed therapy. If 
local treatment is necessary, this should 
occur before study entry”Clarification 
around 
identification 
and 
manag ement of 
asymptomantic 
brain metsNon-substantial
11.5.2 Exclusion Criteria 
(Cohort A and Cohort B), 
Medical ConditionsExclusion criterion #4a -Addition of 
the text “and direct factor Xa 
inhibito rs”Addition of 
class of drugs 
that can lead to 
INR elevationNon-substantial
11.6.5 Concomitant 
TherapyDeletion of text 
“Paracetamol/Acetaminophen, at doses 
of ≤2grams/day, is permitted for use 
anytime during the study. Other 
concomitant medication may be 
considered on a case by [CONTACT_592776]”Rem oval of text 
from protocol 
template left in 
errorNon-substantial
[IP_ADDRESS] Concomitant 
Therapy , Supportive CareMoving of the text “Participants 
already  receiving ery thropoietin at the 
time of screening for the study may 
continue it providing they have been 
receiving it for more than one month at 
the time study intervention is started” 
to Section [IP_ADDRESS] Inclusion Criteria, 
Screening Part 2 (Study Eligibility), 
Type of Participant and Diseas e 
Characteristics
Deletion of the text “Prophylactic 
erythropoietin should not be started 
during Cycle 1 of the study, but may be 
started during Cycle 2 and after, 
following discussions with the 
Principal Investigator [INVESTIGATOR_76349]”Movement of 
text -
clarificatio n
Deletion of text 
-correctionNon-substantial
[IP_ADDRESS] Individual 
Stoppi[INVESTIGATOR_2121], HepaticAddition of text “or other vitamin K 
antagonists, or direct factor Xa 
inhibito rs”Addition of 
class of drugs 
that can lead to 
INR elevationNon-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 155of [ZIP_CODE].7 Discontinuation of 
study Intervention and 
Participant 
Discontinuation/Withdrawal 
–Module 1Addition of text “Patients may receive 
study intervention until objective 
disease progression, or as long as they 
are continuing to show clini cal benefit, 
as judged by [CONTACT_093], or 
treatment discontinuation criteria are 
met”Clarification of 
length of study 
treatmentNon-substantial
11.8.2 Module Assessments 
and Procedures -Module 1, 
Safety AssessmentsAddition of text “For all participants, 
results of all safety assessments must 
be available and must be reviewed by 
[CONTACT_592777]. Samples can 
be collected the day before dosing 
cycle start. Prior to discharge from 
each in -patient and clinic visit, the 
Investigator or their deputy will be 
responsible for reviewing all available 
safety data, including vital signs and 
ECGs”Clarification Non-substantial
[IP_ADDRESS] Human Biological 
Sample Biomarkers, 
Collection of Archival 
Tumour Sa mplesDeletion of text “Bone samples are 
inadequate for central testing”Details to be 
added to lab 
manual 
allowing bone 
biopsies post 
validationNon-substantial
11.9.2 Sample Size 
Determination Cohort ADeletion of text “ensuring at least 60% 
of particip ants with ATM IHC ≤ 5%”
Addition of text “ dosed at ceralasertib 
160mg BID”see overall 
rationaleSubstantial
11.9.2 Sample Size 
Determination Cohort BDeletion of text “ensuring at least 60% 
of participants with ATM IHC ≤ 5%”
Addition of text “ dosed at ceralasertib 
160mg BID”see overall 
rationaleSubstantial
11.9.2 Sample Size 
DeterminationDeletion of text “It is intended to 
ensure at least 60% of participants have 
ATM IHC ≤ 5%, in order to have an 
adequate number of participants for 
exploration of efficacy in this subset”see overall 
rationaleSubstantial
11.9.4 Summary of 
Analy ses and Data Cut -off Deletion of text “with at least 60% 
ATM IHC ≤5%)”Please see 
overall rationaleSubstantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 156of 170Triggers Cohort A (Table 
13)
11.9.4 Summary of 
Analy ses and Data Cut -off 
Triggers Cohort B (Table 
13)Deletion of text “with at least 60% 
ATM IHC ≤5%)”Please see 
overall rationaleSubstantial
[IP_ADDRESS] Interim Analyses 
Cohort ADeletion of text “with at least 60% 
ATM IHC ≤5%”
Addition of text “ dosed at ceral asertib 
160mg BID”Please see 
overall rationaleSubstantial
[IP_ADDRESS] Interim Analyses 
Cohort BDeletion of text “with at least 60% 
ATM IHC ≤5%”
Addition of text “ dosed at ceralasertib 
160mg BID”Please see 
overall rationaleSubstantial
Throughout Minor administrative changes To correct 
errors in format, 
typography  or 
languageNon-substantial
Amendment 2 (27 -May -2021)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n. 
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 157of 170Overall Rationale for the Amendment:
Inclusio n of updates made for Am endment FRA -1, a l ocal protocol  amendment applicable in 
[LOCATION_009] that was prepared in response to queries from the French National Agency for 
Medicines and Healt h Products Safet y (ANSM), to implement urgent safet y measures (adding 
extra safet y visits and red ucing dose to 160 mg BID), and for template and other updates to 
aid sense and flow of the document.
Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
CORE
2.2 Background Deletion of the text “This modular 
study will investigate the 
efficiency and tolerability of 
ceralasertib in patients with 
various molecular alterations”.Module [ADDRESS_781944] 
Mitigation During 
Study Disruptions 
Due to Cases of 
Civil Crisis, 
Natural Disaster, 
or Public Health 
CrisisAddition of new section/text 
relating to study disruption.To allow greater flexibility 
for study conduct during 
current COVID -19 pandemic 
or other similar situations.Substantial
5.1 Inclusion 
CriteriaInclusion criterion 6 regarding 
ability  to swallow tablets was 
moved to Module 1, Section 
[IP_ADDRESS].Future modules may not 
include tablets.Non-substantial
7.1 
Discontinuation of 
Study InterventionText additions clarifying the 
situatio ns for study intervention 
discontinuation.Template text update. Non-substantial
7.2 Participant 
Withdrawal from 
the StudyText describing procedure for 
withdrawal of consent for 
disclosure of future information 
and use of existing samples has 
been added.Template text update. Non-substantial
Text describing modified follow -
up options was deleted.This is not applicable to this 
study.Non-substantial
Text describing a study 
interventio n discontinuation visit 
was deleted.Visit deleted as there is no 
such visit in the study.Non-substantial
8.2.3 
ElectrocardiogramsText describing triplicate ECG 
recordings was added from 
Module 1 Section [IP_ADDRESS].Generic screening ECG 
details retained in the Core 
section.Non-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 158of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
8.3.1 Time Period 
and Frequency for 
Collecting AE and 
SAE InformationText was amended to clarify that 
AEs will be collected throughout 
treatment period.Clarification that AEs will 
be collected from start of 
study treatment period and 
not from screening.Non-substantial
8.3.9 .1 Maternal 
ExposureThe text was changed from 
“congenital abnormalities” to 
“congenital anomaly”.Template text update. Non-substantial
Throughout Minor administrative changes. This revision was made to 
correct errors in format, 
typography  or language.Non-substantial
MODULE 1 (Section 11):
Ceralasertib Monotherapy in ATM Altered Advanced Solid Tumours (aST) and Prostate Cancer
11.1.1 Sy nopsis Number of participants was 
updated to include “Addition of 
the text “At the time of protocol 
amendment 2, 1 participant had 
been dosed at 240 mg BID in 
Cohort A, and 8 participants had 
been dosed at 240 mg BID in 
Cohort B. Following the reduction 
of the starting dose from 240 mg 
BID to 160 mg BID in protocol 
amendment 2, the intention is to 
enrol an additional t otal of ~25 and 
~27 participants in Cohort A and 
B, respectively, at the 160 mg 
BID” .Clarification of sample size 
following dose reduction to 
160mg BID .Substantial
11.[ADDRESS_781945] the updated dose 
of 160 mg BID .Update following dose 
reductio n to 160 mg BID .Substantial
11.1.3 Schedule of 
ActivitiesIn Table 3 (Schedule of 
Activities), the time window for 
Cycle 2 Day  1 and from Cy cle 3 
Day 1 onwards updated to “ -1/+3 
days”.Update allows for any 
required assessment results 
to be received.Non-substantial
In Table 3 (Schedule of 
Activities), the time window for 
last dose of study intervention was 
updated from “± 7 days” to “+ 7 
days”.There is no possibility of a 
time window prior to last 
dose.Non-substantial
In Table 3 (Schedule of 
Activities), “Provide copy of local 
NGS testing report” was added.Clarification of this 
requirement at screening.Non-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 159of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
In Table 3 (Schedule of 
Activities), “Optional tumour 
sample” was added as a separate 
row.Clarification of tumour 
sampling in SoA. Mandatory 
at screening and optional at 
last dose and follow -up. 
Optional samplings are not 
archival o r standard of care.Non-substantial
In Table 3 (Schedule of 
Activities), “Peripheral blood for 
 was moved up in order of 
appearance in the table.To group together 
assessments performed at 
screening.Non-substantial
In Table 3 (Schedule of 
Activities), addition of “triplicate” 
in the ECG assessment row for 
screening. Deletion of assessment 
timepoints during the study period.Clarification that triplicate 
ECGs would be collected at 
screening only.Substantial
In Table 3 (Schedule of 
Activities), addition of assessment 
time points for Cycle 1 Day 14 and 
Cycle 2 Day  14.To confirm vital signs 
assessment during the 
treatment period.Substantial
In Table 3 (Schedule of 
Activities), “Clinical safety 
laborato ry assessments” was 
changed to “Complete blood count 
and other clinical safety laboratory 
assessments”.Clarification. Non-substantial
In Table 3 (Schedule of 
Activities), “Serum testosterone 
(not required in participants after 
bilateral orchiectomy) and PSA (if 
no radiographic progression, local 
assessment” was added. Clarification of this 
requirement as per inclusion 
criteria for Cohort B .Non-substantial
In Table 3 (Schedule of 
Activities), footnote d for ECG 
was deleted as no longer required. 
Subsequent footnote numbering 
was updated.Footnote is no longer 
required.Non-substantial
In Table 3 (Schedule of 
Activities), additional Day8 visits 
were added for Cycle 1 and 
Cycle2.Precautionary monitoring of 
safety assessments related to 
≥ G3 thrombocytopenia or ≥ 
G3 neutropenia.Substantial
Footnotes were updated, including 
re-numbering.Clarification. Non-substantial
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 160of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
11.2 Introdu ction –
Module 1Text was updated from “ATM 
IHC  ≥5%” to “ATM IHC  >5%”.Definitio n should be more 
than 5% (not equal or more).Non-substantial
Text was updated to include 
“Definitions of qualifying ATM 
mutations include 
deleterious/suspected deleterious, 
pathogenic/likely pathogenic, 
disease, or cancer -associated 
variants. Variants or unknown 
significance or benign variants are 
not eligible for enrolment” .Clarify  definitio n of ATM 
mutations .Non-substantial
11.2.1 Module 
RationaleText was updated from “Ataxia 
telangiectasia and rad3 related 
protein…” to “Ataxia 
telangiectasia mutated protein 
loss..”.Updated to reflect the 
description of ataxia 
telangiectasia.Non-substantial
Text was added to describe further 
details of the first in huma n ATR 
inhibito r study .IRB request. Non-substantial
[IP_ADDRESS] Prostate 
CancerText was added “The concept of 
synthetic lethality  of DDR 
inhibito rs in DDR -deficient 
backgrounds has been explored 
clinically in mCRPC: PARPi [INVESTIGATOR_592717]1/2 mutations
and HRR mutations, including 
ATM mutations.” to replace the 
original text “Targeted next 
generation sequencing of advanced 
prostate cancer has identified an 
8% incidence of ATM mutations 
(Beltran et al, 2013 and Choi et al, 
2016).”Clarity  in the descript ion of 
BRCA mutations.Non-substantial
[IP_ADDRESS] Disease 
LinkageText was deleted “...a rare, 
autosomal recessive disorder that 
leads to progressive 
neurodegeneration (cerebellar 
ataxia), orbital telangiectasia, 
immunodeficiency ..”To aid clarity and flow. Non-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 161of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
11.3 Objectives 
and Endpoints –
Module 1In Table 5 (Objectives and 
Endpoints –Cohort A), one of the 
secondary endpoints/variables was 
reworded to remove the details 
regarding the urinalysis and 
coagulatio n.These parameters are not 
collected during the study. Non-substantial
In Table 5 (Objectives and 
Endpoints –Cohort A), one of the 
secondary endpoints/variables was 
reworded to remove the details 
regarding ECG.ECG is not an 
endpoint/variable in the 
study.Non-substantial
In Table 5 (Objectives and 
Endpoints –Cohort A), the 
exploratory objective for  
 
”.Clarification . Non-substantial
In Table 6 (Objectives and 
Endpoints –Cohort B), the 
primary  objective was reworde d to 
remove the details regarding the 
previous treatments of participants.To align objectives with the 
revised Inclusion Criterion 3 
for Co hort B. Non-substantial
In Table 6 (Objectives and 
Endpoints –Cohort B), addition of 
a secondary endpoint//varia ble 
“Duration of radiological 
response” .Consistency since it is also 
listed in the statistics section.Non-substantial
In Table 6 (Objectives and 
Endpoints –Cohort B), one of the 
secondary endpoints/variables was 
reworded to remove the details 
regarding the urinalysis and 
coagulatio n.These parameters are not 
collected during the study. Non-substantial
In Table 6 (Objectives and 
Endpoints –Cohort B), one of the 
secondary endpoints/variables was 
reworded to remove the details 
regarding ECG.ECG is not an 
endpoint/variable in the 
study.Non-substantial
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 162of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
In Table 6 (Objectives and 
Endpoints –Cohort B), addition of 
the exploratory endpoints/variables 
“  
 
 
 
 
 
”.For consistency since it is 
also listed in the statistics 
section.Non-substantial
In Table 6 (Objectives and 
Endpoints –Cohort B), the 
exploratory endpoint/variable for 
 
  Non-substantial
In Table 6 (Objectives and 
Endpoints –Coho rt B), the 
exploratory objective for  
 Clarification . Non-substantial
In Table 6 (Objectives and 
Endpoints –Cohort B), the 
exploratory endpoint/variable for 
 
 was added. Clarification to be consistent 
with the objective.Non-substantial
[IP_ADDRESS] Cohort A Figure [ADDRESS_781946] the updated dose 
of 160 mg BID .Update following dose 
reductio n to 160 mg BID .Substant ial
[IP_ADDRESS] Cohort B For Figure 4 (Study Design –
Cohort B) the footnote was 
updated with “in addition to 
having a deleterious or suspected 
deleterious mutation in the ATM 
gene”.For consistency with the 
footnote for Figure 3 (Study 
Design –Cohort A) .Non-substantial
Figure [ADDRESS_781947] the updated dose 
of 160 mg BID .Update following dose 
reductio n to 160 mg BID .Substantial
[IP_ADDRESS] 
Confirmation of 
ATM Protein 
Expression and Section [IP_ADDRESS] was moved from 
“Human biological samples” to 
“Study  design” as a new 
subsection.To aid clarity since the 
description of ATM 
expression and mutation 
confirmatio n is part of the 
study design.Non-substantial
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agen ts-D5339C00001
CONFIDENTIAL AND PROPRIETARY 163of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
ATM Mutation 
StatusThe text description was updated 
to better describe the process for 
confirming ATM protein 
expression and ATM mutation 
status. Text was also updated to 
define qualifying ATM mutations.Clarification. Non-substantial
The text “This may only be 
implemented in the study after the 
7th participant in the aST cohort or 
the 4th participant in prostate 
cancer cohort has been enrolled 
and is positive for ATM protein 
staining of > 5% by [CONTACT_4658]” was 
deleted .To allow flexibility for study 
conduct .Non-substantial
11.4.3 Justification 
for DoseThe whole section was upd ated to 
include a description of the change 
in dose from 240 mg BID to 
160mg BID.To implement urgent safety 
measures including reducing 
dose to 160 mg BID.Substantial
11.5.1 Inclusion 
CriteriaAddition of the text “All 
participants must submit blood and 
FFPE tumour samples for central 
confirmatio n of ATM mutation 
and ATM IHC testing”.Clarification that submission 
of a tumour sample is 
required for central 
confirmatio n even if the 
participant has a local NGS 
report available.Non-substantial
[IP_ADDRESS] Screening 
Part 1 (Molecular 
eligibility)Addition of text describing 
requirements for local ATM NGS 
testing. Also confirming that all 
participants must submit a FFPE 
tumour sample for central NGS 
and IHC confirmation. Prospective 
ATM NGS testing may be 
introduced.Clarification of the 
requirements for Screening 
Part 1.Non-substantial
Screening Part [ADDRESS_781948] 
deleterious or suspected 
deleterious ATM mutation in 
tumour o r blood.To allow participants with 
germline mutations to avoid 
local testing of the tumour.Non-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 164of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
Screening Part 1 Inclusion 
Criterio n 2 was revised to include 
“Definitions of qualifying ATM 
mutations include 
deleterious/suspected deleterious, 
pathogenic/likely pathogenic, 
disease, or cancer -associated 
variants. Variants or unknown 
significance or benign variants are 
not eligible for enrolment” .Clarify  definitio n of ATM 
mutations .Non-substantial
Screening Part 1 Addition of a new 
inclusion c riterio n regarding 
tumour sample for central 
confirmatio n of ATM mutation 
and ATM IHC testing.For clarity, existing text in 
the section was moved 
down/edited and added to 
the list of criteria.Substantial
[IP_ADDRESS] Screening 
Part 1 (Study 
eligibility)Screening Part [ADDRESS_781949] treatment available.Revision was requested by 
[CONTACT_592778].Substantial
[IP_ADDRESS] Cohort A -
aSTCohort A –aST Inclusion 
Criterio n 2 was revised to include 
“The site needs to refer to the 
pathology manual for acceptable 
tissue ty pes for testing. Specimens 
from bone biopsies and fine needle 
aspi[INVESTIGATOR_19328].”For clarity in terms of 
acceptable tissue types for 
testing.Non-substantial
[IP_ADDRESS] Cohort B -
mCRPCCohort B –mCRPC Inclusion 
Criterio n 2 was revised to include 
“The site needs to refer to the 
pathology manual for acceptable 
tissue ty pes for testing. Specimens 
from bone biopsies and fine needle 
aspi[INVESTIGATOR_19328].”For clarity in terms of 
acceptable tissue types for 
testing.Non-substantial
Cohort B –mCRPC Inclusion 
Criterio n [ADDRESS_781950] one taxane 
regimen (unless the participant has 
contraindications to taxanes).Requested by [CONTACT_592779]. Substantial
Cohort B –mCRPC Inclusion 
Criterio n 7 was revised to add 
“(not required for participants after 
bilateral orchiectomy)”.For clarity. Non-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 165of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
11.5.2 Exclusion 
CriteriaExclusion Criterion was added 
under medical conditions to 
exclude participants with INR 
≥1.5 (except those who receive 
vitamin K antagonists) or with 
other evidence of impaired hepatic
synthesis function. Requested by [CONTACT_592780][INVESTIGATOR_2121].Substantial
11.6.1 Study 
Intervention 
AdministeredTable 7 Investigational Products 
was updated to include the change 
for dose from 240 mg twice daily 
to 160 mg twice daily. A footnote 
was also added to clarify the 
change and additional information.To implement urgent safety 
measures including reducing 
dose to 160 mg BID.Substantial
11.6.5 
Concomitant 
TherapyText was added to detail anti -
cancer therapi[INVESTIGATOR_592718] a llowed 
during the study.To specify in more detail the 
allowed anti -cancer 
treatments during the study.Non-substantial
[IP_ADDRESS] Guidance 
for Dose 
Modification and 
InterruptionAdditional test was added 
“Participants with ≥ G3 anaemia, 
neutropenia, thromb ocytopenia 
during Cycle 1 and Cycle 2 will be 
required to attend for additional 
Day 8 and Day  14 assessments 
until there is no evidence of ≥ G3 
anaemia, neutropenia, 
thrombocytopenia for at least 2 
cycles. Participants who develop a 
≥ G3 anaemia, neutropen ia, 
thrombocytopenia later in their 
treatment, will also need to have 
additional Day 8 and Day 14 
assessments until there is no 
evidence of ≥ G3 anaemia, 
neutropenia, thrombocytopenia for 
at least 2 cycles”. Precautionary monitoring of 
safety assessments related to 
≥ G3 anaemia, neutropenia, 
and thrombocytopenia.Substantial
Table [ADDRESS_781951] be stopped after 
2occurrences of Grade 4 non -
haematological toxicities. Requested by [CONTACT_592779]. Substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 166of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
Table 9 Dose Reduction Levels for 
Ceralasertib was updated to 
include the change for dose from 
240 mg twice daily to 160 mg 
twice daily. A footnote was also 
added to clarify the change and 
additional information.To implement urgent safety 
measures includi ng reducing 
dose to 160 mg BID.Substantial
[IP_ADDRESS] Individual 
Stoppi[INVESTIGATOR_592719] -heading was moved up to 
include the “Cardiovascular” 
subheading under it.For clarity of text. Non-substantial
11.6.7 Intervention 
after the End of the 
StudyPossibility to continue treatment 
after the end of the study was 
added.Requested by [CONTACT_592779]. Substantial
Additional detail describing the 
possibility of an extension study 
was added.Template text update. Non-substantial
[IP_ADDRESS] Bone 
lesions assessment 
in Co hort B 
(mCRPC) (Based 
on PCWG3 
Criteria)In Table 10 (Requirements for 
Documentation of Progression), 
the “Week 8 scan” and 
“Subsequent scans” visit time 
windows were updated. Minor 
updates for criteria for bone 
progression definitions.Clarification of time 
windows for assessments.Non-substantial
Text describing  
 
was added from Section 
11.8.6 “Human Biological Sample 
Biomarkers” to Section [IP_ADDRESS].For clarity since both are 
efficacy assessments and to 
clarify  between clinical and 
.Non-substantial
[IP_ADDRESS] 
ElectrocardiogramsText describing triplicate ECG 
recordings at Screening Part 2 was 
moved to Core Section 8.2.3.To keep the generic 
screening ECG details in the 
Core section.Non-substantial
[IP_ADDRESS] B rain 
ScanText describing the brain scan 
process was re -ordered. To aid clarity and flow. Non-substantial
[IP_ADDRESS] Clinical 
Safety Laboratory 
AssessmentsIn Table 11 (Laboratory safety 
variables), footnote c was added to 
confirm that “Coagulation and 
urinaly sis are o nly scheduled for 
baseline and as clinically indicated 
post-baseline”.To clarify collection of 
coagulatio n and urinaly sis at 
baseline only.Non-substantial
[IP_ADDRESS] 
PharmacodynamicsAddition of the text “This sample 
may also be used to assess 
.”Clarification . Non-substantial
CCI
CCI
CCI
Clinic al Study  Protocol -Amendment 4 [COMPANY_008]
DNA-damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 167of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
[IP_ADDRESS] Collection 
of Archival 
Tumour SamplesCollection of archival tumour 
samples was moved under Section 
11.8.6 Human Biological Sample 
Biomarkers and updated to remove 
“decalcified samples” and add 
“Bone samples are inadequate for 
central testing”.Bone biopsies are not 
suitable for IHC.Non-substantial
[IP_ADDRESS] Collection 
of Exploratory 
 
 Text w as added to differentiate 
that these are exploratory  
samples.To clarify the clinical  
samples (efficacy) and these 
exploratory  samples.Non-substantial
11.9.2 Sample Size 
DeterminationAddition of the text “At the time 
of protocol amendment 2, 1 
participant had been dosed at 240 
mg BID in Cohort A, and 8 
participants had been dosed at 240 
mg BID in Cohort B. Following 
the reduction of the starting dose 
from 240 mg BID to 160 mg BID 
in protocol amendment 2, the 
intention is to enrol an additiona l 
total of ~25 and ~27 participants in 
Cohort A and B, respectively, at 
the 160 mg BID” .Clarification of sample size 
following dose reduction to 
160mg BID .Substantial
11.9.3 Population 
for AnalysesIn Table 12 (Population for 
Analy sis) updates to descr iption 
text for CTC count and inclusion 
of a footnote defining molecularly 
eligible centrally confirmed.To clarify the description of 
populatio n sets regarding 
CTC count and to clarify 
what is considered 
molecularly eligible 
centrally  confirmed.Non-substantial
11.9.4 Statistical 
Analy sesIn Table 13 (Summary of Analyses 
and Data Cut -off Triggers) 
addition of “ evaluable for 
response ” when describing 
molecularly eligible participants.To clarify the definition of 
participants as molecularly 
eligib le centrally confirmed 
evaluable for response 
participants.Non-substantial
[IP_ADDRESS] General 
ConsiderationsText was updated to confirm data 
presentation for safety and efficacy 
data.To clarify that only 160 mg 
BID data will be presented 
in summary effic acy tables. 
All other information will be 
included in the listings.Non-substantial
CCI
CCI
CCI
CCI
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 168of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
[IP_ADDRESS] Safety Text was updated to removed 
“ECG changes” from safety 
analy sis.ECG is not an 
endpoint/variable in the 
study.Non-substantial
[IP_ADDRESS] 
Pharmacokinetic 
VariablesText was updated to delete 
“Pharmacokinetic analysis of the 
plasma concentration data for 
study intervention will be the 
responsibility of Covance.” To remove specific details of 
laborato ries which will be 
documented separately.Non-substantial
[IP_ADDRESS] Efficacy Addition of text description under 
secondary endpoints for 
“Percentage Change in Tumour 
Size”.For consistency between 
listed endpoints/variables in 
Section and the statistical 
Section 11.3.Non-substantial
Throughout. Clarify ing the de scription of the 
mutation in the ATM gene 
throughout from “deleterious 
mutation” to “deleterious or 
suspected deleterious mutation”.To include participants with 
suspected deleterious 
mutations in addition to 
participants with deleterious 
mutations.Non-substantial
Update of “AST” to “aST” for 
advanced solid tumours.To clarify the abbreviations 
for advanced solid tumour 
(aST) and aspartate 
transaminase (AST).Non-substantial
Minor administrative changes. To correct errors in format, 
typography  or language.Non-substantial
Appendix A 
Changes Related to 
Mitigation of 
Study Disruptions 
Due to Cases of 
Civil Crisis, 
Natural Disaster, 
or Public Health 
CrisisAddition of appendix relating to 
study disruption.To describe processes during 
the current COV ID-19 
pandemic or other similar 
situatio ns.Substantial
Appendix H 
Adverse Events: 
Definitio ns and 
Procedures for 
Recording, 
Evaluating, 
Follow -up, and 
ReportingUnder Section H2, the text was 
changed from “congenital 
abnormalities” to “congenital 
anomaly ”.Template text update. Non-substantial
Clinical Study Protocol -Amendment 4 [COMPANY_008]
DNA -damage response agents -D5339C00001
CONFIDENTIAL AND PROPRIETARY 169of 170Section # and 
NameDescription of Change Brief Rationale Substantial/ 
Non-substantial
Appendix G 
Guidelines for 
Evaluatio n of 
Objective Tumour 
Response Using 
PCWG3 (Prostate 
Cancer Working 
Group Criteria 3) 
in Bone LesionsMinor update of Table 27 title 
from “Best Overall Response 
When confir mation of CR and TR 
Required” to “Best Overall 
Response When confirmation of 
CR and PR Required”.Typographical correction. Non-substantial
Appendix K ATM 
Alterations 
Classification 
GuidanceAn appendix was created to 
provide details on the rules for 
qualifying ATM mutations.To provide clarification for 
ATM  mutation definitions.Substantial 
Appendix M
Protocol 
Amendment 
Histor yAn appendix was created to 
include summary of changes of 
previous amendments.This appendix is required per 
template when amending the 
protocol more than once.Non-substantial
Amendment 1 ([ADDRESS_781952] -2020)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n. 
Overall Rationale for the Amendment:
Table 8 has been updated to add clarity on the m anagem ent of  neutropeni a, anaemia and 
prolonged or intolerable Grade 2 toxicit y.
Section # 
and NameDescription of Change Brief Rationale Substantial/Non -
substantial
[IP_ADDRESS], 
Guidance for 
Dose 
Modification 
and 
Interruption, 
Table 8.Addition of 
“discontinuations” to table 
title.To clarify that that the table provides 
guidance for dose modifications, 
interruption and discontinuations for 
ceralasertib.Substantial
Addition of definition for 
prolonged Grade 2 toxicity.To provide greater clarification for the 
management of Grade 2 toxicity.Substantial
Addition of “Grade 2” for 
thrombocytopenia” under 
Grade 2 events.To provide greater clarification for the 
management of Grade 2 neutropenia and 
Grade 2 thrombocytopenia.Substanti al
Addition of “Grade 3 -4 
neutropenia or Grade 4 
anaemia” under Grade [ADDRESS_781953] that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d5339c00001-csp-amendment-4
Document Title: D5339C00001 Clinical Study Protocol Amendment 4
Document ID: Doc ID-004244130
Version Label: 7.[ADDRESS_781954] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by [CONTACT_24557]
11-Nov-2022 14:06 UTC Content Approval
11-Nov-2022 18:17 UTC Content Approval
11-Nov-2022 13:19 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an [COMPANY_008] document management system.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]